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Dendritic cells (DCs) play a central role as bridges between innate and 
adaptive immunity and are the most potent antigen presenting cells essential 
for initiating adaptive immune responses. Autologous DC-based therapy is 
being established as a novel modality for cancer treatment. To move from 
expensive individualized vaccines to more generally applicable cancer 
vaccine formulations, we have derived DCs from human embryonic stem cells 
(hESCs). We then investigated expression of transgene in our DCs using 
baculoviral vectors.   After successful gene transfer for enforced up-regulation 
of CD1d, we demonstrated that administration of these genetically modified 
DCs could significantly improve the function of DCs in survival of animals in a 
mouse breast cancer model. This result indicates that baculoviral engineering 
hESC of derivatives can possibly be used as scalable and broadly applicable 
cancer therapeutics. In view of the significance of DCs in antitumor immunity 
and emerging applications of stem cells as cancer-targeting vectors to treat 
tumors, we studied in the second part of the project whether mesenchymal 
stem cells (MSCs) and neural stem cells (NSCs), including MSCs and NSCs 
derived from hESCs, affect the activity of DCs. After comparing inhibitory 
effects of human MSCs and NSCs on generation, differentiation and functions 
of human DCs, we observed that NSCs displayed less immunosuppressive 
activity than MSCs. Therefore, a balanced consideration between tumor 
targeting properties and immune-regulatory functions should be given when 
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1.1 Dendritic cells (DCs) and cancer therapy 
Cancer remains a main cause of illness-related mortality in humans (Jemal et 
al. 2011). Despite improvements in the conventional techniques of cytotoxic 
chemotherapy and radiation, the outcome of treatment remains poor. This 
poor outcome is mainly due to the survival of a fraction of cancer cells, which 
causes a high relapse rate in the majority of patients (Attarbaschi et al. 2008; 
Kuroda et al. 2008). Therefore, the activation of patients’ immune system to 
identify and fight residual cancer cells is a major goal in cancer 
immunotherapy.  
 
Immunity plays a pivotal role in the prevention and treatment of cancer. 
Adaptive immunity recognizes a wide range of antigens and responses. 
Currently, the majority of cancer treatments based on adaptive immunity use 
antibodies or vaccination against the viral reagents that might contribute to the 
development of cancer. In addition, therapies based on activation of T cell 
responses have only recently gained attention. Dendritic cells (DCs) are the 
main activators of T cells and act as gate keepers for the application of T cells 
as a “cellular drug library”. DCs have a key role in both the identification of 
antigens and the orchestration of an immune response to these antigens. 
These cells constantly sample their environment with their branch like 
appendages for antigens (Banchereau et al. 2000; Liu et al. 2001). After 
exposure to inflammatory signals, DCs mature from antigen-processing cells 
to antigen-presenting cells. During the maturation process, DCs up-regulate 
the expression of CD83, T cell co-stimulatory molecules (CD80, CD40 and 
CD86) and class II major histocompatibility complex (MHC), and they produce 
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additional pro-inflammatory cytokines such as tumor necrosis factor- (TNF-
) and interleukin-12 (IL-12) (Mellman et al. 2001; Lechmann et al. 2002). 
Depending on the type of co-stimulatory molecule expressed on the cell 
surface of DCs and cytokines secreted by them, DCs can activate T cells or 
suppress them. Due to importance of surface markers in function of DCs as 
well as qualification of their progenitor cells, surface markers used in this 
study are summarized in Table 1.1.  
 
In addition to initiating an immune response against pathogens, DCs play a 
role in autoimmune inflammation, allergic responses and graft rejection 
(Steinman et al. 2007). Due to their immunomodulatory effect, directed 
modifications of DCs can lead to a targeted immune response, including a 
directed response toward cancer cells.  
 
Due to the role of DCs in initiating the immune response, DCs have been 
studied for the treatment of several types of cancer. This treatment approach 
provides several advantages. First, cancer cells express a variety of potential 
antigens that can induce an immune response if they are presented by DCs. 
DCs can simultaneously activate the immune system to target different 
antigens and multiple epitopes of each antigen. This broad response 
decreases the possibility of a mutation-based immune escape by cancer cells. 
Secondly, DCs can activate different arms of cellular immunity and initiate a 
broad spectrum of immune responses (Steinman et al. 2007). Finally, 
functional DCs can be generated from their progenitors in vivo and then 
introduced to patients (Paczesny et al. 2004). Because DCs will direct the 
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attention of the immune system toward tumor cells, they have been named 
“cellular vaccines” (Blattman et al. 2004).  
 
A recent review by Palucka et al. highlights the current  approaches that are 
being investigated for DC based cancer therapy (Palucka, K. et al. 2012). 
Activation of DCs against cancer is mainly achieved through treatment of 
these cells with tumor cells and their derivatives or genetic modification of 
DCs.  Examples of recent clinical trials with activated DCs via treatment with 
tumor cells and their derivatives are highlighted in table 1.2. Two review 
articles cover the clinical trials of genetically modified DCs (Smits et al. 2009; 
Shurin et al. 2010). Most importantly, the FDA approved the first dendritic cell-
based cancer therapy for metastatic prostate cancer in 2010 following 
successful clinical trials (DeFrancesco 2010). These studies highlight the 





Table 1.1 List of surface markers used in the current study 
Marker Description Application References 
CD1a - A member of the CD1 family of 
trans-membrane glycoproteins. 
- Involved in presentation of 
glycolipid antigens to T cells. 
- Upregulated during 
differentiation of DCs from 
monocytes. 
- Surface marker used for 
evaluation of the effects of 
adult stem cells on 
differentiation of DCs from 
monocytes. 
 
(Melian et al. 1996; 
Palucka, K. A. et al. 
1998) 
CD1d - A member of the CD1 family of 
trans-membrane glycoproteins. 
- Expressed in APCs and is 
involved in activation of NKT cells. 
 
- Functional gene used in our 
baculoviral system for genetic 
modification of hESC-DCs for 
validation of transduction 
efficiency. 
- Functional gene used for 
baculoviral modification of 
hESC-DCs for treatment of 
animal tumor model. 
(Melian et al. 1996; 
Joyce 2001) 
CD14 - A phospholipid anchored 
membrane protein. 
- A co-receptor for bacterial LPS 
and is involved in cellular to LPS. 
- Expressed in monocytes and is 
down regulated upon their 
differentiation to DCs. 
- Surface marker used for 
evaluation of the effects of 
adult stem cells on 
differentiation of DCs from 
monocytes. 
(Simmons et al. 1989; 
Palucka, K. A. et al. 
1998; Kitchens 2000) 
CD11c  - A type I trans-membrane 
glycoprotein. 
- Expressed at high levels in 
myeloid DCs. 
- Surface marker used for 
validation of DC differentiation 
from hESCs.  
(Steinman et al. 1997; 
Dzionek et al. 2000) 
CD34 - A type I trans-membrane 
glycoprotein. 
-  Expressed in early 
hematopoietic tissues and HPCs. 
- Surface marker used for 
validation of differentiation of 
HPCs from hESCs. 
(Egeland et al. 1993; 
Nielsen et al. 2008) 
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CD40 - A type I trans-membrane 
glycoprotein from TNF receptor 
superfamily. 
- Expressed in APCs and binds to 
CD40 ligand on surface of T cells.  
- Upregulated in DCs upon 
maturation. 
 
- Surface marker used for 
validation of differentiation of 
DCs from hESCs.  
- Used for evaluation of the 
effects of adult stem cells on 
differentiation of DCs from 
monocytes. 
- Used for evaluation of the 
effects of adult stem cells on 
differentiation of LPS-induced 
DCs from monocytes. 
(Mellman et al. 2001; 
O'Sullivan et al. 2003; Xu 
et al. 2004) 
CD43 - A type I trans-membrane 
glycoprotein.  
- Expressed in majority of 
leukocytes as well as early 
hematopoietic progenitor cells. 
- Surface marker used for 
validation of differentiation of 
HPCs from hESCs. 
(Moore et al. 1994; 
Woodman et al. 1998; 
Vodyanik et al. 2006) 
CD45 -   A type I trans-membrane 
glycoprotein with phosphatase 
activity. 
- Is present on all nucleated 
hematopoietic cells and hence is 
named‎“leukocyte‎common‎
antigen”.‎ 
-Surface marker used for 
validation of purity leukocytes 
derived from hESCs.  
- Surface marker used for 
excluding NSCs and MSCs 
from cocultures with 
monocytes.    
(Ralph et al. 1987; 
Huntington et al. 2004) 
CD80 - A type I trans-membrane 
glycoprotein from Ig superfamily. 
- Expressed on surface of APCs 
and acts as co-stimulatory 
molecule during T cell activation. 
- Upregulated on surface of DCs 
upon maturation. 
- Surface marker used for 
validation of differentiation of 
DCs from hESCs.  
- Used for evaluation of the 
effects of adult stem cells on 
differentiation of DCs from 
monocytes. 
- Used for evaluation of the 
effects of adult stem cells on 
differentiation of LPS-induced 
DCs from monocytes. 
(Koulova et al. 1991; 
Schwartz 1992; Mellman 





CD83 - A type I trans-membrane 
glycoprotein from Ig superfamily. 
- Expressed on surface of APCs.  
- Required for strong stimulation 
of T cells by DCs. 
- Upregulated on surface of DCs 
upon maturation. 
- Surface marker used for 
validation of maturation of 
hESC-DCs after exposure to 
BV.  
- Used for evaluation of the 
effects of adult stem cells on 
differentiation of LPS-induced 
DCs from monocytes. 
(Zhou et al. 1995; 
Lechmann et al. 2002; 
Prechtel et al. 2007) 
CD86 -  A type I trans-membrane 
glycoprotein from Ig superfamily. 
- Expressed on surface of APCs 
and acts as co-stimulatory 
molecule during T cell activation. 
- Upregulated on surface of DCs 
upon maturation. 
-  Surface marker used for 
validation of differentiation of 
DCs from hESCs.  
- Used for evaluation of the 
effects of adult stem cells on 
differentiation of DCs from 
monocytes. 
- Used for evaluation of the 
effects of adult stem cells on 
differentiation of LPS-induced 
DCs from monocytes. 
(Caux et al. 1994; Chen 
et al. 1994; Engel et al. 
1994; Mellman et al. 
2001) 
CD209 - A type II trans-membrane 
protein.  
- Highly expressed in DCs. 
-  Surface marker used for 
validation of differentiation of 
DCs from hESCs.  
(Geijtenbeek et al. 2000) 
HLA-DR - A MHC class II type II trans-
membrane glycoprotein. 
- Expressed on surface of APCs. 
- Upregulated on surface of DCs 
upon maturation. 
-  Surface marker used for 
evaluation of the effects of 
adult stem cells on 
differentiation of LPS-induced 
DCs from monocytes. 
(Gay et al. 1987; 
Mellman et al. 2001; 
Whiteside et al. 2004) 
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Table 1.2 List of selected clinical trials for treatment of cancer using 








Autologous DCs derived 
from PBMC treated with 
tumor lysate 
I - Stabilisation of disease in 
3 out of 10 patients. 
- No toxicity or side effects 
were observed. 
(Bachleitner-




Autologous DCs derived 
from PBMC fused with 
tumor cells 
I - Tumor regression was 
observed in 2 out of 10 
patients with breast 
carcinoma and disease was 
stabilized in one patient.  
- No toxicity or side effects 
were observed.  




Autologous DCs derived 





- Stable disease was found 
in 5 out of 10 patients with 
renal carcinoma. 
- No toxicity or side effects 
were observed 




Autologous DCs derived 
from PBMC treated with 
tumor cells 
 
I/II - Increased infiltration of 
CD8+ T cells to tumor site. 
- 3 patients out of 17 
patients survived more than 
5 years while no survival 
was observed in control 
historical patients. 
- Median survival was 
increased to 525 days in 
treated group, compared to 
380 days in historical 
control patients.  




Autologous DCs derived 
from PBMC treated with 
tumor lysate 
II - Stable disease was found 
in 4 out of 17 patients. 
- No toxicity or side effects 
were observed. 





1.2 Adult stem cells and cancer therapy 
Stem cells, by definition, possess two main characteristics. Stem cells are 
able to produce daughter cells that retain their stem cell potential (self-
renewal), and they have the ability to produce various types of specialized 
cells under permissive environmental conditions (differentiation).  
 
The first reliable reports on existence of adult stem cells were published after 
World War II, during the efforts to find a treatment for patients exposed to 
lethal dosage of radiation. It was initially demonstrated that intravenous 
administration of bone marrow could save lethally irradiated animals (Lorenz 
et al. 1951) and subsequent studies showed that the rescue was due to 
lymphohematopoietic cells that arise from administered bone marrow (Ford et 
al. 1956; Makinodan 1956). Following studies led to the identification of the 
blood lineage progenitor cells, hematopoietic stem cells (HSCs) (Becker et al. 
1963; Morstyn et al. 1980). Within a few years, a series of studies identified a 
non-hematopoietic population of stem cells that could give rise to bone, fat, 
cartilage and fibrous tissue (Tavassoli et al. 1968; Friedenstein et al. 1987). 
These cells were eventually named mesenchymal stem cells (MSCs). The 
existence of neural stem cells (NSCs) as progenitors of astrocytes, 
oligodendrocytes and neurons was finally accepted in the 1990s, although the 
concept was first proposed in the 1960s (Altman 1962).  All of the above 
mentioned cells are categorized as adult stem cells. They constitute a small 
population of their respective tissues and have a limited differentiation and 




Since the discovery of adult stem cells, their application in regenerative 
medicine has been a major focus of attention. Adult stem cells can provide a 
renewable resource for lost cells and tissues. Prominent examples for the 
potential application of adult stem cells in cellular therapy include the 
treatment of diabetes, Alzheimer’s and Huntington’s diseases and stroke.   
 
One major clinical application of adult stem cells in cancer therapy is based 
upon their regenerative potential. HSCs are currently studied in clinical trials 
for their ability to reconstitute the blood after several rounds of chemotherapy. 
(Lenz et al. 2004; Balduzzi et al. 2005; Berthold et al. 2005). In these cases, 
adult stem cells repopulate the ameliorated immune system and other blood 
lineages that are affected by high doses of chemotherapy.  
 
A more recent concept in the treatment of cancer is to use adult stem cells as 
delivery vehicles to target tumor cells. In year 2000, it was reported for the 
first time that NSCs possess tumor tropic potential (Benedetti et al. 2000). 
This study was followed by observation of tumor tropism by MSCs as well as 
endothelial progenitor cells (Studeny et al. 2002; Anderson et al. 2005). NSCs 
and MSCs are the two major types of adult stem cells that are being studied 
as delivery vehicles for cancer therapy (Aboody et al. 2008). These cells will 




1.2.1 Mesenchymal stem cells (MSCs) and their application in cancer 
therapy 
In 1968, the derivation of clonogenic cells with fibroblast-like morphology from 
postnatal bone marrow was reported (Friedenstein et al. 1968). These cells 
were subsequently named colony-forming unit-fibroblasts (CFU-F). CFU-Fs 
were found to be capable of differentiating into adipocytes, chondrocytes and 
osteocytes. However, the potential clinical application of MSCs received 
extensive attention only after they were reintroduced in 1999 (Pittenger et al. 
1999). Since then, the differentiation of MSCs into cardiomyocytes, neurons, 
and astrocytes has also been reported (Jori et al. 2005; Tokcaer-Keskin et al. 
2009). These cells have been studied for the treatment of renal and 
cardiovascular ailments. (Szczypka et al. 2005; Abdel-Latif et al. 2007). 
 
In addition to the application of MSCs in regenerative medicine, these cells 
have been studied for the delivery of therapeutic reagents to the tumor sites. 
Several characteristics make MSCs suitable vehicles for the treatment of 
cancer: 
1. MSCs can be obtained from various sources and can be expanded 
in vitro. 
2. MSCs exhibit high migratory potential toward sites of injury (Studeny 
et al. 2002). 
3. MSCs have low immunogenicity due to low levels of expression of 




4. MSCs do not exhibit any tumorigenicity in animal models (Sato et al. 
2005).  
5. MSCs are permissive to genetic modification with a wide range of 
viral and non-viral vectors in vitro prior to their clinical administration 
(Hu, Y. L. et al. 2010).  
  
The attraction of MSCs to tumors has been reported for a wide range of 
experimental tumor models, including malignant melanoma, Kaposi's 
sarcoma, colon cancer, ovarian cancer, pancreatic cancer, Ewing’s sarcoma, 
fibrosarcoma, breast cancer and renal cell carcinoma (Studeny et al. 2002; 
Hung et al. 2005; Khakoo et al. 2006; Komarova et al. 2006; Kallifatidis et al. 
2008; Duan et al. 2009; Fernandez-Garcia et al. 2009; Kidd et al. 2009; Xiang 
et al. 2009; Gao et al. 2010). Upon systematic or local administration of MSCs 
in a glioma model, these cells exhibited a strong migratory ability (Lee, D. H. 
et al. 2009). Genetically engineered MSCs can deliver therapeutic reagents or 
oncolytic viruses to the tumor sites (Nakamizo et al. 2005; Sonabend et al. 
2008; Bak et al. 2011). These studies highlight the potential application of 
MSCs as vessels for the delivery of therapeutic reagents to tumor sites.  
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1.2.2 Neural stem cells (NSCs) and their application in cancer therapy 
Although the existence of dividing cells capable of producing neurons in the 
brains of adult mammals was first suggested in the 1960s (Altman 1962), the 
direct evidence of the presence of NSCs was not reported until the late 1980s 
and early 1990s. During this period of time, a series of studies discovered a 
rare population of single cells in the developing nervous systems of 
mammalian embryos that had differentiation potential toward both neural and 
glial lineages (Temple 1989; Cattaneo et al. 1990; Reynolds et al. 1992; 
Stemple et al. 1992; Kilpatrick et al. 1993). However, the presence of NSCs 
after the embryonic stage was unknown until NSCs were isolated from an 
adult mammalian brain (Reynolds et al. 1992). 
 
NSCs can differentiate toward downstream neural and glial lineages. In 
addition they have migratory potential toward inflammation site. These 
characteristics make NSCs a plausible therapeutic candidate in regenerative 
medicine (Martino et al. 2006). To investigate the potentials of NSCs in 
regenerative medicine, these cells are currently being studied for treatment of 
hemorrhagic stroke, remyelination after spinal cord injuries, multiple sclerosis 
and Parkinson’s disease. (Temple 2001; Cummings et al. 2005; Richardson et 
al. 2005; Lee, H. et al. 2007). 
 In addition to the potential application of NSCs in regenerative medicine, 
NSCs have also been studied in cellular treatments for cancer. The discovery 
of the inherent tumor-tropic properties of NSCs in 2000 provided the means 
for the development of therapies that use NSCs as vehicles to target invasive 
tumor cells. In a preliminary study, fluorescence-labeled NSCs migrated 
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significant distances to reach the tumor sites (Aboody et al. 2000).  Since 
2000, many studies have investigated the application of NSCs in targeting 
intracranial glioma (Aboody et al. 2008). NSCs have been engineered to 
deliver therapeutic cytokines, antibodies and oncolytic viruses to tumor sites. 
(Ehtesham et al. 2002; Frank et al. 2009; Tyler et al. 2009; Zhao et al. 2010). 
NSCs and neural precursor cells effectively target both intracranial and 
extracranial tumors of neural and non-neural origins (Brown et al. 2003). 
NSCs have demonstrated their migratory potential toward breast cancer (Joo 
et al. 2009), melanoma brain metastases (Aboody et al. 2006), interacerebral 
medulloblastoma (Kim, S. K. et al. 2006) and disseminated neuroblastoma 
(Sims et al. 2009). Following characteristics make NSCs suitable cellular 
vehicles for treatment of cancer (Ahmed et al. 2010):  
1. NSCs show strong tumor tropism potential. 
2. NSCs can be purified in vitro and expanded to a clinical scale. 
3. NSCs are permissive to transduction by oncolytic viruses.  
4. NSCs can evade detection by the immune system of the recipient.  
In short, promising results from above mentioned studies support the potential 
application of NSCs in the treatment of cancer. 
 
 
1.3 Human embryonic stem cells (hESCs) as a source of therapeutic 
cells  
In 1964, researchers isolated a new type of stem cell from a teratocarcinoma 
that could differentiate into the three germ layer lineages of endoderm, 
mesoderm and ectoderm (Kleinsmith et al. 1964). Later on in 1981, a stem 
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cell line with similar properties was established from normal pre-implanted 
mouse embryos and was named embryonic stem cells (ESCs) (Evans et al. 
1981; Martin 1981). Nearly two decades later, the human counter part of 
these cells was introduced by extraction of the inner cell mass from a 
blastocyst stage embryo (100-200 cells) from redundant embryos derived for 
in vitro fertilization purposes (Thomson et al. 1998). Later, other groups 
reported the derivation of human embryonic stem cells (hESCs) from embryos 
at the morula stage (30-40 cells) (Strelchenko et al. 2004), arrested embryos 
(arrested at 16-24 cell stage) (Zhang et al. 2006), single blastomere cells 
isolated from embryos at the 8 stage (Klimanskaya et al. 2006) and even 2-4 
cell stage blastomeres (Geens et al. 2009). hESCs maintain their 
undifferentiated morphology and normal chromosomal integrity over long 
culturing periods. These cells also express transcription factors (including 
OCT4, SOX2 and Nanog) and surface markers (SSEA-3, SSEA-4, TRA-1-60 
and TRA-1-81), which are markers of pluripotent stem cells. 
 
 Functional characterizations of ESCs are consisted of spontaneous 
differentiation in culture, the formation of embryoid bodies (EBs) and the 
formation of teratomas in immune-compromised mice.  
 
hESCs can be maintained for many divisions in laboratory conditions and can 
differentiate into any specialized cell in an adult body, including adult stem 
cells. These two characteristics make hESCs a plausible source of cells for 




1.2.1 hESCs as a source of DCs 
DCs are commonly derived from blood monocytes via culture with 
granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-
4 (IL-4) (Sallusto et al. 1994). DCs develop from CD34+ hematopoietic 
progenitor cells via two independent pathways of interstitial cells and 
Langerhans cells (Caux et al. 1996). DCs can also be produced from INF--
producing plasmacytoid cells (Grouard et al. 1997).  Harvesting primary 
progenitor cells by these methods is invasive and can pose health risks to 
donors. In addition, variations among donors are an intrinsic limitation of 
primary adult stem cells.  
 
 However, the derivation of DCs from hESCs offers a renewable and constant 
source of cells. Additionally, this approach provides the opportunity for the 
genetic modification of DCs at early stages. hESC-derived DCs pose fewer 
biosafety concerns compared to products originating from blood and are 
relatively cheaper. These advantages make  hESCs a plausible source for the 
production of DCs. To harness these advantages, several studies have 
reported the successful derivation of DCs from hESCs (Slukvin et al. 2006; 
Senju et al. 2007; Su et al. 2008). 
 
1.2.2 hESCs as a source of NSCs 
The discovery of NSCs was immediately followed by an assessment of their 
therapeutic potential. However, primary human NSCs must be obtained from 
the nervous systems of human donors; apart from the intrinsic moral problems 
associated with this process, the primary NSCs suffer from 
17 
 
immunocompatibilty and biosafety issues. In addition, unlike their rodent 
counterparts, human NSCs express low levels of telomerase and undergo 
senescence in culture, which is a potential obstacle for the prolonged 
maintenance of these cells (Ostenfeld et al. 2000). To address these 
limitations, there has been a trend toward developing alternative sources for 
human NSCs. One potential approach is the trans-differentiation of other cell 
lineages harvested from the patient. For instance, it has been reported that 
MSCs, hematopoietic progenitor cells and skin cells can be used for the 
production of NSC-like cells (Hao et al. 2003; Hermann et al. 2004; Joannides 
et al. 2004). While trans-differentiation might address the limitations regarding 
the use of primary NSCs, the clinical feasibility of these techniques for the 
production of large amounts of cells and the extent to which of these cells 
resemble NSCs are yet to be determined.  
 
 hESCs were recently reported as a source for the production of NSCs 
(Itsykson et al. 2005; Guillaume et al. 2008). hESCs can be propagated 
virtually indefinitely in vitro before being used for the production of NSCs, 
hence addressing the problem of the limited source of cells. In addition, the 
derivation and maintenance of hESCs in defined conditions can address the 
biosafety issues of primary NSCs.  
 
1.2.3 hESCs as a source of MSCs 
Since the discovery of MSCs, bone marrow (BM) has been the primary source 
of these cells. However, harvesting BM is a highly invasive procedure. 
Moreover, the number, differentiation potential and maintenance life of bone 
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marrow MSCs (BM-MSCs) differs among donors (Nishida et al. 1999; Mueller 
et al. 2001; Stenderup et al. 2003). Subsequently, there is major interest in 
searching for alternative sources of MSCs. A more recently tapped source for 
MSCs is adipose tissue (Zuk et al. 2002). Adipose MSCs can be obtained 
after liposuction procedures, and they possess multilineage differentiation 
potential similar to that of BM-MSCs. Another source for MSCs is umbilical 
cord blood (Erices et al. 2000; Lee, O. K. et al. 2004). However, this source is 
controversial, and several groups have failed to harvest MSCs from full-term 
umbilical cord blood (Mareschi et al. 2001; Wexler et al. 2003). Moreover, the 
presence of populations of MSCs in the connective tissue of skeletal muscle, 
dermis and even dental pulp has also been reported (Lucas et al. 1988; 
Young et al. 2001; Shi, S. et al. 2003). 
 
Nevertheless, several obstacles limit the clinical application of primary MSCs.  
Harvesting MSCs from the abovementioned sources usually requires invasive 
procedures. Furthermore, only a limited number of MSCs can be obtained 
from each donor, and although the expansion capacity of MSCs in culture is 
significant, it remains limited (Zimmermann et al. 2003; Shibata et al. 2007).  
There is also variation in the differentiation and expansion potential of primary 
MSCs harvested from different donors (D'Ippolito et al. 1999; Shibata et al. 
2007). 
 
 A potential solution to the abovementioned obstacles is the derivation of 
MSCs from hESCs. hESCs offer a renewable source of MSCs and will 
eliminate the need for invasive harvest procedures. Additionally, hESC-
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derived MSCs are expected to be more consistent in their characteristics 
across batches. To investigate these advantages, several studies have 
recently reported the successful derivation of MSCs from hESCs (Lian et al. 
2007; Hwang et al. 2008).  These cells were characterized based on their 
differentiation potential and phenotypic features. The derivation of MSCs from 
hESCs enables the derivation of these cells in fully defined conditions, which 







DCs play an active role in antitumor immunity and are thus administered as 
cellular vaccines against cancer. An important approach for directing the 
function of DCs against tumors is through the genetic engineering of these 
cells (Smits et al. 2009). However, DCs used for clinical applications are 
currently obtained from blood monocytes and progenitor cells through 
invasive methods. Additionally, these primary cells are prone to donor-
dependent variations and bear intrinsic safety concerns. To investigate the 
possibility of a more consistent approach, we will use hESCs as an alternative 
source for DCs. We will subsequently confirm the DC characteristics of cells 
we produce from hESCs. Then, we will examine the expression of a reporter 
gene in hESC-derived DCs using our safe viral vector (baculovirus). Finally, 
we will investigate whether the modification of hESC-derived DCs (hESC-
DCs) with a functional gene can augment the therapeutic effects of 
administered hESC-DCs in a tumor model. These aims will be emphasized in 
chapter 2.2. 
 
In addition to the well-known application of adult stem cells in regenerative 
medicine, these cells have recently been studied as cellular vehicles to deliver 
therapeutic loads to tumor cells. However, several factors can limit this 
promising application. One obstacle is the limited supply of adult stem cells 
and the inherent variation of primary cells. However, hESCs can provide a 




An important factor for the clinical application of adult stem cells in cancer 
therapy is the nature of their interaction with different branches of the immune 
system that are involved in tumor immunity. DCs are key modulators of 
immunity, they play a significant role in the tumor response, and their 
immunosuppression can overshadow the beneficial effects of administered 
cells. In fact, MSCs have been shown to have a strong suppressive effect on 
the activity of DCs (Jiang et al. 2005) and promote tumor growth in animal 
models (Djouad et al. 2003). Compared to the well-studied 
immunosuppressive effects of MSCs, there are few studies thus far that have 
investigated the effect of NSCs on the development of DCs. In chapter 3, we 
will compare the immunosuppressive effects of hESC-derived NSCs and 
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The genetic modification of DCs offers a promising approach to improve the 
antitumor function of DCs. In first part of this chapter, I will review the current 
methods used for the genetic modification of DCs. Baculovirus has emerged 
as a promising vector for the genetic modification of a wide range of 
mammalian cells, and it has been shown to induce the maturation of DCs, 
which makes it a suitable candidate for the delivery of transgenes to DCs. 
CD1d is a surface molecule that triggers the activation of a special subtype of 
T cells known as natural killer T (NKT) cells, which have shown promising 
antitumor potential. Therefore, CD1d is a suitable candidate as a functional 
transgene to be used in a baculoviral setting. 
 
2.1.1 Genetically engineered DCs for cancer gene therapy 
DCs have been studied as potential cancer vaccines due to their central role 
in antitumor immunity. There are numerous publications that have reported 
different treatments for the activation of DCs to fight tumors (Shurin et al. 
2010). These treatments include pulsing DCs with peptide epitopes of tumor-
specific antigens, tumor cell lysate, apoptotic or necrotic tumor cells and even 
the fusion of DCs with primary tumor cells. An alternative approach for 
directing the function of DCs is through the genetic engineering of these cells. 
 




1. Gene or mRNA encoding tumor-specific antigens can be introduced 
into DCs (Chan et al. 2006; Bontkes et al. 2007). The overexpression 
of these antigens will eventually lead to their presentation by DCs. 
2. To enhance the antigen-presenting function or the lifespan of DCs, 
genes encoding costimulatory molecules (Wiethe et al. 2003; 
Yurkovetsky et al. 2006), cytokines (Yamanaka et al. 2002), and 
antiapoptotic molecules (Pirtskhalaishvili et al. 2000; Balkir et al. 2004) 
can be introduced into these cells.     
 
Genetically modified DCs provide several advantages over antigen-loading 
strategies. First of all, expression of the antigen eliminates the need for 
knowledge of MHC molecules in patients and can also lead to the 
simultaneous expression of a wide range of antigens. Secondly, genetic 
engineering allows prolonged antigen presentation by DCs. Thirdly, viral 
vectors can trigger the maturation of DCs and cause a robust immune 
response (Smits et al. 2009).  
 
A wide range of viral vectors have been studied for use in gene delivery to 
DCs. Adenoviral vectors have been used to augment the function of DCs for 
cancer therapy and are reviewed in detail by Breckpot, et al. (Breckpot et al. 
2004) Insect baculoviral vectors have emerged as a promising tool for the 
genetic engineering of wide range of mammalian cells in the last two decades. 
The next section will cover the potential advantages of baculoviral vectors and 
will review the current understanding regarding the genetic modification of 




2.1.1.1 Baculoviral vectors for gene delivery to DCs 
Baculoviruses are a family of double-stranded DNA viruses, which infect more 
than 500 species of insects. Autographa californica multiple 
nucleopolyhedrovirus (AcMNV) is the most commonly used strain. The 
potential application of baculovirus as a gene delivery vector came to light 
after two groups demonstrated that baculoviral vectors harboring mammalian 
expression cassettes can induce the strong expression of transgenes in 
mammalian cells (Hofmann et al. 1995; Boyce et al. 1996). Following these 
pioneering studies, baculoviruses have been shown to transduce a wide 
range of cells of vertebrate origin (Wagle et al. 2003). 
 
 Several advantages make baculoviruses a plausible candidate for gene 
delivery to mammalian cells: 
 1. Baculoviruses do not replicate in mammalian cells, they have a low level of 
toxicity, and viral DNA is degraded in transduced cells over time (Kost et al. 
2005). 
  2. The large size of baculoviral genome allows for a significant cloning 
capacity of at least 38 kb of insert (Cheshenko et al. 2001).  
3. The production of the virus is easy, and high titers of virus can be produced 
through the infection of insect cells. 
 4. Due to the safe nature of baculoviruses in mammalian hosts, these viruses 




Baculoviruses have been shown to efficiently transduce many clinically 
relevant cells, including human coronary smooth muscles cells (Grassi et al. 
2006), MSCs (Ho et al. 2006), MSC-derived chondrogenic, adipogenic and 
osteogenic progenitor cells (Ho et al. 2006) and hESC-derived NSCs and 
neurons (Zeng et al. 2007; Zeng et al. 2009).  
 
Several studies have investigated the effects of baculoviral exposure on DCs. 
In humans and mice, the exposure of DCs to baculovirus leads to the strong 
expression of costimulatory molecules and the secretion of pro-inflammatory 
cytokines by these DCs (Schutz et al. 2006; Suzuki et al. 2010). However, 
there is no evidence that these effects are due to the transduction of DCs by 
baculovirus. In fact, it has been reported that while the exposure to 
baculovirus leads to a maturation phenotype in DCs, the expression 
frequency of the reporter gene is as low as 6.1% in a high multiplicity of 
infection (MOI) 1000 (Strauss et al. 2007). This low frequency of expression of 
the transgene has also been reported in other cell lines from the 
hematopoietic lineage (Abe et al. 2005; Kim, C. H. et al. 2007). However, the 
lack of expression of the transgene is not necessarily due to the inability of 
baculovirus to enter the cells, as baculoviruses have been shown to enter 
refractory DCs (Kim, C. H. et al. 2007). Other mechanisms, including nuclear 
transport or the rapid degradation of viral particles in the cytoplasm, might be 
the reason for the observed low transduction levels.  
 
As described in the introductory chapter, hESCs can be used as raw material 
for the production of DCs. Subsequently, baculovirally engineered hESCs can 
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provide an alternative means for the production of genetically modified DCs. 
Baculoviruses have also been reported to be efficient in the transduction of 
hESCs and have been used for the transient and stable expression of 
transgenes in hESCs (Zeng et al. 2007). In this study, recombinant 
baculovirus containing the elongation factor-1 (EF1) promoter and 
Woodchuck hepatitis post-transcriptional regulatory element (WPRE) were 
shown to transduce up to 80% of hESCs and embryoid bodies. In the same 
study, the stable expression of eGFP was induced using a hybrid system 
using the Rep gene and inverted terminal repeat sequences from adeno-
associated virus. A recent study also reported the stable expression of a 
transgene in hESCs using a system that includes zinc-finger nucleases for 
site-specific genetic engineering of hESCs (Lei et al. 2011). In both cases, the 
transduction of hESCs with baculovirus did not affect the expression of 
pluripotency markers or the differentiation potential of the hESCs. These 
observations implicate baculovirus as a plausible candidate for both the stable 
and transient genetic modification of hESCs.  A limitation for both studies was 
the use of mouse embryonic fibroblasts as feeder cells for the maintenance of 
hESCs. Feeder cells actively absorb the viral particles and subsequently limit 
the potential exposure window for the administration of baculovirus to cell 
clumps during the subculture of hESCs. Currently, feeder-free culture 
methods for hESCs (Ludwig et al. 2006) offer a new opportunity for 
baculoviral engineering of hESCs without the limitations of methods that rely 




In short, while exposure to baculovirus induces the maturation of DCs, the 
expression of reporter genes in DC populations via baculoviral transduction is 
low. The question of whether this low expression frequency can lead to 
functional improvements remains to be determined. Additionally, genetically 
modified hESCs provide a potential source for the production of engineered 
DCs. 
 
2.1.1.2 CD1d as a potential candidate gene for DC-based cancer therapy 
The CD1 family of glycoproteins, including CD1d, is expressed on the surface 
of human antigen-presenting cells. CD1d exclusively presents lipid antigens to 
special type of rare T cells also known as natural killer T (NKT) cells. CD1d 
has a conserved structure, and CD1d molecules from mice and humans can 
present lipids to the NKTs of the other species (Godfrey et al. 2005). It has 
been demonstrated that upon activation, NKT cells rapidly produce a wide 
range of cytokines, including interferon- (IFN-) and interleukin-4 (IL-4). –
Galactosylceramide (-GalCer) is a specific ligand for CD1d that triggers 
immune response by NKT cells upon presentation (Van Der Vliet et al. 1999). 
The presentation of DCs with -GalCer triggers a robust NKT response. The 
prominent anti-tumor role of NKT cells is well documented in both clinical 
studies and animal models (Dhodapkar 2009; Taniguchi et al. 2010; Hix et al. 
2011). In light of the above review, the CD1d gene is a promising candidate to 




Due to the central role of DCs in antitumor immunity, these cells are 
administered as cellular vaccines against cancer. However, the main source 
of these cells is progenitor cells harvested from donors through invasive 
procedures (Slukvin et al. 2006). In addition to being invasive, the number of 
cells harvested is limited, and there are inherent concerns regarding donor 
variation and safety issues involved in the use of primary cells. On the other 
hand, hESCs offer a renewable source for the production of DCs. As the first 
aim of this project, we attempted to harness this potential by producing DCs 
from hESCs and confirming the identity of these cells via morphological and 
surface marker analyses. 
 
The derivation of DCs from hESCs provides a unique opportunity to derive 
DCs from genetically modified hESC lines. A pure and stable hESC line will 
eliminate the need for the modification of DCs in each batch. In addition, if a 
transgene is inserted in safe genomic locations, it provides an advantage to  
genetically engineeredhESCs modified via random integration. Our lab has 
previously reported both the transient and stable genetic modification of 
hESCs on feeder cells (Zeng et al. 2007). The emergence of feeder-
independent culture methods for hESCs may potentially enhance the utility of 
baculoviral genetic engineering of hESCs (Ludwig et al. 2006). Subsequently, 
as the second aim for this project, we will investigate the baculovirus vector-
mediated transient expression of a reporter gene in hESCs. Should promising 
results occur, we will extend our approach to the production of stably modified 
hESCs via a novel hybrid system. These genetically modified hESCs will be 
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used to investigate this approach as a novel way of producing DCs that stably 
express a transgene. 
 
Baculoviruses have been shown to induce the maturation of DCs in other 
models. We will examine the direct effect of baculoviral transduction on 
hESC-DCs. We will investigate two independent CMV and EF1 promoters 
that have been shown to be efficient in other cell lines in the presence or 
absence of WPRE. Upon selection of the more favorable setting for the 
expression of the reporter gene, we will proceed to analyze the expression of 
CD1d on the surface of DCs after baculoviral transduction. We will also 
investigate the potential improvement of the therapeutic effects of hESC-DCs 
in an animal model for breast cancer.  




2.3 Material and methods 
2.3.1 Maintenance of hESCs and embryoid body formation 
H1 hESCs (WiCell, Madison, WI, USA) were cultured in feeder-free conditions 
according to the technical manual Maintenance of Human Embryonic Stem 
Cells in mTeSRTM1 (StemCell Technologies, Vancouver, BC, Canada). Stable 
colonies of genetically modified hESCs were produced as previously reported 
(Ramachandra et al. 2011) (Contributed by Chrishan J.A. Ramachandra). 
Embryoid bodies were generated by treating hESC colonies with dispase 
(Gibco) followed by scraping off the colonies of hESCs. Cell clumps were then 
transferred to non-coated bacterial plates in medium containing DMEM/F12 
supplemented with 20% KnockOut™ Serum Replacement (Invitrogen, 
SIngapore), 0.1 mM non-essential amino acids (Invitrogen), 1 mM L-glutamine 
and 1% penicillin-streptomycin. Half of the medium was changed every day, 
and total RNA was extracted from cultures on day 10 using TRIzol® 
(Invitrogen).    
 
2.3.2 Production and preparation of DCs from hESCs 
DCs were differentiated from hESCs following a published protocol (Slukvin et 
al. 2006). To summarize, 100-mm tissue culture dishes were coated overnight 
with 6 ml of 0.1% gelatin A (Sigma, Singapore). OP9 cells (ATCC, Manassas, 
VA, USA) were maintained on gelatin-coated dishes in 10 ml of OP9 growth 
medium, which consisted of α-MEM (Gibco-Invitrogen, Carlsbad, CA, USA) 
supplemented with 20% FBS (HyClone, Logan, UT, USA). OP9 cells were 
passaged every 4 days at a split ratio of 1 to 8. The OP9 cells were originally 
derived from newborn op/op mouse calvaria (Kodama et al. 1994). Due to a 
mutation in the M-CSF gene, these cells are unable to produce functional M-
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CSF. M-CSF impedes the differentiation of embryonic stem (ES) cells into 
blood cells other than macrophages.  To prepare OP9 cells for hematopoietic 
differentiation of hESCs, half of the medium was changed on day 4, and the 
culture dishes were maintained for an additional 4 days. On day 8, OP9 
medium was replaced with 20 ml of hematopoietic differentiation medium, 
which consisted of α-MEM supplemented with 10% FBS (HyClone) and 100 
μM monothioglycerol (MTG; Sigma). One well each of wild type and 
genetically modified hESCs was harvested and added to each dish of 
overgrown OP9 cells. The differentiation medium was fully replaced on day 1, 
and half of the medium was changed every 2 days beginning on day 4 of 
coculture.  For the expansion of myeloid progenitor cells, cocultured plates 
were harvested on day 8 using collagenase type IV and trypsin (Gibco-
Invitrogen), and the cell suspension was filtered through a 70 μM nylon filter 
(cell strainer; BD Labware, Bedford, MA, USA). Cells were resuspended in 20 
ml of expansion medium, which consisted of α-MEM supplemented with 10% 
FBS (HyClone), 100 μM MTG and 100 ng/ml GM-CSF (PeproTech, London, 
UK), and the cells were added to T75 flasks coated with the anti-adhesive 
polymer poly(2-hydroxyethyl methacrylate) (pHEMA; Sigma). Half of the 
expansion medium was changed on days 3, 6 and 8.   
 
For differentiation of myeloid precursors to DCs, the expanded suspension of 
cells was harvested on day 10. The cell suspension was filtered through a 70 
μM nylon filter, and dead cells were removed using 25% Percoll solution 
(Sigma). Cells were resuspended in 20 ml of dendritic differentiation medium, 
which consisted of StemSpan serum-free expansion medium (SFEM; Stem 
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Cell Technologies, Vancouver, Canada) supplemented with Lipid Mixture 1 
(Sigma), 100 ng/ml GM-CSF, and 100 ng/ml IL-4 (Peprotech). Half of the 
medium was changed every 4 days, and cells were harvested between days 8 
to 14 of differentiation. 
 
To prepare the cells for transplantation into an animal tumor model, DCs were 
transduced with baculovirus at an MOI of 100. After 24 hours, -
Galactosylceramide (-GalCer; Axxora, Switzerland) was added to cultures at 
a final concentration of 100 ng/ml for an additional 24 hours. Because -
GalCer was initially dissolved in PBS-10% DMSO, the control groups without 
-GalCer were treated with same amount of blank vehicle during the 
treatment with -GalCer. Cells were subsequently washed vigorously three 
times prior to injection.   
 
2.3.3 Baculovirus preparation and cell transduction 
Recombinant baculovirus was then produced and propagated in Sf9 insect 
cells according to the Bac-to-Bac Baculovirus Expression system manual 
(Invitrogen). In short, insert DNA is cloned into a pFastbac donor plasmid. 
This recombinant plasmid is then in turn used for transposition mediated 
delivery of insert into the bacmid using DH10bac cells. Recombinant bacmid 
DNA (which is the genome of baculovirus) is in turn used for transfection of 
insect cells which will produce the recombinant baculovirus stock.  
Recombinant baculovirus was constructed through the modification of the 
pFastbac1 shuttle vector (Invitrogen, Carlsbad, CA). Human cytomegalovirus 
immediate-early gene promoter and enhancer (cytomegalovirus [CMV] 
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promoter) was amplified by polymerase chain reaction (PCR) and placed 
between the BamHI and EcoRI cloning sites of the vector. The human 
elongation factor-1 (EF1) promoter, originally from pEF1V5-HisA 
(Invitrogen), was inserted between BamHI and EcoRI of pFastBac1. The 
woodchuck hepatitis post-transcriptional regulatory element (WPRE) is a DNA 
fragment that forms a tertiary structure when transcribed that increases 
expression and is, therefore, able to increase the expression in viral vectors 
(Lee, Y. B. et al. 2005). WPRE was PCR-amplified from psubCMV-eGFP-
WPRE (kindly provided by Dr. Juan Du) and inserted between SpeI and XbaI 
sites. The coding sequence of human CD1d was cloned from pORF9-hCD1D 
(InvivoGen, San Diego, CA) through PCR to include the Kozak consensus 
sequence upstream of its start codon, in addition to SalI and SpeI restriction 
sites at its termini. This fragment was added to the plasmid using its terminal 
restriction sites. Likewise, the coding sequence of enhanced green 
fluorescence protein was cloned from pF1CMV-eGFP-WPRE (kindly provided 
by Dr. Juan Du), which included EcoRI and SpeI restriction sites at its termini. 
These fragments were added to the plasmid using their terminal restriction 
sites (The pFastbac donor plasmid maps highlighting the respective restriction 
sites used are depicted in Figure 2.4). Empty pFastbac1 shuttle vector was 
used for the production of control baculovirus. 
Cell debris was removed from the viral solution through centrifugation for 15 
minutes at 500 g upon harvest. Viral particles were then were pelleted via 
centrifugation at 28,000 g for 60 minutes. The resulting pellet was then 
resuspended in appropriate volumes of 0.1 M phosphate-buffered saline 
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(PBS), and the viral titer (plaque-forming units [pfu]) was determined by 
plaque assay on Sf9 cells.   
 
Baculoviral vectors for stable and site-specific genetic modifications of hESCs 
were prepared as reported (Ramachandra et al. 2011) (Contributed by 
Chrishan J.A. Ramachandra). For transduction, the appropriate volumes of 
concentrated baculovirus for desired MOIs were added to the culture. U87 is a 
model glioma cell line used in this study for controlling the quality of produced 
baculovirus, these cells were maintained as reported (Wang et al. 2006).  
 
2.3.4 Animal tumor model 
4T1 cells were purchased from Caliper Life Sciences and maintained 
according to provided protocol. A total of 10,000 4T1 cells were injected into 
mammary fat pads of BALB/c mice to induce tumor formation. One week after 
injection of the tumor cells, 1 million DCs were administered to each animal 
group via tail vein injection. The survival of animals was monitored 
accordingly. SigmaStat (Jandel, San Rafael, CA) software was used for the 
statistical analysis of survival data. All handling and care of animals was 
carried out according to the Guidelines on the Care and Use of Animals for 
Scientific Purposes (National Advisory Committee for Laboratory Animal 
Research, Singapore).   
 
2.3.5 Characterization of differentiated cells 
Total RNA was extracted using TRIzol (Invitrogen), and SuperScript III First-
Strand Synthesis System (Invitrogen) was used for cDNA synthesis. DNA was 
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eliminated from samples using TURBO DNase (Ambion, Austin, 
TX). PCR was performed by adding the cDNA to Platinum Supermix 
(Invitrogen) as instructed. PCR reactions included an initial denaturation step 
at 94°C for 4 minutes followed by 30 cycles of 94°C for 30 seconds, 55°C for 
30 seconds, and 72°C for 60 seconds. Reactions were also subject to an 
additional extension at 72°C for 6 minutes after the last step. RT-PCR primers 
used are listed in Table 2.1. 
 
For the immunostaining of hESCs, cultures were fixed with PBS containing 
4% PFA and then permeablized with PBS-0.3% Triton X-100. Samples were 
subsequently blocked with PBS-5% BSA and incubated at 4C overnight with 
the primary antibody diluted in PBS-1%BSA. On the following day, samples 
were washed 3 times with PBS and incubated for 1 hour at room temperature 
with the secondary antibody. Samples were subsequently washed 5 times 
with PBS. Primary antibodies used for the detection of Oct-3/4, SOX2, Nanog 
and SSEA-4 in EGFP-hESC1 were obtained from the Human Embryonic 
Stem Cell Marker Antibody Panel Plus (R&D Systems MN, USA). The Texas 
Red-conjugated rabbit anti-mouse secondary antibody was obtained from 
Abcam (Cambridge, MA, USA), diluted in PBS-1% BSA and used accordingly. 
 For live cell imaging of cocultures, 100 µl of PE-conjugated CD34 antibody 
(clone 563, BD Biosciences) was added to 1 ml of medium in cocultures in 
each well of a 6-well plate. The same amount of isotype control was added to 
the control wells, and samples were observed under a microscope 15 minutes 




2.3.6 Flow cytometric analysis 
Flow cytometry was used to evaluate the morphology of the cells and the 
expression frequency of eGFP and surface markers. Cells were stained with 
monoclonal antibodies against human CD11c (clone B-ly6), CD34 (clone 
563), CD40 (clone 5C3), CD43 (clone 1G10), CD45 (clone HI30), CD80 
(clone L307.4), CD83 (clone HB15e), CD86 (clone 2331[FUN-1]) and their 
respective isotype controls (all obtained from BD Pharmingen, San Diego, 
CA). Flow cytometry data were obtained using a 
FACSCalibur flow cytometer (BD Biosciences) and analyzed using CellQuest 
software (BD Biosciences).     
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 Reverse: GATAAGCCCTTGCAAAGCGT 
 
BRACHYURY T 
 Forward: CAACCACCGCTGGAAGTAC 
 Reverse: CCGCTATGAACTGGGTCTC 
 
AFP 









 Reverse: CGTCGCCGATGGGGGTGTTC 
 
Homologous recombination detection   
Forward: ACTTCCTGACTAGGGGAGGAGTAGAAGGTG  
 Reverse: GTTGGTAGGGGTTTGAGTTCTCATCCTGTG 
 
Site-specific integration detection  
Forward: AAAGAAAGACAATCCTAGGAAGCAGGGTCA 







2.4.1 hESCs differentiate into DCs after three phases of culture 
In order to produce DCs from hESCs we followed a published protocol by 
Slukvin et al. with minor amendments (Slukvin et al. 2006). We however 
maintained our hESCs in feeder free condition. Based on this approach the 
production of DCs from hESCs involves three phases of differentiation. In the 
first phase, hESCs are differentiated into hematopoietic progenitor cells 
(HPCs). The second phase involves the differentiation of HPCs into myeloid 
progenitor cells (MPCs) using GM-CSF in suspension culture. The last phase 
involves the derivation of DCs from MPCs via exposure to GM-CSF and IL-4.  
The overall pathway of the generation of DCs from hESCs is summarized in 
Figure 2.1. 
 
2.4.1.1 hESCs differentiate into HPCs upon coculture with OP9 cells 
The generation of blood progenitor cells is the initial step in the derivation of 
DCs from hESCs. OP9 cells have been shown to promote the hematopoietic 
differentiation of hESCs, hence the coculture of hESCs with OP9 cells 
(Vodyanik et al. 2005) (Figure 2.2 A). Next, we monitored the presence of 
HPCs in our cocultures via flow cytometry for the expression of the human 
CD34 marker. Expression frequency of CD34 was detected in more than 3% 
of cells on day 6 and peaked at more than 7% of population on day 10 and 
expressed by more than 5% of cells in subsequent time points.  (Figure 2.2 
B). Day 10 was chosen as the suitable time point for the harvest of cocultures 




CD43 is another marker for human HPCs (Vodyanik et al. 2006). The day 10 
population was further evaluated for the presence of CD43, and a distinct 
population of cells with strong expression of CD43 was observed, further 
confirming the successful expansion of HPCs (Figure 2.2 C). 
 
 To investigate the localization of CD34+ cells in the cocultures, we proceeded 
with live cell immunostaining of differentiated hESC colonies. Interestingly, the 
main population of CD34+ cells is located in the peripheral regions of 
differentiated colonies with OP9 stromal cells. CD34+ cells form organized 
root-like structures that penetrate the OP9 portion of the coculture. OP9 cells 
are mouse bone marrow stromal cells and share many characteristics of 
MSCs, including morphology and the potential to differentiate into adipocytes. 
We subsequently speculate that the observed structure might mimic the niche 
of the HPCs in the bone marrow. 
 
Our finding confirms the reported expansion of CD34+ cells from hESCs in the 
presence of OP9 cells. Based on the above observations, day 10 was 
selected as the optimal time point for harvest, followed by the differentiation of 








Figure 2.1. Overview of the derivation of DCs from hESCs. (A) Cell 
lineages involved in differentiation of DCs from hESCs are listed. (B) 
Schematic diagram of steps involved in production of dendritic cell highlighting 
the important aspects of each step. P, phase. Figure is adapted from Slukvin 






Figure 2.2. hESCs differentiate into HPCs upon coculture with OP9 cells. 
(A) hESCs were cocultured with OP9 cells to induce hematopoietic differentiation. 
(B) Cultures were harvested and analyzed for the expression of the hematopoietic 
progenitor marker CD34 every 4 days from day 2 until day 18. The grey line 
represents stained cells, and the black line represents the isotype control. (C) The 
expression of the CD43 marker in the harvested population on day 10 was monitored 
via flow cytometry. (D) Live cell staining of samples on day 10 shows the localization 
of CD34 cells in coculture. Upper row, phase-contrast; bottom row, immunostaining 
with PE-conjugated anti-human CD34 antibody (CD34) and the respective isotype 
control (Iso). Data shown are representative of two independent experiments. Scale 
bars: , 100 µm; , 500 µm.   
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2.4.1.2 HPCs differentiate into MPCs in the presence of GM-CSF 
Phase 2 induces the expansion and differentiation of HPCs into MPCs in the 
presence of GM-CSF. Harvested cocultures from phase 1 were transferred to 
non-adherent pHEMA coated flasks in the presence of GM-CSF for 10 days.  
After the first 24 hours, adherent cells, including OP9 stromal cells, form 
round clumps of cells in suspension. In contrast, the differentiated population 
of MPCs stays in suspension as single floating cells. This distinctive 
localization of MPCs paves the way for their downstream purification (Figure 
2.3 A). At the end of phase 2, cell clumps were removed using a cell strainer. 
Next, dead cells were excluded from the culture via Percoll purification. Flow 
cytometry was performed to assess the expression frequency of the leukocyte 
specific marker CD45, confirming that the yielded population is purely derived 
from a leukocyte origin (Figure 2.3 B).          
 
2.4.1.3 MPCs differentiate into DCs in the presence of GM-CSF and IL-4 
Harvested cells at the end of phase 2 were transferred to pHEMA-coated 
plates for their differentiation into DCs via exposure to IL-4 and GM-CSF. At 
the end of phase 3, cells started to increase in size and show DC-specific 
morphology, which includes the presence of numerous cytoplasmic 
appendages (veils). Cells were then transferred to normal wells of a plastic 6-
well plate to allow the attachment of the cells with the distinctive 
characteristics of DCs, including high granularity and branch-like appendages 
(Figure 2.3 C). The resulting DCs were also analyzed for the expression of 
surface markers of the DC lineage (Figure 2.3 D). The majority of cells were 
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found to express CD11c, CD86 and CD80, which are important markers of the 
DC lineage.   
Hence, both morphological characteristics and the surface marker expression 
of cells at the end of phase 3 confirm the successful production of DCs from 





Figure 2.3. Cells harvested from suspension cultures exhibit the 
morphology and markers of DCs. (A) Phase 2 cultures were observed under the 
microscope. (B) Clumps and dead cells were removed from cultures at the end of 
phase 2, and the subsequent population was analyzed for the expression of leukocyte-
specific marker CD45 via flow cytometry. (C) At the end of phase 3, cultures were 
observed microscopically (left). Clumps were removed, and cells were individually 
observed under the microscope (middle) or transferred to cell culture plates to allow 
the attachment of cells. Attached cells were observed at 48 hours post-transfer (right).  
(D) Populations at the end of phase 3 were analyzed for the expression of DC lineage 
markers. Experimental groups (black line) were compared with their respective 
isotype controls (grey line).Data shown are representative of three independent 




2.4.2 Stable transgene expression in hESC-DCs using baculoviral 
vectors  
It is suggested that genetically modified DCs can be used to regulate the 
function of immune system (Lu et al. 1999; Ribas 2005). We confirmed 
production of DCs from unmodified hESCs in previous section. Additionally, 
hESCs have been shown to be modified by baculoviral vectors (Zeng et al. 
2007). We subsequently decided to investigate the possibility of usage of 
baculovirally modified stable hESCs as a renewable source for production of 
genetically modified hESC-DCs. We first investigated the potential application 
of baculoviral vectors for the stable genetic modification of hESCs in feeder-
free culture conditions. Next, we demonstrated that these engineered hESCs 
can be used for the derivation of DCs that stably express the transgene. 
  
 2.4.2.1 Baculoviral vectors harboring EF1 or CMV promoters in 
combination with WPRE were constructed, and their expression was 
confirmed in U87 cells    
The CMV promoter and EF1 promoter are two commonly used promoters 
with strong expression in mammalian cells (Kim, J. H. et al. 2005; Zheng et al. 
2005). WPRE is a DNA fragment that forms a tertiary structure when 
transcribed that increases expression and is, therefore, able to increase the 
expression in viral vectors (Lee, Y. B. et al. 2005).  We subsequently decided 
to compare the expression frequency of the reporter eGFP under the control 
of these two promoters in the presence or absence of WPRE.  After cloning 
the fragments into the multiple cloning site of pFastBac1 as depicted in Figure 
2.4 A, the vectors were used for the transformation of DH10Bac competent 
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bacteria to produce the viral genome. The viral genome was subsequently 
used for the transfection of Sf9 insect cells to produce viral particles. 
Baculoviruses were expanded for three passages on Sf9 cells. On the third 
passage, the supernatant containing the viral particles was harvested, 
concentrated and titrated via plaque assay. U87 is a model glioma cell line 
that has been reported permissive to baculoviral transduction (Wang et al. 
2006). Therefore, we confirmed the function of produced viruses by 
transducing U87 cells at a multiplicity of infection (MOI) of 100 (Figure 2.4 B). 
Microscopic observation and flow cytometric analysis confirmed the 
expression of eGFP after transduction with four types of baculovirus. As 
expected, the presence of WPRE increased the intensity of eGFP expression 





Figure 2.4. Baculoviral vectors harboring EF1 or CMV promoters in 
combination with WPRE were constructed, and their expression was 
confirmed in U87 cells.  (A) Schematic presentation of eGFP expression 
cassettes in targeting vector used for virus production. (B) U87 cells were 
transduced at an MOI of 100 with baculoviral vectors. Cells were 
subsequently used for microscopic observation and flow cytometry at 48 
hours post-transduction. The results presented are representative of two 
independent experiments.  
Scale bar: , 100 µm; E.E., Ef1α promoter-eGFP; E.E.W., Ef1α promoter-
eGFP-WPRE; C.E., CMV promoter-eGFP; C.E.W., CMV promoter-eGFP-
WPRE; MFI: Mean Fluorescence Intensity.  
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2.4.2.2 Baculoviruses can efficiently transduce hESCs in feeder-free 
culture conditions   
Baculoviral vectors have been reported as promising vectors for the genetic 
modification of hESCs on feeder cells (Zeng et al. 2007). However due to 
absorption of viral particles by feeder cells, baculoviral modification of hESCs 
is only limited to subculture process when hESC clumps are free from feeder 
cells. To address this limitation we decided to investigate the efficiency of 
baculoviral transduction of hESCs in feeder-free conditions. hESC colonies 
were transduced with the baculoviral vector expressing eGFP under 
regulation of EF1 promoter and WPRE element at an MOI of 100 for one or 
two days and were monitored under a microscope or via flow cytometry 24 
hours after transduction for the expression of eGFP. eGFP expression was 
observed in hESC colonies after two days of transduction (Figure 2.5 A). Flow 
cytometry further confirmed robust transgene expression in the majority of 
cells (Figure 2.5 B). These observations demonstrate that baculoviruses can 
efficiently transduce hESCs. This finding paved the way for the stable genetic 
engineering of hESCs described in the following. Morphological comparisons 
of hESCs by microscopy and by monitoring the side scatter (SSC) and 
forward scatter (FSC) of transduced populations compared to wild-type 
hESCs using flow cytometry indicated no significant change in cell 
morphology (Figure 2.5 C).  
 
In short, baculoviruses were demonstrated to be an efficient vector for the 
transduction of hESCs in feeder-free conditions. In addition, no drastic 




Figure 2.5. hESCs are efficiently transduced by baculoviruses in feeder-
free condition while retaining their normal morphology. hESCs were 
maintained in feeder-free conditions for 4 days. Cells were then transduced 
with baculovirus containing eGFP under the control of EF1  promoter, 
followed by WPRE, at an MOI of 100 for one or two subsequent days. Normal 
hESCs were used as the control. (A) The morphologies of transduced hESCs 
for two days were compared with normal hESCs via microscopic observation 
(phase-contrast), and the expression of eGFP was also assessed 
(fluorescence). (B) Cells were analyzed by flow cytometry to measure the 
expression of eGFP (grey line) after one or two days of transduction; 
untransduced cells were used as the control (black line). (C) Comparison of 
SSC and FSC in normal hESCs (black line) with cells transduced for one day 
(pale grey) and two days (dark grey). Scale bar: , 100 µm.   
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2.4.2.3 Production of genetically modified hESCs via recombinase-
mediated cassette exchange at AAV1 locus using baculoviral vectors    
The adeno-associated virus integration site 1 locus (AAVS1) resides within 
protein phosphatase 1 regulatory subunit 12C (PPP1R12C) and has been 
shown to be resistant to gene silencing (Lamartina et al. 2000; Philpott et al. 
2004). There are no reports of any side effects upon insertion of expression 
cassettes into this location (DeKelver et al. 2010). The Cre/loxP system is an 
efficient tool for the genetic engineering of mammalian cells in which Cre 
recombinase targets loxP sites and exchange a genomic fragment flanked by 
two loxP sequences (Sauer et al. 1988; Nagy 2000).  
 
In the previous section, we reported that baculovirus can efficiently transduce 
hESCs in feeder-free conditions. We subsequently decided to use our 
baculoviral technique to produce stable colonies of genetically modified 
hESCs. Baculoviruses were used as delivery vector for exchange cassettes to 
deliver the desired expression cassettes into the AAVS1 site using the 
Cre/loxP system.  
 
Stable cell lines containing loxP sites in their AAVS1 site were produced using 
homologous recombination. For this purpose, the pBS-PGK-neo-lox vector 
containing a floxed neomycin resistance marker flanked by left and right 
homology arms with ~7kb of homology with the PPP1R12C gene was used 
(Figure 2.6 A) This vector was used for the transfection of hESC colonies in 
three independent experiments. A total of 39 colonies grew after G418 
selection.  To validate the site-specific integration of this vector, DNA was 
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extracted from these colonies and used for PCR amplification. Primer specific 
for the PGK promoter present in the vector (Forward homologous 
recombination detection primer in Table 2.1) and primer specific for 
chromosome 19 (Reverse homologous recombination detection primer in 
Table 2.1), downstream of the right homologous arm, were used for 
amplification. The amplification of a 3.3 kb fragment indicated the modification 
of AAVS1 (Figure 2.6 B). In total, 11 out of 39 colonies were found to contain 
the modified locus. Loxp-hESC2 was used as the master cell line for 
downstream studies.  
 
We subsequently proceeded with Cre recombinase-mediated cassette 
exchange using our baculoviral system.  First, the baculovirus vector was 
designed to encode the Cre recombinase (BV-EF1-Cre), whereas the 
second vector was designed to act as the transgene donor (BV-EF1-EGFP-
hyg-lox) (Figure 2.6 C). Both viruses were used to simultaneously transduce 
hESC colonies, and 2 days after transduction, the cells were subjected to 
hygromycin (25 µg/ml) selection for 3 weeks. A total of 33 EGFP-hESC 
colonies exhibiting the stable expression of eGFP were derived from three 
independent experiments. Site-specific cassette exchange was validated 
through by subjecting the DNA harvested from hESC colonies for PCR 
amplification. One primer set was designed specifically for chromosome 19 
(Forward site-specific integration detection primer in Table 2.1) and the other 
for the EF1 promoter within the exchange cassette (Reverse site-specific 
integration detection primer in Table 2.1). Amplification of a 4.2 kb fragment 
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confirmed the site-specific integration of the exchange cassette in 30 colonies. 
EGFP-hESC1 cells were used for downstream studies (Figure 2.6 D). 
 
Microscopic observation of the EGFP-hESC1 cells confirms the stable 
expression of the transgene (Figure 2.7 A). This observation was further 
confirmed using flow cytometry, which indicated that the hESC populations 
maintain their expression of eGFP even 20 weeks after selection (Figure 2.7 
B). The expression of pluripotency markers by genetically engineered 
colonies was assessed using immunostaining (Figure 2.7 C). The cells were 
positive for the expression of the pluripotency markers Oct-3/4, SOX2, Nanog 
and SSEA-4. To investigate the potential of hESCs to differentiate into the 
three germ layers, embryoid bodies were generated from these cells. 
Microscopic observation confirmed that eGFP expression is stable after 
differentiation into EBs, and RT-PCR indicated the presence of endoderm, 
mesoderm and ectoderm markers and the absence of pluripotency marker 
expression (Figure 2.7 D, E). These observations indicate that genetically 
engineered hESCs maintain their differentiation potential to form the three 
germ layers.  
 
The abovementioned data collectively demonstrate that recombinant 
baculoviral vectors can be used for the strong induction of stably expressed 
transgenes in hESCs without any significant side effects. These genetically 
modified hESCs also maintain their pluripotency and the expression of the 




     
 
Figure 2.6. LoxP-hESCs were generated via homologous recombination, 
and the eGFP gene was introduced into the AAV1 site of loxP-hESCs. 
(A) Schematic overview of homologous recombination at AAVS1 within the 
PPP1R12C gene, the targeting vector, and the modified AAVS1 with 
heterospecific lox sites following homologous recombination. e1, e2 and e3: 
the first three exons of the PPP1R12C gene. (B) PCR analysis to confirm 
recombination at AAVS1. LoxP-hESC clones were identified through the 
amplification of a 3.3 kb fragment, as indicated in (A).  
(C) Schematic representation of the generation of the EGFP-hESC line 
through BV-RMCE. LoxP-hESC2 cells containing a genomically modified 
AAVS1 were transduced with two baculoviral vectors for site-specific 
transgene integration. (D) PCR analysis to confirm the site-specific transgene 
integration. EGFP-hESC clones that underwent site-specific integration were 
identified through amplification of a 4.2 kb fragment, as indicated in (C).  (The 
data presented here is published as Fig. 1 and Fig. 2 in Nucleic Acid 






Figure 2.7. Genetically engineered hESCs exhibit stable transgene 
expression after AAVS1 integration while maintaining their pluripotency 
markers and differentiation potential. Loxp-hESC2 cells were transduced 
with baculovirus to insert the eGFP cassette within the AAVS1 region. 
Resulting colonies underwent selection for 3 weeks and were monitored at 3 
and 20 weeks after selection. (A) Microscopic images of transduced loxp-
hESC2 colonies immediately after transduction (left) and 3 and 20 weeks after 
selection (middle, right). (B) EGFP expression was monitored in EGFP-
hESC1 cells via flow cytometry. The cells were collected and analyzed at 3 or 
20 weeks after selection (grey line). Unmodified cells were used as the control 
(black line). (C) EGFP-hESC1 cells were used for immunostaining of the listed 
pluripotency markers at 20 weeks after selection. (D) Embryoid bodies were 
formed from EGFP-hESC1 cells and observed under a microscope for eGFP 
expression. (E) RNA was extracted from embryoid bodies on day 10, and the 
expression of different germ layer markers was confirmed via RT-PCR. Scale 
bar: ,100 µm. (The data presented here is published as Fig. 3 in Nucleic 
Acid Research, 2011, 1-13, doi:10.1093/nar/gkr409).  
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2.4.2.4 Production of pure populations of genetically modified DCs from 
stable colonies of engineered hESCs 
Genetically modified hESCs can offer a renewable source for production of 
genetically modified DCs without the need for genetic modification of 
individual batches of cells. We subsequently decided to investigate the 
potential usage of our baculovirally modified hESCs as a source for the 
derivation of genetically modified DCs. DCs were produced from genetically 
modified EGFP-hESC1 cells following the procedure that was described in 
sections 2.3.1-3. Microscopic observation confirms the expression of the 
transgene at the end of phase 3 in most of the DCs. Flow cytometric analysis 
also confirmed expression of eGFP by a majority of the harvested cells at the 
end of phase 2 and phase 3 (Figure 2.8 B). Robust expression of the 
leukocyte specific marker CD45 at the end of phase 2 and DC markers at the 
end of phase 3 further confirmed that genetically modified hESCs retain their 
potential to differentiate into DCs (Figure 2.8 C, D).  
 
Based on the above mentioned data, we demonstrate that baculovirally 
modified hESCs can provide a renewable source for the production of 





Figure 2.8.  EGFP expressing DCs were successfully derived from 
EGFP-hESC1 cells. EGFP-hESCs were used for the derivation of DCs. 
Intermediate MPCs and DCs were subsequently monitored for expression of 
eGFP and lineage-related markers. (A) Phase 3 cultures were observed 
under a microscope to observe eGFP expression. (B) At the end of phases 2 
and 3, populations were monitored for eGFP expression (black line). DCs 
derived from wild-type hESCs were used as the control (grey line) (C) At the 
end of phase 2, the expression of the leukocyte-specific marker CD45 was 
investigated via flow cytometry (black line) and compared with the respective 
isotype control (grey line). (D) At the end of phase 3, cultures were used for 
the expression of DC markers. Experimental groups (thick line) were 
compared with their respective isotype controls (thin line). Results shown are 
representative of three independent experiments. Scale bar: , 100 µm.  
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2.4.3 Transient transgene expression in hESC-DCs using baculoviral 
vectors 
Baculoviruses have been shown to induce the maturation of DCs (Schutz et 
al. 2006). Baculovirus has also been used for successful gene delivery to a 
range of mammalian cells possibly through endosomal escape mechanism 
(Hu, Y. C. 2008). We therefore decided to investigate the possibility of using 
baculoviruses to directly induce the expression of a transgene in hESC-DCs. 
We first investigated the expression of eGFP as a reporter gene in different 
expression cassettes to choose the most efficient combination, and we then 
used this cassette for the expression of a functional surface marker gene with 
potential downstream applications.  
 
2.4.3.1 Baculoviral vectors can transduce hESC-DCs and induce 
maturation in these cells 
Due to the vast number of potential applications for genetically engineered 
DCs, we decided to investigate direct transgene expression in DCs using 
baculoviral vectors. Wild-type hESC-DCs were transduced with baculoviral 
vectors mentioned in section 2.4.2.1 to determine the preferred setting for the 
expression of eGFP. The maximum transduction efficiency was observed in 
the group infected with a baculovirus vector containing the CMV promoter in 
the presence of WPRE at an MOI of 1000. At an MOI of 100, the strength of 
the signal was stronger in the transduced group with the abovementioned 
vector; however, the transduction efficiency was within a similar range in the 
different groups (Figure 2.9 A). Expression of eGFP was also confirmed in 
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baculovirally transduced hESC-DCs via microscopic observation (Figure 2.9 
B). 
 
We then proceeded to monitor the effect of baculoviral transduction on the 
expression of a major dendritic cell maturation marker, CD83. Expression of 
CD83 was almost doubled after transduction with the baculovirus at an MOI of 
100 compared to the untransduced group. Our observation highlights the 
potential application of baculoviruses both as an adjuvant for the maturation of 





Figure 2.9. Different baculoviral vectors were compared for their ability 
to deliver the transgene to hESC-DCs.  (A) hESC-DCs were harvested at 
the end of phase 3 and transduced with the eGFP-containing baculoviral 
vectors (black line) mentioned in figure 2.4 at MOIs of 100 (upper panel) and 
1000 (lower panel). hESC-DCs transduced with control baculovirus containing 
an empty expression cassette were used as the control group (grey line). 
Flow cytometry was performed 48 hours after transduction. (B) Microscopic 
observation of a transduced hESC-DC at an MOI of 100 with C.E.W. is 
provided. (C) The effect of transduction with baculovirus at an MOI of 100 on 
the expression of the DC maturation marker CD83 was investigated via flow 
cytometry 48 hours after transduction. Data provided are representative of 
three independent experiments. E.E., Ef1α promoter-eGFP; E.E.W., Ef1α 




2.4.3.1 Transduction of hESC-DCs with CD1d-containing baculovirus 
leads to the overexpression of CD1d and elevated CD83 expression  
Due to the earlier success in the induction of eGFP expression in hESC-DCs 
via baculoviral vectors, we decided to use this system to induce the 
expression of a functional gene in our hESC-DCs. It has been reported that 
the expression of CD1d on the surface of antigen-presenting cells in the 
presence of -GalCer can induce a robust immune response by NKT cells 
(Borg et al. 2007). Therefore, we decided to induce the expression of CD1d in 
hESC-DCs using our baculoviral system.  The coding sequence of CD1d was 
cloned into a plasmid backbone that was, in turn, used for baculovirus 
production (Figure 2.10 A). The functionality of this CD1d-harboring 
baculovirus (CD1d-BV) was tested via the transduction of U87 cells (Figure 
2.10 B). Strong expression of CD1d was observed in transduced cells, 
confirming the functionality of the expression cassette. Next, we used the 
same virus for the transduction of hESC-DCs. To confirm that the 
overexpression of CD1d is due to the expression of the transgene and not 
due to a nonspecific adjuvant effect of the baculovirus, we included a control 
group of cells transduced with baculovirus containing the empty expression 
cassette (Ctrl-BV). Flow cytometric observation after 48 hours confirmed the 
successful upregulation on the surface of CD1-BV. In addition, the 
overexpression of the CD83 maturation marker was observed in the presence 
of baculovirus in both the CD1d-BV and the Ctrl-BV group. This observation 






Figure 2.10. Transduction of U87 cells and hESC-DCs with CD1d 
baculovirus leads to the overexpression of CD1d as well as elevated 
expression of CD83 in hESC-DCs. (A) Schematic representation of the 
CD1d-containing expression cassette in targeting vector used for virus 
production. (B) CD1d baculovirus (CD1d-BV) was used for the transduction of 
U87 cells at an MOI of 100, and frequencies of CD1d expression were 
measured 48 hours post-transduction by flow cytometry. (C) hESC-DCs were 
harvested and transduced with CD1d baculovirus at MOI 100. Frequencies of 
CD1d and the maturation marker CD83 (grey line) were measured against 
their respective isotype controls (black) at 48 hours post-transduction via flow 
cytometry. Baculovirus containing an empty expression cassette (Ctrl-BV) 
was used as the control. Percentages of positive cells are shown below each 




2.4.4 Genetic modification of hESC-DCs with the CD1d baculoviral 
vector improves the survival rate in an animal tumor model  
We used a tumor model to investigate the effects of the genetic modification 
of hESC-DCs with CD1d baculovirus. A schematic view of the experimental 
procedure is provided in figure 2.11 A. In short, 50,000 4T1 cells were injected 
into the mammary fat pad of BALB/c mice to induce tumor formation one 
week before the administration of DCs. hESC-DCs were transduced with 
CD1d baculovirus at an MOI of 100. -GalCer was added to the cultures 24 
hours after transduction to a final concentration of 100 ng/ml. Forty-eight 
hours after transduction, cultures were extensively washed three times, and 1 
million DCs were injected into tumor-bearing mice. The survival rates were 
monitored accordingly (Figure 2.11 B). Control groups included DCs 
transduced with CD1d baculovirus (CD1d-BV) as well as DCs transduced with 
control baculovirus (Ctrl-BV) and treated with -GalCer. Interestingly, 
administration of DCs transduced with CD1d-BV alone or transduced with 
Ctrl-BV in the presence of -GalCer increased the lifespan of tumor-bearing 
animals. However, this improvement was not statistically significant. As 
expected, only the presence of both CD1d and treatment with -GalCer 
significantly increased lifespan. These data demonstrate that the genetic 
modification of DCs via baculoviral vectors can significantly improve the 






Figure 2.11. Genetic modification with CD1d followed by treatment with 
-GalCer significantly improves the therapeutic effect of hESC-DCs in a 
4T1 breast cancer model. (A) hESC-DCs were transduced with CD1d 
baculovirus at an MOI of 100. -GalCer was added to the cultures 24 hours 
after transduction to a final concentration of 100 ng/ml. Forty-eight hours after 
transduction, cultures were extensively washed and injected into tumor-
bearing mice. The survival rates were then evaluated (B). Control groups 
included were DCs transduced with CD1d baculovirus (CD1d-BV) and DCs 
transduced with control baculovirus (Ctrl-BV) treated with -GalCer (Gal). ***, 
p<0.001.  (Data presented were coauthored with Dang Hoang Lam). All 
handling and care of animals was carried out according to the Guidelines on 
the Care and Use of Animals for Scientific Purposes (National Advisory 
Committee for Laboratory Animal Research, Singapore). 





In this section we first discuss the successful derivation of DCs from hESCs 
following a published protocol with minor amendments. Next we cover the 
baculoviral genetic modification hESC-DCs at hESC or DC stages. After that 
we elaborate on genetic modification of hESC-DCs with CD1d gene and 
subsequent improvement in survival of a breast cancer tumor model upon 
administration of these cells. Last, future direction of baculoviral genetic 
modification of hESC-DCs based on our current findings will be discussed.    
 
2.5.1 Validation of DC production from hESCs 
Limitations of production of DCs from their primary progenitor cells make 
hESCs a plausible source for DCs (Slukvin et al. 2006). Several publications 
have covered production of DCs from hESCs in recent years (Senju et al. 
2007; Vodyanik et al. 2007; Bandi et al. 2008). Population of cells produced 
via method described by Bandi et al. is heterogeneous and impure for DC 
markers, which is evident in provided flow cytometric graphs (Bandi et al. 
2008). The protocol described by Senju et al. also suffers from a similar 
drawback (Senju et al. 2007). In fact, no quantitative value is provided in their 
study to demonstrate the purity of the final population of DCs. In addition 
compared to method described by Slukvin et al. this study relies on usage of 
an additional cytokine (macrophage colony-stimulating factor, M-CSF) which 
increases the cost of the differentiation procedure (Slukvin et al. 2006). On the 
other hand, protocol described by Slukvin et al. provides a reliable way for 
production of a pure population of hESC-DCs as demonstrated by elaborate 
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and quantitative characterization of DCs in their study. We subsequently 
produced DCs from hESCs following this publication in three steps.  
 
The first step for production of hESC-DCs involves the derivation of HPCs 
from hESCs. This aim is achieved through coculture of hESCs with OP9 cells. 
The OP9 cells were originally derived from newborn op/op mouse calvaria 
(Kodama et al. 1994). Due to a mutation in the M-CSF gene, these cells are 
unable to produce functional M-CSF. M-CSF impedes the differentiation of 
embryonic stem (ES) cells into blood cells other than macrophages. Upon 
coculture with mouse ES cells, OP9 cells promote the differentiation of the 
mouse ES cells into myeloid, lymphoid, erythroid and megakaryocyte lineages 
(Nakano et al. 1994; Nakano et al. 1996; Eto et al. 2002). OP9 cells have also 
been reported to support the derivation of human CD34+ cells from hESCs 
(Vodyanik et al. 2005). 
 
In our study we used H1 cells maintained in feeder free and defined condition 
for coculture with OP9 cells as opposed to the original publication which relies 
solely on maintenance of hESCs on feeder cells. Following a brief monitoring 
of CD34 expression we harvested the cells at day 10 for further differentiation 
to DCs. The percentage of CD34+ cells observed in our experiments is lower 
than the original report at this time point (around 6% as opposed to 9%) and 
CD43 expression is higher (around 8% as opposed to 5%). These variations 
might be due to differences in maintenance of the original populations of 
hESCs with regards to feeder cells. Additionally, variations in batches of OP9 
cells might be the source of observed differences. Nevertheless, these 
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differences had no impact on successful derivation of pure population hESC-
DCs in subsequent steps.   
 
Next HPCs were differentiated into MPCs through suspension culture in 
presence of GM-CSF. As mentioned above, in both original protocol and our 
experiments the initial percentage of harvested HPCs after phase 1 is low. 
However, only hematopoietic cells are capable of division in suspension 
culture in this step. On the other hand, irrelevant lineages and OP9 cells form 
cell aggregates in suspension culture. Hence, through removal of dead cells 
and cell aggregates from culture at the end of phase 2, a pure population of 
MPCs derived from HPCs could be obtained (more than 95% of population 
was positive for pan-leukocyte marker CD45). Next, MPCs were differentiated 
into DCs through exposure to GM-CSF and IL-4 in another round of 
suspension culture. In line with the original report, the expression of surface 
markers, including CD11c, CD80 and CD86, as well as the observed 
morphological characteristics of high granularity and veil structures confirm 
the identity of our cells as DCs. Our relative yield of DCs from four 
independent experiments per seeded hESC was 4.3 ± 2.1 (mean± SD) which 




2.5.2 Baculoviral modification of hESC-DCs 
We then investigated two different approaches for production of genetically 
modified DCs. In the first approach we used baculoviral vectors to produce 
stable colonies of genetically modified hESC. We then used these modified 
hESCs for derivation of engineered DCs. This approach provides a renewable 
source of DCs and eliminates the need for genetic modification of individual 
hESC-DCs batches. In the second approach we used baculoviral vectors for 
genetic modification of differentiated hESC-DCs to investigate duel role of 
baculovirus as both activator of hESC-DCs and as a gene delivery vector. 
 
2.5.2.1 Production of engineered DCs from baculovirally modified hESCs    
Our lab has reported both transient and stable genetic engineering of hESCs 
cultured on feeder cells (Zeng et al. 2007). However, feeder cells absorb most 
of the baculoviral particles and, hence; represent an obstacle for the efficient 
transduction of hESCs. In our earlier technique, the transduction of hESCs 
was limited to subculture times, when pure clumps of hESCs were exposed to 
baculoviral particles. In the current study, we expanded our work to feeder-
free hESC culturing condition (Ludwig et al. 2006). We observed a 
transduction efficiency of almost 90% upon one round of transduction and 
almost 100% after a second round of transduction, without any significant 
effect on morphology of the cultured cells. 
 
 Based on these encouraging observations, we proceeded with the stable 
modification of hESCs using a hybrid baculoviral system in combination with a 
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strong Cre/loxP site-specific recombination technique. We first inserted the 
loxP sequences into the safe genomic location of AAVS1 (Lamartina, Sporeno 
et al. 2000; Philpott, Gomos et al. 2004) using transfection and the 
homologous recombination technique. Derivation a primary hESC clone with 
this approach proved to be error prone with regards to site specific integration 
of the vector. The colonies were assessed both by PCR and Southern blot for 
screening the correct insertion of the loxP-harboring vector. We then 
proceeded with the introduction of the Cre recombinase and an exchange 
cassette with eGFP under the control of the Ef1 promoter using our efficient 
baculoviral system.  
 
This method proved to be very accurate with nearly all selected colonies 
containing an eGFP vector integrated into the AAVS1 site.  After selection, 
these colonies proved to maintain a high level of transgene expression over 
prolonged passages and exhibited key characteristics of hESCs, including the 
expression of the pluripotency markers OCT4, SOX2 and Nanog. These cells 
also retained their differentiation potential to form all three germ layers, as 
investigated by EB formation and the observed expression of specific markers 
of each layer.  
 
Upon the successful derivation of a stable hESC line expressing eGFP as 
reporter gene, we used this cell line for the production of hESC-DCs. Cells 
retained a high frequency (more than 95%) of transgene expression 
throughout the development and differentiation of the DCs. The produced 
cells also expressed key morphological features and surface markers of the 
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DC lineage, including CD11c, CD40, CD86 and CD209. These observations 
confirm that our method offers a venue for the production of genetically 
modified DCs with safe genomic profiles from genetically engineered hESCs. 
 
2.5.2.2 Direct genetic modification of hESC-DCs using baculoviral 
vectors 
A broad range of viral and non-viral gene delivery systems are available for 
genetic modification of DCs (Shurin et al. 2010). However, most non-viral 
vectors do no provide high efficiency of gene transfer to DCs. Several viral 
gene delivery systems are currently used for modification of DCs including 
vectors based on lentiviruses, retroviruses, pox viruses, herpes simplex 
viruses (HSVs), adeno-associated viruses (AAVs).  
 
Retroviruses are RNA viruses that replicate via a DNA intermediate that is 
integrated into the genome. Retroviruses are inefficient in transduction of non-
dividing cells and hence CD34+ HPCs are initially transduced with 
retroviruses before differentiation to DCs. The average transduction efficiency 
of 10-20% is obtained via this approach (Heemskerk et al. 1999).  
Lentiviruses are a subclass of retroviruses that are more efficient in 
transduction of non-dividing cells and it has been demonstrated that up to 
70% of DCs can be transduced with lentiviral vectors (Chinnasamy et al. 
2000). Nevertheless, a major concern with regards to application of 
retroviruses and lentiviruses is their random integration into the genome which 
can lead to insertion mutations (Breckpot et al. 2004).   AAVs are single 
stranded DNA viruses that are efficient in transduction of non-dividing cells. 
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Transduction efficiencies up to 55% have been reported via transduction of 
DCs with AAVs (Ponnazhagan et al. 2001). However, unlike wild type AAVs, 
recombinant AAV randomly integrates into chromosomal DNA (Podsakoff et 
al. 1994). This random integration is also source of major concern for 
insertional mutagenesis. In addition to their insertional mutagenesis potential, 
low insertional capacity of AAVs, retroviruses and lentiviruses is another 
limitation for their application in genetic engineering of DCs (Breckpot et al. 
2004).  
 
Orthopox viruses are DNA viruses that have also been studied for gene 
delivery to DCs. These viruses do not integrate into the genome and hence 
provide transient expression of the transgene. Transduction efficiency of up to 
60% is reported after treatment of DCs with vaccinia based and canarypox 
based systems (both of which belong to Orthopox family) (Di Nicola et al. 
1998; Marovich et al. 2002). However, transduction with these viruses leads 
to impaired maturation and apoptosis in DCs (Engelmayer et al. 1999; 
Ignatius et al. 2000). HSVs are another type of DNA viruses that are studied 
for gene delivery to DCs. While transduction efficiency of up to 70% is 
reported by these viruses, HSV infection also has an inhibitory effect on 
maturation of DCs (Salio et al. 1999; Willis et al. 2001). 
 
 Replication-deficient adenoviral vectors are one of the most commonly used 
vectors for genetic modification of DCs (Smits et al. 2009). They have large 
cloning capacity and do not integrate into the genome. Furthermore, DC 
transduction efficiency of up to 100% is reported by these vectors (Dietz et al. 
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1998). In addition, adenoviral transduction contributes to the maturation of 
DCs (Rouard et al. 2000). As mentioned in the introduction section, 
baculoviruses share several of these beneficial characteristics with adenoviral 
vectors. Like their adenoviral counterparts, baculoviral vectors have large 
cloning capacity and do not integrate to the genomic DNA of their mammalian 
host. In addition exposure of DCs to baculoviral vectors contributed to their 
maturation and subsequent activation (Schutz, Scheller et al. 2006; Suzuki, 
Chang et al. 2010). Based on these characteristics of baculoviral vectors, we 
investigated the efficiency of baculoviral transduction in our hESC-DCs.     
 
Choice of promoter and transcriptional elements can affect the expression 
level of baculoviral vectors in mammalian cells. It has been shown that the 
choice of the mammalian promoter is important in determining the expression 
of the transgene. The CMV promoter is strongly active in a wide range of 
mammalian cell lines (Spenger et al. 2004). However, the expression of the 
EF1 promoter has been shown to be stronger than the CMV promoter in 
certain cell lines, including MSCs and hESCs (Lee, H. P. et al. 2007; Zeng et 
al. 2007). It has also been reported that the addition of WPRE sequence to 
the 3’ end of the transgene can augment the expression levels of baculoviral 
vectors (Mahonen et al. 2007). We subsequently constructed four 
independent baculoviral vectors for the expression of the eGFP reporter gene 
under the control of EF1 or CMV promoters, with or without WPRE. 
Functional tests of these vectors in u87 cells confirmed the robust expression 
of eGFP upon transduction and an enhancing effect of WPRE in these 




After construction of baculoviral vectors we proceeded to investigate 
transduction efficiency of baculoviral vectors on our unmodified hESC-DCs. 
We noticed that the overall expression frequency of the eGFP was low in 
DCs. This observation is in line with earlier reports that baculoviruses can 
enter the DCs and other lineages of hematopoietic origin; however, they do 
not efficiently express eGFP in these cells (Kim, C. H. et al. 2007). It was also 
demonstrated that a portion of hematopoietic progenitor cells that were 
successfully transduced with the eGFP-bearing adenoviral vector did not 
express a detectable amount of eGFP. We speculate that this observation is 
due to a lower expression frequency of eGFP in satellite DNA fragments in 
blood lineage cells and does not represent the actual transduction level 
(Sakurai et al. 2005).  Nevertheless, in our experiment a fraction of DCs were 
observed to express the eGFP, as confirmed by direct visualization as well as 
flowcytometry analysis. Our results also demonstrate that the CMV promoter 
is a stronger than EF1 promoter in hESC-DCs and that the WPRE boosts 
expression of the transgene in hESC-DCs. We additionally confirmed that 
exposure to baculovirus leads to increase of the CD83 expression, a key 
maturation marker for DCs (Lechmann et al. 2002; Prechtel et al. 2007), thus 
confirming the role baculovirus in the activation of DCs.  
 
After observing the relatively higher levels of eGFP expression in the 
presence of the CMV promoter and WPRE, we cloned the coding sequence of 
the human CD1d gene into this baculoviral expression cassette. Transduction 
of hESC-DCs with this construct led to a higher frequency of CD1d+ cells. 
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The higher frequency of CD1d expression compared eGFP highlights the 
importance of selecting a suitable reporter gene to investigate the 
transduction efficiency. It is possible that a fluorescent transgene might be 
expressed below the visual detection threshold. Nevertheless, since the exact 
mechanism of baculoviral transduction of mammalian cells is still illusive. Full 
understanding of the exact mechanism for the difference observed between 
eGFP and CD1d as reporter genes needs better understanding of molecular 
mechanism involved in baculoviral transduction and gene expression in 




2.5.3 Improved survival rate upon administration of baculovirally 
modified DCs in a breast cancer tumor animal model  
After successful overexpression of CD1d in hESC-DCs we proceeded with the 
injection of our genetically modified DCs into a solid tumor model for breast 
cancer in the presence of -GalCer, a specific ligand for CD1d, which triggers 
the activation of NKT cells upon activation by antigen-presenting cells such as 
DCs. While we observed an increased lifespan in mice treated with DCs 
transduced with empty baculovirus and in the absence of CD1d, the increased 
lifespan was significant only upon treatment with DCs transduced with CD1d 
baculovirus and exposed to -GalCer. These observations are expected to be 
due to the specific activation of NKT cells via CD1d-mediated presentation of 
-GalCer. CD1d is proven to be evolutionary conserved, and cross-
presentation between human and mouse antigen-presenting cells and NKT 
cells of other species is also well documented (Godfrey et al. 2005). These 
observation emphasizes the potential clinical application of baculoviral vectors 
with their dual role of directing the function of hESC-DCs via the expression of 
a transgene and an improvement of the maturation state of DCs.  
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2.5.3 Future directions 
Our results demonstrate that stable baculovirally modified hESCs can be used 
as raw material for production of genetically modified DCs. Additionally, direct 
genetic modification of hESC-DCs with baculovirus for the expression of 
CD1d significantly improved the performance of DCs in our tumor animal 
model. These two observations suggest that the derivation of genetically 
engineered hESCs that stably express CD1d can provide renewable source 
hESC-DCs with ectopic expression of CD1d and potentially improved 
antitumor activity. Due to the time restrictions, we could not investigate the 
feasibly of this approach in the current study. Hence the potential application 
of this technique remains to be investigated in future.   
 
In addition, administration of hESC-DCs directly modified with CD1d gene 
alone improved the survival in the breast cancer tumor model. This 
improvement is based on activation of NKT via genetically modified DCs. As 
mentioned earlier NKTs are responsible for systematic activation of immune 
system and our approach does not directly triggering a tumor specific immune 
response. Currently a major aim for gene delivery to DCs is delivery of tumor 
specific antigens (Shurin et al. 2010). Baculoviral vectors allow cloning of 
large inserts including multiple expression cassettes. Subsequently, including 
of a coding sequence of a tumor specific antigen in addition to current CD1d 
gene can mediate induced expression of both genes in DCs. These DCs 
might in turn trigger activation of NKT cells as well as tumor specific immune 
response and further improve the observed therapeutic effects. Such a duel 











EFFECTS OF HUMAN EMBRYONIC STEM CELL-DERIVED 
STEM CELL VEHICLES ON THE DEVELOPMENT AND 





Both NSCs and MSCs have yielded promising results as vehicles for the 
cellular treatment of cancer. However, due to the importance of the immune 
system in the tumor response, the impact of the administration of cellular 
vehicles on the immune system remains a determinant factor for the outcome 
of the treatment. In the first part of this chapter, I will emphasize the 
suppressed phenotype of DCs in the case of cancer. Subsequently, I will 
review the overall impact of MSCs and NSCs on the immune system. 
Because T cells and DCs are two important of arms of immunity in the cancer 
response, I will describe the current knowledge of the effects of NSCs and 
MSCs on each of these lineages in final two sections.   
    
3.1.1 DC function and cancer         
DCs have a central role in anti-tumor immunity, and there is a correlation 
between the attenuation of DC function and the development of cancer. A 
higher density of DCs at the tumor site has been shown to be correlated with 
a higher survival rate in advanced human gastric cancer (Tsukayama et al. 
2005). Early studies reported the defective function of DCs in animal tumor 
models and in cancer patients (Tas et al. 1993; Chaux et al. 1997; Gabrilovich 
et al. 1997; Nestle et al. 1997; Ishida et al. 1998; Yanagimoto et al. 2005). 
Subsequent studies suggested that tumor-mediated dendritic cell dysfunction 
is due to either the abnormal differentiation of DCs from monocytes (Almand 
et al. 2000; Kusmartsev et al. 2002) or the accumulation of immature DCs 
(Baleeiro et al. 2008). These observations further emphasize the potential 
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detrimental effects of treatments that suppress the development and function 
of DCs on the overall results of cancer treatment.   
 
3.1.2 NSCs and MSCs as immune regulatory cells    
As described in chapter 1, MSCs and NSCs represent two types of adult stem 
cells. NSCs are a group of rare and self-renewing multipotent cells that 
generate the neural and glial lineages in the developing brain (Temple 2001). 
NSCs can be isolated from the nervous system or can be differentiated from 
embryonic stem cells. NSCs can be genetically manipulated and expanded in 
vitro before being reintroduced into the pathologically altered nervous system. 
NSCs have strong migratory and pathotropic characteristics and have been 
studied for replacing lost nervous tissue and for the treatment of autoimmune 
diseases and cancer (Einstein et al. 2008). Similar to NSCs, MSCs constitute 
a rare, multipotent population of stromal cells that can be isolated primarily 
from adult tissues, including bone marrow and adipose tissues, as well as 
from hESCs cells. MSCs can be expanded and genetically modified in vitro 
before clinical administration. These cells have been studied extensively for 
their therapeutic potential in regenerative medicine, autoimmune diseases 
and the treatment of cancer. 
 
A determinant factor for the clinical application of adult stem cells is the nature 
of their interaction with the immune system. A strong immunosuppressive 
effect is favorable for the treatment of autoimmune diseases to dampen the 
function of autoreactive immunity. However, immunosuppression is 
considered to be a limitation for the treatment of cancer because it further 
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undermines the body’s already attenuated defense mechanism. While both 
NSCs and MSCs exhibit promising tumor-tropic characteristics, many factors 
can influence their clinical application.  
 
In addition to the applications of MSCs in regenerative medicine, the strong 
immunosuppressive effect of MSCs has attracted attention in recent years. 
Subsequently, these cells have been clinically administered with HSCs to 
alleviate graft-versus-host disease (GvHD)(Gonzalo-Daganzo et al. 2009). 
Moreover, it has been reported that cotransplantation of MSCs with HSCs 
could reduce the transplantation side effects and enhance marrow recovery 
(Lazarus et al. 2005; Macmillan et al. 2009). MSCs are also studied for the 
treatment of autoimmune diseases, including multiple sclerosis and 
autoimmune encephalomyelitis (Gerdoni et al. 2007; Uccelli et al. 2011). Due 
to the immunosuppressive potential of MSCs, the administration of these cells 
upon solid organ transfer increases the chance of success. For example, 
MSCs increase the chance of kidney engraftment by inhibiting the function of 
the alloreactive T cells of the recipient (Crop et al. 2009).  
 
Several studies have also demonstrated the immunomodulatory potential of 
NSCs in animal models (Ben-Hur 2008). The immunosuppressive effects of 
NSCs have been demonstrated in several animal models of experimental 
autoimmune encephalomyelitis (EAE) and multiple sclerosis. The 
administered NSCs migrate to sites of inflammation and reduce the severity of 




The immune system has a critical role in the cancer response, and 
subsequently, a potential obstacle for the application of NSCs and MSCs in 
the treatment of cancer is their immunosuppressive effect, which could 
outweigh their beneficial effect. In fact, MSCs have already been shown to 
promote tumor growth via their strong immunosuppressive properties (Djouad 
et al. 2003; Yu et al. 2008). This finding highlights the importance of 
investigating the interaction of adult stem cells with the immune system prior 
to their clinical administration.  
 
The major focus of studies regarding the interaction of adult stem cells with 
the immune system has been on two key lineages of adaptive immunity: T 
cells and DCs. T cells are the major executors of the adaptive immune 
response. DCs, in turn, are the key antigen-presenting cells and have the 
critical role of coordinating the function of immune cells, including T cells. 
 
3.1.3 Effects of NSCs and MSCs on T cells  
The immunosuppressive effect of MSCs on T cells is well documented. MSCs 
do not express the main costimulatory molecules that are required for T cell 
activation, such as CD40, CD80 and CD86, or MHC II molecules (Tse et al. 
2003). The absence of costimulatory molecules is one potential mechanism 
through which MSCs cause T cell immune unresponsiveness (Majumdar et al. 
2003). MSCs also modulate the activity of T cells via the expression of 
programmed death-1 (PD-1), which binds to its ligands PD-L1 and PD-L2 on 
the surface of T cells. (Augello et al. 2005). Interestingly, exposure to the 
inflammatory cytokine IFN- leads to the expression of the T cell antigen-
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presenting molecules of MHC II in MSCs. However, this expression does not 
lead to a proliferative response in T cells (Gotherstrom et al. 2004). 
Stimulation by INF- also induces the expression of indoleamine 2,3-
dioxygenase (IDO) by MSCs. IDO catalyzes the conversion of tryptophan to 
kynurenine and has been shown to have T cell inhibitory effects. Production of 
nitric oxide (NO) by MSCs has also been proposed as a mechanism through 
which MSCs inhibit the proliferative response of T cells (Meisel et al. 2004). 
Collectively, the abovementioned findings indicate that MSCs suppress the 
activity of T cells via multiple and redundant pathways.  
 
Compared to the well-studied immunosuppressive effects of MSCs, 
investigations regarding the impact of NSCs on the function of T cells are at 
relatively early stages. The inhibition of T cells by NSCs has been reported in 
an animal model of EAE (Einstein et al. 2007). The suppressive effects of 
NSCs on the activity of human T cells was recently reported (Akesson et al. 
2009), but the mechanism behind this suppressive effect remains to be 
elucidated. 
 
Adult stem cells can also indirectly modulate the activity of T cells by 
influencing the development and functions of DCs. DCs regulate the activity of 
many lineages of the immune system, including T cells. The next section will 





3.1.4 Effects of NSCs and MSCs on DCs  
Both MSCs and NSCs have been considered for the cellular treatment of 
cancer because of their promising tumor-tropic characteristics. DCs, which 
are the most potent antigen-presenting cells, have a major role in anti-tumor 
immunity. Therefore, it is of interest to investigate the effects of tumor-tropic 
adult stem cells on the development and function of DCs.  
 
There is accumulating evidence indicating that MSCs have strong 
immunosuppressive characteristics (Aggarwal et al. 2005; Shi, Y. et al. 2010). 
The proposed mechanisms that underlie the strong suppressive effects of 
MSCs on the development and activity of DCs include the secretion of soluble 
factors, such as IL-6, TGF-β, and M-CSF, and suppression via cell-cell 
contacts, such as the Notch signaling pathway (Jiang et al. 2005; Nauta et al. 
2006; Li et al. 2008). It has also been shown that these suppressive effects 
lead to cell cycle arrest in DCs and involve STAT3 signaling (Gur-Wahnon et 
al. 2007; Ramasamy et al. 2007).  
 
Unlike the well-studied suppressive effect of MSCs, the immunosuppressive 
effect of NSCs on DCs is less well explored. In mice, NPCs have been 
reported to suppress the maturation of DCs via a BMP-4-dependent pathway 
(Pluchino et al. 2009). A comparison of the impact of the immunosuppressive 
effect of NSCs and MSCs on the differentiation and function of DCs in 





In view of the above review, the interaction of NSCs with the immune system 
is an important factor in their potential clinical applications in tumor therapy. 
DCs are the most important antigen-presenting cells and have a significant 
role in orchestrating the immune response. However, to the best knowledge of 
this author, no studies to date have compared the interactions of NSCs and 
MSCs with DCs in the human context. It has also been emphasized that due 
to limited resources and the ethical issues of the application of primary adult 
stem cells, hESCs are considered to be an alternative source of NSCs. It is 
therefore of interest to compare the immunomodulatory effects of hESC-
derived NSCs and MSCs as well as cell lines representing MSC and NSC 
lineage on the differentiation of DCs. 
 
Subsequently, the purpose of this study is as follows: 
 Use human embryonic stem cells as a source for the production of 
NSCs and MSCs and to investigate the effect of these cells on the 
differentiation of DCs.   
 Compare the immunomodulatory effects of NSCs with those of MSCs 
with regard to the development and function of DCs. 
 
Considering that both NSCs and MSCs are included in the study, the results 
will also serve as a platform for comparing the immunomodulatory effects of 
both of the stem cell lineages. These findings will contribute to a better 
understanding of the effects of adult stem cells on DCs and can ultimately be 




The focus of this study is to determine the effects of human adult stem cells 
on human monocyte-derived DCs in an in vitro model. Hence, investigating 
these interactions in the patient’s body after the administration of these cells is 
beyond the scope of the current study. The methods used to investigate the 
effect of NSCs and MSCs on the development and function of monocyte-





3.3 Materials and methods 
3.3.1 Culture of stem cells  
Human bone marrow MSCs (BM-MSCs) were obtained from Lonza (Basel, 
Switzerland), and the ReNcell CX Immortalized cell line was obtained from 
Millipore (Billerica, MA, USA). These cells were maintained according to the 
technical manual provided by the manufacturer.  
H1 hESCs (WiCell, Madison, WI, USA) were cultured in feeder-free conditions 
according to the technical manual: “Maintenance of Human Embryonic Stem 
Cells in mTeSRTM1” (StemCell Technologies, Singapore). hESC-derived 
NSCs (hESC-NSCs) were produced as follows. Neurospheres were derived 
from hESCs following a published protocol (Reubinoff et al. 2001). Briefly, 
hESCs clumps containing an estimated number of 150 cells were cut using a 
microglass pipette. These fragments were then transferred to non-adherent 
plastic dishes and were maintained in NSC medium, which consisted of 
DMEM-F12, the B27 supplement (1:50), L-glutamine at 2 mM, penicillin at 50 
units/mL and streptomycin at 50 pg/mL (Gibco, Singapore). This medium was 
supplemented with 20 ng/mL of human recombinant bFGF and 20 ng/mL of 
EGF (Peprotech, Rocky Hill, NJ). The cell clumps formed round spheres in 
the suspension culture. The spheres were subcultured every 7 to 21 days 
(when their diameter reached 0.5 mm) by dissecting the spheres into smaller 
fragments using no. 20 surgical blades (Swann-Morton, Sheffield, UK). Half of 
the medium was exchanged every four days. 
Single cells were derived from the neurospheres for the coculture and 
differentiation studies. The neurospheres were centrifuged at 150 g for 1 
minute, the supernatant was discarded, and the spheres were washed twice 
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with PBS then incubated with Accutase (StemCell Technologies, Singapore) 
for 10 minutes at 37°C. The solution was subsequently neutralized using fresh 
medium, and the cells were centrifuged at 300 g for 5 minutes. Afterwards, 
the cells were resuspended in NSC medium and were seeded onto 6-well 
plates that had been coated overnight with laminin (20 µg/mL). The cells were 
used for differentiation or coculture 4 days after the initial seeding on laminin. 
hESC-derived MSCs (hESC-MSCs) were generated and fully characterized in 
our lab as previously reported (Bak et al. 2011).  
 
3.3.2 Characterization of hESC-NSCs and ReN cells 
RT-PCR was used to monitor the expression of neural stem cell markers in 
NSCs. Total RNA was extracted using Trizol (Invitrogen), and the SuperScript 
III First-Strand Synthesis System (Invitrogen) was used for cDNA synthesis. 
The PCR reactions included an initial denaturation step at 94°C for 4 minutes 
followed by 30 cycles of the following: 94°C for 30 seconds, 55°C for 30 
seconds, and 72°C for 60 seconds. The reactions were also subjected to an 
additional extension at 72°C for 6 minutes after the last step. The RT-PCR 
primers used are listed in Table 3.1.  
 
The differentiation potential of adherent NSCs and ReN cells into neurons and 
astrocytes was assessed using a published protocol (Swistowski et al. 2009). 
Briefly, for neural differentiation, NSCs were cultured for 10 days in NSC 
medium supplemented with NEAA, L-glutamine (2 mM), B27, 200 ng/mL of 
Shh (R&D Systems, Minneapolis, MN, USA) and 100 ng/mL of FGF8 (R&D 
Systems). In the subsequent 10 days, Shh and FGF8 were replaced by 20 
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ng/mL of BDNF (R&D Systems), 20 ng of GDNF (R&D Systems), 1 µM of 
TGF-β3 (R&D Systems) and 1 mM dcAMP (Sigma). For the differentiation of 
NSCs into astrocytes, adherent NSCs were cultured in DMEM-F12 
supplemented with L-glutamine (2 mM), NEAA, N2 and B27 (Gibco) for two 
weeks.  
 
For immunostaining of the differentiated cells, the samples were fixed using 
PBS containing 4% PFA then permeabilized using PBS-0.3% Triton X-100. 
The samples were subsequently blocked with PBS-5% BSA and were 
incubated overnight at 4C with a primary antibody that was diluted in PBS-
1%BSA. The following day, the samples were washed 3 times with PBS and 
were incubated for 1 hour at room temperature with a secondary antibody. 
Next, the cells were washed 5 times with PBS, and Hoechst (Invitrogen) was 
added to the samples for one minute before the final wash. The primary 
antibodies used included mouse anti-human GFAP (Sigma-Aldrich) and 
mouse anti-human βIII tubulin (Promega), and the secondary antibody was 








 Reverse: CGAGTAGGACATGCTGTAGGT 
SOX-1  
Forward: CAATGCGGGGAGGAGAAGTC 
 Reverse: CTCCTCTGGACCAAACTGTG 
PAX-6  
Forward: AACAGACACAGCCCTCACAAACA 
 Reverse: CGGGAACTTGAACTGGAACTGAC 
NESTIN  
Forward: GAAACAGCCATAGAGGGCAAA 
 Reverse: TGGTTTTCCAGAGTCTTCAGTGA 
MUSASHI-1 
 Forward: GGCCGAGCCCCTGGAACCAT 
 Reverse: CAGTGTCGCTGGGCAAGCCC 
ACTIN  
Forward: CAGCAAGCAGGAGTATGACG 




3.3.2 Differentiation and maturation of DCs 
Purified blood CD14+ monocytes were purchased from Lonza. The 
differentiation medium for the derivation of DCs from monocytes consisted of 
RPMI-1640 (Gibco, Singapore) supplemented with 10% FBS (HyClone, 
Logan, UT, USA) and 100 ng/mL of IL-4 and GM-CSF (both obtained from 
Peprotech, Rocky Hill, NJ). Medium without cytokines was used to maintain 
the control monocyte group. To prepare the cocultures, each cell line was 
seeded into differentiation medium according to the reported cellular ratios. 
CD14+ cells were then added to bring the final cellular density to 1 million 
cells/mL in 2 mL of medium per each well of a 6-well plate. Medium was 
changed on days 3 and 5 as follows: a volume of 300 l of medium from each 
well was harvested and centrifuged at 300 g for 5 minutes. The supernatant 
was discarded, and the cellular pellet was resuspended in 500 l of fresh 
medium and was added back to the respective well. The cells were harvested 
for analysis on day 7, and the media were stored at -80C for the 
measurement of cytokine levels. 
 
The maturation medium was made by adding S. typhi LPS (Sigma-Aldrich, 
Singapore) to the differentiation medium to a final concentration of 100 ng/mL. 
In experiments that included an extension of the differentiation step to 
maturation, the medium was changed on day 7 as previously described, and 
LPS was added to the fresh medium to bring the final concentration of LPS to 




3.3.3 Flow cytometry of cell-surface markers  
To determine the expression frequencies of surface markers, the cells were 
stained with monoclonal antibodies against human CD1a (clone HI149), CD4 
(clone RPA-T4), CD14 (clone M5E2), CD80 (clone L307.4), CD83 (clone 
HB15), CD86 (clone 2331[FUN-1]) and HLA-DR (clone G46-6) as well as with 
the respective isotype controls for these antibodies (all obtained from BD 
Pharmingen, San Diego, CA). To exclude contaminating cells of non-
leukocyte origin from the analysis, positively stained cells with anti-human 
CD45 (clone HI30, BD Pharmingen) were gated. Flow cytometry data were 
obtained using a FACSCalibur flow cytometer (BD Biosciences) or a 
FACS Aria cell sorter (BD Biosciences) and were analyzed 
using FlowJo software (Treestar, Inc., San Carlos, CA).  
 
3.3.4 T cell stimulation assay 
Peripheral blood mononuclear cells (PBMCs) were purchased from StemCell 
Technologies. CD4+ T cells were purified from PBMCs by magnetic cell 
sorting (MACS) using positive selection with anti-human CD4 (Miltenyi 
Biotech, Singapore) according to the manufacturer's instructions. The 
cocultures of cell lines with DCs were harvested and stained with APC-
conjuagted anti-human CD45. A total of 1 x 104 CD45+ cells from each group 
were seeded into the wells of a flat-bottom 96-well plate using a 
FACS Aria cell sorter (BD Biosciences). A total of 1 x 105 CD4+ T cells were 
subsequently added to each well as a responder population. The cells were 
cultured in RPMI-1640 (Gibco) supplemented with 10% FBS for 3 days 
(HyClone). The supernatants were harvested and stored at -80C for the 
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measurement of interferon- (IFN-) secretion. All of the experiments were 
performed in triplicate. 
 
3.3.5 Cytokine production 
The levels of human IL-10, IL-12p70, TNF- and IFN- were measured using 
a BD OptEIA human enzyme-linked immunosorbent assay (ELISA) kit II 
according to the provided instructions. The harvested media from the cultures 
were centrifuged at 300 g for 5 minutes to exclude cells, and the cell-free 
supernatants were either used immediately for an ELISA or were stored at -
80C. Whenever the measured concentration of a cytokine was above the 
detection range, the media were diluted accordingly to bring the concentration 




3.4 Results  
3.4.1 hESC-NSCs and immortalized ReN exhibit neural stem cell 
characteristics 
 The neural stem cell properties of hESC-NSCs and ReN cells were confirmed 
in a series of experiments. To monitor the expression of genes related to 
NSCs, total RNA from hESC-NSCs and ReN cells was extracted using Trizol 
and was used for cDNA synthesis. The expression levels of the SOX-1, SOX-
2, NESTIN, PAX-6 and MUSASHI-1 genes were monitored using RT-PCR. 
The ACTIN gene was included as a positive control, and reactions that 
included RNA without the reverse transcriptase treatment were used as 
negative controls to exclude the possibility of genomic DNA contamination. 
The results shown in Figure 3.1 confirm that both cell lines expressed SOX-1, 
SOX-2, PAX-6, NESTIN and MUSASHI-1, all of which are reported markers 
for NSCs (Peh et al. 2009). 
 
 By definition, NSCs are capable of differentiation into both the neural and 
glial lineages. To confirm the differentiation potential of our hESC-NSCs and 
ReN cells into the glial lineage, these cells were exposed to astrocyte 
differentiation medium for two weeks. The samples were subsequently used 
for immunostaining for glial fibrillary acidic protein (GFAP). GFAP is an 
intermediate marker expressed by astrocytes of the central nervous system 
(CNS) and has been shown to be of critical importance for the normal function 
of astrocytes (Pekny et al. 2004). A high level of expression of GFAP in the 
cells derived from both the hESC-NSCs and ReN cells confirmed the glial 




To verify the neurogenic potential of the hESC-NSCs and ReN cells, the cells 
were exposed to neural differentiation medium in a two-step process. On day 
20, the cells were used for immunostaining for βIII-tubulin. βIII-tubulin is 
exclusively expressed in the neurons of higher vertebrates and is used as a 
neural-specific marker (Sullivan et al. 1986; Burgoyne et al. 1988). The 
observation of a high level of expression of βIII-tubulin indicated that neurons 
could be successfully derived from both hESC-NSCs and ReN cells. 
Altogether, the above results demonstrate that both hESC-NSCs and ReN 












                  
 
Figure 3.1. hESC-NSCs and immortalized ReN cells express neural stem 
cell markers. Extracted total RNA from each cell line was used for cDNA 
production, which in turn was used for RT-PCR analysis for the expression of 
markers. RNA samples without the addition of reverse transcriptase were 
used as negative controls to exclude the possibility of genomic DNA 
contamination. Actin was included as a positive control of the RT-PCR 
procedure. Control groups without reverse transcriptase are represented by 
the minus sign, and the experimental groups are represented by the plus sign. 








Figure 3.2. hESC-NSCs and immortalized ReN cells can differentiate into 
neurons and astrocytes. (A) hESC-NSCs and ReN cells seeded on laminin 
were used for neural differentiation. The cell lines were cultured in the 
presence of Shh and FGF8 for 10 days. In a second step, the cells were 
cultured with BDNF, GDNF and TGF-β3 for an additional 10 days. The 
cultures were subsequently used for immunostaining for the neural marker 
βIII-tubulin and were observed under a microscope. (B) The cell lines seeded 
on laminin were used for differentiation to astrocytes. After 14 days, the 
cultures were used for immunostaining for GFAP. The nuclei in A and B were 
stained with Hoechst (blue). Scale bar: , 50 µm. (The data presented are 





3.4.2 Human NSCs are more permissive than MSCs to initial 
differentiation of CD1a+ DCs from CD14+ monocytes 
Purified CD14+ monocytes (purity higher than 95%) were differentiated into 
DCs the presence of GM-CSF (100 ng/mL) and IL-4 (100 ng/mL). While 
cultured monocytes with no cytokine treatment were used as control. Cells 
were subsequently used for microscopic observation (Figure 3.3) and flow 
cytometric analysis on day 7. Majority of both monocytes and DCs were 
observed as round floating cells with no adherence to the surface of the 
vessel at day 7. Floating state of these cells could be detected through slight 
jerking of the vessel under microscope and monitoring the subsequent turmoil 
in the media. To investigate the differentiation status of the monocytes, the 
cultures were harvested and analyzed for the expression of the monocyte 
marker CD14 and the DC marker CD1a (Figure 3.4 A). As expected, in the 
mono-DC group, CD14 expression was replaced by the expression of CD1a, 
while the monocyte control group maintained a high frequency of CD14 
expression.  
 
  In order to investigate the effects of each cell line on the differentiation of 
monocyte-derived DCs (mono-DCs), the adult stem cells were seeded at 
serial ratios with the monocytes (stem cell/monocytes ratios of 1:1, 1:10, 1:50, 
and 1:100) in presence of both GM-CSF and IL-4. On day 7, the cell cultures 
were observed under a microscope (Figure 3.3), then were harvested and 




Interestingly, in the cocultures with the MSC lines, cells with round 
morphology of monocytes/DCs were mainly distributed on the surface of the 
stromal cells and would not move in response to the turmoil in the media. In 
the cocultures with the NSC lines, this phenomenon was observed with lower 
frequency. Based on these observations we speculate that MSCs (and to 
lesser extent NSCs) provide anchorage for monocyte derivatives in coculture.  
 
We subsequently evaluated the effect of coculture with adult stem cells on the 
expression of CD14 and CD1a on monocyte derivatives (Figure 3.4 B). In 
presence of BM-MSCs and hESC-MSCs, the CD14 expression frequency was 
higher than the mono-DC group. Additionally, CD1a expression was strongly 
suppressed in the presence of MSCs, and only with the lowest density of 
MSCs did CD1a expression exceed the expression of CD14. In contrast, in 
the presence of ReN cells and hESC-NSCs, the frequency of CD1a 
expression was higher than those of CD14 at all of the seeding ratios. 
However, at high densities of both of the NSC lines, there was a decrease in 
the expression frequency of CD1a compared to the mono-DC group. These 
data demonstrate that the suppressive effect of MSCs on the differentiation of 
DCs from monocytes is stronger than that of NSCs. 
 
Both fibroblasts and MSCs have been reported to inhibit the differentiation of 
monocytes into DCs (Chomarat et al. 2000; Jiang et al. 2005). The optimal 
suppressive effect of fibroblasts was obtained at a ratio of 1 fibroblast to 4 
monocytes. Our data indicate that while MSCs maintain their strong 
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suppressive effect at cellular ratios as low as 1:50, this suppressive effect is 





Figure 3.3. Microscopic observations of cell lines and cocultures with 
monocytes. CD14+ monocytes were cocultured with MSCs or NSCs at a cell 
line/monocyte ratio of 1:1 in the presence of GM-CSF and IL-4. Seven days 
later, the cocultures were used for microscopic observation. Scale bar: , 





Figure 3.4. Human NSCs are more permissive than MSCs to initial 
differentiation of CD1a+ DCs from CD14+ monocytes. CD14+ monocytes 
were cocultured with MSCs or NSCs at different ratios in the presence of GM-
CSF and IL-4. Seven days later, the cells were harvested and gated using 
APC-conjugated anti-human CD45 to exclude adult stem cells from the 
analysis. The CD14 and CD1a expression frequencies in the monocyte-
derived cells were assessed by flow cytometry using PE-conjugated 
monoclonal antibodies against CD1a and CD14. (A) Expression of CD14 and 
absence of CD1a in initial population of monocytes (B) CD14 expression was 
replaced by CD1a expression upon the differentiation of monocytes. In the 
monocyte control group, the cells retained a high frequency of CD14 
expression and had low frequency of CD1a. The histograms show the staining 
by antibodies against the indicated markers (black line) and by the isotype 
controls (grey line). The percentage of positive cells is indicated. (B) The 
effect of different ratios of adult stem cells on CD14 and CD1a expression.  
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3.4.3 Effects of BM-MSCs and NSCs on expression of costimulatory 
molecules and IL-10 secretion during differentiation of mono-DCs   
Purified CD14+ monocytes (purity higher than 95%) were differentiated into 
DCs in the presence of GM-CSF (100 ng/mL) and IL-4 (100 ng/mL). To 
investigate the effects of each cell line on the differentiation of monocyte-
derived DCs (mono-DCs), the cell lines were seeded with the monocytes with 
cell line/monocyte ratio of 1:10. Monocytes in medium without cytokines were 
used as a negative control. On day 7, the cell cultures were harvested and 
centrifuged at 300 g for 5 min. Cells were used for flow cytometry analysis for 
costimulatory surface markers of DCs and cell free supernatants were used 
for measurement of IL-10 secretion. 
 
3.4.3.1 BM-MSCs and NSCs trigger a mild upregulation of costimulatory 
molecules and CD83 in mono-DCs  
The harvested cells were analyzed for the expression of CD14, CD1a and 
surface costimulatory molecules (CD40, CD80 and CD86) as well as the 
maturation marker CD83 (Figure 3.5). In the group exposed to hESC-MSCs, 
the expression frequencies of CD1a, CD40, CD80 and CD83 were as low as 
the isotype control, and the expression frequency of CD86 resembled that of 
the control monocyte group, which is indicative of a strong suppressive effect 
of MSCs on the differentiation of DCs. 
Interestingly, in the cocultures of BM-MSCs and both NSC lines, increased 
frequencies of costimulatory molecules and the maturation marker CD83 were 
observed. The upregulation was prominent for CD80 and CD86 and mild for 
CD40 and CD83. The upregulation was also stronger in the BM-MSC group 
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compared to the NSC groups. The mild upregulation of CD83 and CD40 might 
be due to the allogeneic origin of the administered cells. The strong 
upregulation of CD80 and CD86 is of interest due to the dual nature of these 
molecules in the regulation of T cell function. CD80 and CD86 have been 
shown to be involved in both the activation and attenuation of T cells based 
on the combination of available molecules (Carreno et al. 2002). 
Subsequently, the licensing of DCs by adult stem cells for the expression of 
these molecules might be involved in the suppressive effect of adult stem 
cells on the T cell stimulatory potential of DCs. Additionally, due to the 
signaling function of these molecules, they might also be involved in cellular 
communication between adult stem cells and monocytes. This explanation is 
consistent with the observation of a strong anchoring of monocytes to the 
surface of the BM-MSCs during differentiation. Similar anchoring was also 
observed in the cocultures with NSCs, but at a lower frequency.  
 
3.4.3.2 Elevated levels of IL-10 were detected during the differentiation 
step of the monocyte coculture with MSCs but not with NSCs  
IL-10 is a well-characterized anti-inflammatory cytokine. In addition, IL-10 is a 
potent suppressor of the secretion of pro-inflammatory cytokines by APCs. It 
has also been suggested that IL-10 might induce a regulatory phenotype in 
DCs (Wakkach et al. 2003). Therefore, we decided to investigate the 
presence of this cytokine in our system.   
 
Elevated levels of IL-10 were found in the cocultures with both MSC lines 
(Figure 3.6). Additionally, the absence of detectable levels of IL-10 in the 
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control groups of MSCs and DCs alone indicated that the secretion of IL-10 is 
induced upon coculture. In contrast, in the cocultures including ReN cells and 
hESC-NSCs, the levels of this cytokine were as low as in the control groups. 
These observations indicate that the presence of MSCs triggers the secretion 
of IL-10 during differentiation in coculture, while NSCs do not have this effect. 
The secretion of IL-10 in the presence of MSCs is consistent with the earlier 
finding of the suppressive effect of MSCs on the morphology of DCs during 
the differentiation step. Additionally, the higher levels of IL-10 observed in the 
presence of hESC-MSCs is consistent with the inhibition of differentiation 







Figure 3.5. Effects of MSCs and NSCs on the expression of co-
stimulatory molecules during differentiation of monocytes into DCs. 
CD14+ monocytes were cocultured with MSCs or NSCs at a stem 
cell/monocyte ratio of 1:10 in the presence of GM-CSF and IL-4. Seven days 
later, the cells were harvested and used for flow cytometry. The samples were 
stained by an APC-conjugated anti-human CD45 antibody. The expression 
frequencies of other markers in the harvested cells were assessed by PE-
conjugated monoclonal antibodies. The histograms show the staining by 
antibodies against the indicated markers (black line) and by the isotype 
controls (grey line). The percentage of positive cells is indicated. The results 







Figure 3.6. Elevated levels of IL-10 were detected during the 
differentiation step of monocyte cocultures with MSCs but not with 
NSCs. CD14+ monocytes were cocultured with MSCs or NSCs at a stem 
cell/monocyte ratio of 1:10 in the presence of GM-CSF and IL-4. Seven days 
later, cell-free supernatants were collected, and the levels of IL-10 levels were 
measured by ELISA. The IL-10 levels are expressed as the mean ± SD of 
three independent repeats.  Student’s t test was used for the statistical 




3.4.4 Effects of BM-MSCs and NSCs on phenotype and cytokine 
secretion of LPS-induced monocyte-derived DCs 
LPS is a strong stimulator of maturation in DCs. We decided to investigate the 
effects of BM-MSCs and NSCs on generation of LPS-induced DCs from 
monocytes. Monocytes were cultured in the presence of GM-CSF and IL-4 as 
well as adult stem cells at a stem cell/monocyte ratio of 1:10 for 7 days. The 
cells were then cultured in the presence of LPS for an additional 2 days. 
Monocyte group was cultured without GM-CSF, IL-4 or LPS, and the 
immature DC group was cultured without LPS. On day 9, the cell cultures 
were harvested and centrifuged at 300 g for 5 min. Cells were used for flow 
cytometry analysis for costimulatory surface markers of DCs and cell free 
supernatants were used for ELISA to evaluate the concentrations of secreted 
cytokines. 
hESC-MSCs were not included in these experiments due to their high cell 
division rate, which makes the maintenance of their cocultures impractical for 
9 days. 
 
 3.4.4.1 BM-MSCs, but not NSCs, inhibit the generation of LPS-induced 
monocyte-derived DCs 
We decided to investigate whether LPS stimulation could affect the initial 
suppressive effect mediated by MSCs on the differentiation of DCs or whether 
LPS stimulation would affect the expression of CD1a marker in the NSC 
groups. We subsequently evaluated the expression of CD1a and CD14 on 
monocyte derivatives on day 9 using flow cytometry. The cells were stained 
with antibodies against CD14 or CD1a and gated using an APC-conjugated 
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anti-human CD45 to exclude adult stem cells. (Figure 3.7). The results show 
that monocyte cultures with MSCs maintain their undifferentiated phenotype 
even upon stimulation with LPS, while both types of NSCs are permissive for 
the differentiation of mono-DCs as indicated by the expression of CD1a and 




Figure 3.7. BM-MSCs, but not NSCs, inhibit the generation of LPS-
induced monocyte-derived DCs. Monocytes were cultured in the presence 
of GM-CSF and IL-4 as well as adult stem cells at a stem cell/monocyte ratio 
of 1:10 for 7 days. The cells were then cultured in the presence of LPS for an 
additional 2 days. The cells in the monocyte group were cultured without GM-
CSF, IL-4 or LPS, and the cells in the immature DC group were cultured 
without LPS. The cells were harvested and used for flow cytometry. The 
samples were stained by an APC-conjugated anti-human CD45 antibody. The 
expression of other markers in the harvested cells was assessed using PE-
conjugated monoclonal antibodies. The histograms show the staining by 
antibodies against the indicated markers (black line) and by the isotype 
controls (grey line). The percentage of the positive cells is indicated. The 
results are representative of 3 independent experiments.  
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3.4.4.2 BM-MSCs and NSCs inhibit the upregulation of CD83 upon the 
extension of differentiation to the maturation step 
We subsequently investigated the effects of BM-MSCs and NSCs on 
expression of DC costimulatory molecules and maturation markers on LPS-
induced mono-DCs. Therefore, harvested cells on day 9 were used for flow 
cytometric analysis for the costimulatory molecules CD40, CD80 and CD86, 
the maturation marker CD83 as well as HLA-DR (Figure 3.8). 
 
As expected, the frequencies of costimulatory molecules, CD83 and HLA-DR 
were upregulated upon maturation via LPS stimulation in control group 
without adult stem cells. Interestingly, BM-MSCs and NSCs suppressed the 
upregulation of CD83 upon maturation. Our observation that MSCs and NSCs 
are permissive for the upregulation of other costimulatory molecules while 
suppressing the upregulation of CD83 indicates that CD83 potentially has a 
role in the immunomodulatory effect of these adult stem cells on the T cell 
stimulatory potential of DCs. 






Figure 3.8. Effects of MSCs and NSCs on the expression of 
costimulatory molecules on LPS-induced monocyte-derived DCs. 
Monocytes were cultured in the presence of GM-CSF and IL-4 as well as 
adult stem cells at a stem cell/monocyte ratio of 1:10 for 7 days. The cells 
were then cultured in the presence of LPS for an additional 2 days. The cells 
in the monocyte group were cultured without GM-CSF, IL-4 or LPS, and the 
cells in the immature DC group were cultured without LPS. The cultures were 
harvested and used for flow cytometry. The samples were stained by an APC-
conjugated anti-human CD45 antibody. The expression of other markers in 
the harvested cells was assessed using PE-conjugated monoclonal 
antibodies. The histograms show the staining by antibodies against the 
indicated markers (black line) and by the isotype controls (grey line). The 





3.4.4.3 Elevated levels of IL-10 were detected in cocultures of monocytes 
with BM-MSCs and NSCs after differentiation and LPS induction 
The concentrations of IL-10 in supernatants of cultures on day 9 were 
measured via ELISA (Figure 3.9). Elevated levels of IL-10 were found in the 
cocultures with the stem cell lines. However, the absence of detectable levels 
of IL-10 in the control groups of adult stem cells, monocytes and DCs alone 
indicates that the secretion of IL-10 is induced upon stem cell coculture. A 
comparison of this result with those presented in Figure 3.6 indicates that the 
presence of NSCs triggers the secretion of IL-10 only during the stimulation of 
cocultures with LPS. The higher levels of IL-10 observed in the presence of 











Figure 3.9. Elevated levels of IL-10 were detected in cocultures of 
monocytes with BM-MSCs and NSCs after differentiation and LPS 
induction. Monocytes were cultured in the presence of GM-CSF and IL-4 as 
well as adult stem cells at a stem cell/monocyte ratio of 1:10 for 7 days. The 
cells were then cultured in the presence of LPS for an additional 2 days. The 
cells in the monocyte group were cultured without GM-CSF, IL-4 or LPS, and 
the cells in the immature DC group were cultured without LPS. Cell-free 
supernatants were harvested on day 9 and were used for ELISA. The IL-10 
levels are expressed as the mean ± SD of three independent repeats. 
Student’s t test was used for the statistical comparison of experimental 




3.4.4.4 Compared to LPS-induced mono-DCs, there was reduced 
secretion of IL-12p70 and TNF- in the cocultures of monocytes with 
adult stem cells 
TNF- and IL-12 are two important pro-inflammatory cytokines that are 
secreted by APCs upon activation. It has been suggested that the 
suppressive effect of MSCs on DCs involves the reduced secretion of both of 
these cytokines (Aggarwal et al. 2005). Therefore, we evaluated the 
concentration of these cytokines in the presence of adult stem cells as an 
indicator of the effect of adult stem cells on DC function. Both NSCs and 
MSCs suppress the secretion of pro-inflammatory cytokines in the coculture, 











Figure 3.10. The levels of IL-12p70 were reduced in the presence of adult 
stem cells compared to LPS-induced monocyte-derived DCs.   
Monocytes were cultured in the presence of GM-CSF and IL-4 as well as 
Adult stem cells at a stem cell/monocyte ratio of 1:10 for 7 days. The samples 
were then cultured in the presence of LPS for an additional 2 days. The cells 
in the monocyte group were cultured without GM-CSF, IL-4 or LPS, and the 
cells in the immature DC group were cultured without LPS. On day 9, cell-free 
supernatants were harvested and used for an ELISA. The IL-12p70 levels are 
expressed as the mean ± SD of three independent repeats. Student’s t test 
was used for the statistical comparison of LPS-induced DCs with the 










Figure 3.11. The levels of TNF- were reduced in the presence of adult 
stem cells compared to LPS-induced monocyte-derived DCs. Monocytes 
were cultured in the presence of GM-CSF and IL-4 as well as adult stem cells 
at a stem cell/monocyte ratio of 1:10 for 7 days. The samples were then 
cultured in the presence of LPS for an additional 2 days. The cells in the 
monocyte group were cultured without GM-CSF, IL-4 or LPS, and the cells in 
the immature DC group were cultured without LPS. On day 9, cell-free 
supernatants were harvested and were used for an ELISA. The TNF- levels 
are expressed as the mean ± SD of three independent repeats. Student’s t 
test was used for the statistical comparison of the experimental groups. *P 
<0.05; **P <0.01. 
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3.4.5 The exposure of differentiated DCs to MSCs and NSCs during 
maturation did not affect the upregulation of CD83 
There is a significant reduction in the monocyte population upon differentiation 
to DCs, which reduces the number of DCs available for maturation studies. 
Subsequently, there is a limitation on the number of markers that can be 
monitored simultaneously for the potential effects of coculture with adult stem 
cells during the maturation step.  
 
Our earlier results indicated that upon prolonged exposure to MSCs and 
NSCs, CD83 is the main maturation marker that is affected by coculture with 
adult stem cells (Figure 3.8). Subsequently, we monitored the effect of 
coculture with NSCs and MSCs on the expression frequencies of CD83 during 
the maturation step. 
 
Monocytes were cultured in the presence of GM-CSF and IL-4 for 7 days to 
produce immature DCs. Immature DCs were cultured in the presence of LPS 
for an additional 2 days with a cell line/mono-DC ratio of 1:10. As expected, a 
strong upregulation of CD83 was observed in DCs exposed to LPS. 
Interestingly, the exposure of differentiated DCs to MSCs and NSCs during 
the maturation step did not affect the upregulation of CD83. This observation 
indicates that primary exposure during differentiation is required for the 





Figure 3.12 The addition of MSCs or NSCs after the initial differentiation 
of monocyte-derived DCs has no effect on CD83 expression by LPS-
induced DCs. Monocytes were cultured in the presence of GM-CSF and IL-4 
for 7 days to produce mono-DCs. These cells were then co-cultured with 
MSCs or NSCs at a stem cell/mono-DC ratio of 1:10 in the presence of LPS. 
Two days later, cells were harvested, and the samples were used for flow 
cytometry. DCs without LPS treatment (immature DCs) are included for 
comparison. The samples were stained by an APC-conjugated anti-human 
CD45 antibody. The expression of the CD83 marker in the harvested cells 
was assessed using a PE-conjugated monoclonal antibody against CD83 
(black line) and its respective isotype control (grey line). The percentage of 
positive cells is indicated. The results shown are representative of three 
independent experiments.  
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3.4.6 Coculture with BM-MSCs had a stronger suppressive effect on the 
immunostimulation of DCs than coculture with NSCs 
The measurement of IFN- secretion upon the stimulation of T cells is a 
commonly used method for the quantification of T-cell activity. In this 
experiment, DCs derived from cocultures with adult stem cells were used to 
measure their T cell stimulation potential. However, prior to the coculture of 
DCs with T cells, it is essential to exclude the adult stem cells because both 
MSCs and NSCs directly suppress the activity of T cells (Krampera et al. 
2003; Aggarwal et al. 2005). It has also been suggested that MSCs directly 
interfere with the T cell-APC contact (Majumdar et al. 2003). These reports 
highlight the importance of eliminating adult stem cells from the experimental 
samples to prevent their direct suppressive effect on T cells. To achieve this 
aim, we used FACS to select for CD45+ cells after coculture. CD45 is a 
specific marker for leukocytes and is absent on surface of MSCs and NSCs.   
 
Monocytes were cocultured with BM-MSC and NSC cell lines for 7 days of 
differentiation and 2 additional days of maturation in the presence of 100 
ng/mL of LPS. CD45+ cells from each coculture were purified via FACS and 
were seeded into each well of a 96-well plate with CD4+ T cells purified from 
PBMCs using MACS. The CD45+ cell/CD4+ T cell ratio in the cocultures was 
1:10. The supernatants were harvested on day 4, and IFN- levels were 
measured by an ELISA. The results are shown in Figure 3.13. 
 
As expected, CD4+ T cells were not activated in the absence of monocytes, 
which confirms the purity of the CD4+ T cells. Our finding confirms that NSCs 
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can strongly indirectly suppress the activity of T cells by affecting the 
stimulatory potential of DCs derived from monocytes. However, the overall 
suppressive effect was significantly stronger with BM-MSCs compared to 









Figure 3.13. Interferon- (IFN-) production in cocultures of CD4+ T cells 
with monocyte-derived DCs derived in the presence of adult stem cells. 
Monocytes were cultured in the presence of GM-CSF and IL-4 for 7 days with 
a cell line/monocyte ratio of 1:10. LPS was added to the cocultures for an 
additional 48 hours before the cells were harvested. The cocultures of cell 
lines with DCs were harvested and stained with APC-conjugated anti-human 
CD45. A total of 1 x 104 of CD45+ cells from each group were seeded into the 
wells of a flat-bottom 96-well plate using FACS. A total of 1 x 105 CD4+ T cells 
were subsequently added to each well as a responder population. The cells 
were cocultured for 4 days. Cell-free supernatants were used for the 
measurement of interferon- (IFN-) levels by ELISA. The IFN- levels are 
expressed as the mean ± SD of triplicates. Student’s t test was used for the 





In this study, we investigated for the first time the effects of NSCs and MSCs 
on the differentiation and function of mono-DCs in the human context. 
Because ReN cells and hESC-NSCs represented NSCs in this study, we first 
confirmed their NSC characteristics. Cellular markers have an important role 
in the identification of NSCs. Several intracellular proteins, including the 
intermediate filament nestin and the transcription factor SOX2, have been 
reported to be markers for NSCs (Giliarov 2007; Pevny et al. 2010). The 
assessment of the differentiation potential of NSCs into glial and neural 
lineage remains a key step in their characterization process. NSCs were 
characterized through their differentiation potential and the expression of 
neural markers. Both cell lines expressed SOX-1, SOX-2, Nestin, PAX-6 and 
Musashi-1, which are NSC markers, and exhibited differentiation potential 
toward both astrocytes and neurons.  
 
A flow cytometric analysis of monocyte cultures in the presence of the two 
NSC lines indicated that the NSC cell lines did not significantly affect the 
downregulation of the monocyte marker CD14 nor did they prevent the 
upregulation of differentiation markers. In addition, they induced secretion of 
IL-10 in cocultures, which is a key immunosuppressive cytokine that has 
immunosuppressive effects during differentiation. Together, these data 
indicate that NSCs have no strong inhibitory effect on the initial differentiation 
of mono-DCs. MSCs, on the other hand, prevented the downregulation of 
monocyte marker CD14 and prevented the upregulation of CD1a. In addition, 
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they induced secretion of IL-10 in cocultures, confirming that MSCs suppress 
the initial differentiation of DCs. 
  
We noticed that upon the extension of the coculture from differentiation to the 
LPS stimulation step, the expression of CD83 was strongly suppressed in the 
presence of both NSCs and BM-MSCs. Additionally, there was a significant 
decrease in the secretion of pro-inflammatory cytokines in the coculture 
groups with adult stem cells compared to DC group after stimulation with LPS. 
Interestingly, the elevated levels of IL-10 were also detected in the presence 
of NSCs at this stage. These observations closely resemble the induction of 
tolerance in DCs as reported earlier. It has been suggested that in the 
presence of MSCs, APCs are transformed into regulatory APCs (Beyth et al. 
2005). DCs were initially recognized as positive stimulators of the immune 
response. However, later reports emphasized a negative regulatory role for 
DCs in the induction of tolerance to self-antigens (Steinman et al. 2003). It 
has been suggested that the exposure of DCs to apoptotic cells induces 
peripheral tolerance via exposure to self-antigens (Steinman et al. 2000). 
Exposure to apoptotic material decreases the secretion of pro-inflammatory 
cytokines (IL-12 and TNF-) and increases the secretion of the anti-
inflammatory cytokine IL-10 (Voll et al. 1997; Urban et al. 2001). Indeed, 
these reported characteristics of tolerance are consistent with our 
observations regarding the differentiation of DCs in the presence of adult stem 




We also tested the overall effect of NSCs and MSCs on the T cell stimulatory 
function of cocultured DCs. Both adult stem cells significantly suppressed the 
activity of DCs. This immunosuppressive effect was stronger with the 
exposure to MSCs. This observation is consistent with the higher levels of IL-
10 secretion in the MSC coculture groups and with the persistent expression 
of the surface marker CD14 in this group throughout differentiation and 
maturation. 
 
This study provides for the first time a means for the comparison of the 
immunosuppressive effects of NSCs and MSCs on the development and 
function of an immune cell in human context. In view of the above mentioned 
findings, BM-MSCs have a stronger immunosuppressive effect on the 
differentiation of mono-DCs, which can be further extended to their maturation 
step and which is also mirrored in their antigen presentation function. In 
contrast, NSCs exert their immunosuppressive effect mainly during the 
maturation step.  
 
In conclusion, NSCs exhibit a milder immunosuppressive effect than MSCs 
and, hence, might be better candidates for cellular vehicles for therapeutic 
applications that require a minimal effect on the function of the immune 
system, including cancer therapy. However, the levels of immunomodulation 
exerted by these adult stem cells need to be examined with regard to other 
lineages of the immune system and within the human body before they can be 

















Cancer is a leading cause of mortality in human societies (Jemal et al. 2011) 
and the immune system plays a critical role in both prevention and 
development of cancer (de Visser et al. 2006). DCs are important regulators 
of immunity and modulate anti-tumor response (Steinman et al. 2007). In fact, 
immunochemical characterisation of DCs has been demonstrated to possess 
prognosis value for a range of cancers (Chaput et al. 2008). Due to their role 
in antitumor immunity, DCs have been explored as cellular vaccines to trigger 
immune response against cancer. Various methods including the genetic 
modifications of DCs via viral and non-viral vectors, transfection with the 
mRNA of cancer cells as well as treatment with cancer cell lysate have been 
investigated for activation of DCs against tumor cells in clinical studies (Gilboa 
2007). 
 In line with these efforts, first DC-based therapy for the treatment of prostate 
cancer received the FDA approval in 2010 (DeFrancesco 2010).  
 
However, the current sources of DCs are progenitor cells that are harvested 
via invasive methods from the patient. These cells are subject to donor-
related variations and, additionally, provide a limited amount of cells 
(Vodyanik et al. 2007). Since their discovery in the late 1990s, hESCs offer a 
renewable and stable source of downstream cell lines (Thomson et al. 1998). 
In recent years, there have been several successful attempts to harness the 
potential of hESCs as source of DCs (Slukvin et al. 2006). Besides providing 
a renewable source for DCs, these approaches offer a new opportunity in the 
genetic engineering of DCs because they enable the derivation of 
homogenous populations of genetically modified DCs from stable colonies of 
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hESC with a safe genomic profile. In 2007, our lab reported the usage of 
baculoviral vectors as a promising and novel approach for both transient and 
stable gene delivery to hESCs (Zeng et al. 2007). The emergence of new 
feeder-free cultures of hESCs is a powerful new improvement in our 
technique because it enables us to modify hESCs throughout the cell culture 
and without the limitation of feeder cells being the main virus-absorbing cells. 
With this technology at hand, we further improved our technique by the 
insertion of loxP sequences in the safe genomic location of AAVS1, and 
subsequently, the delivery of an exchange cassette and Cre recombinase was 
performed via baculoviral vectors. This technique proved to be efficient, and 
almost all of the colonies derived from the selection had site-specific 
integration and a very stable expression profile for the transgene. These 
hESCs also maintained their differentiation potential and the expression of 
markers of pluripotency. The successful derivation of DCs from these 
genetically modified hESCs provides a proof of concept for the use of this 
technology for the production of genetically modified DCs with a safe genomic 
profile.  
 
We also investigated the effect of baculoviral transduction on differentiated 
hESC-DCs. Baculoviral vectors induced the expression of transgene in hESC-
DCs. CMV promoter demonstrated a stronger expression profile compared to 
the EF1 promoter, and WPRE boosted the expression of the transgene. 
Additionally, consistent with previous reports (Strauss et al. 2007), the 
presence of baculovirus increased the frequency of mature morphology of 
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hESC-DCs as evaluated by the expression of the key maturation marker 
CD83.  
 
Based on the above results, we used a baculoviral vector to express a CD1d 
transgene in hESC-DCs. Transduction led to the expression of CD1d in 
hESC-DCs and non-specifically increased their maturation state due to the 
baculoviral vector. Genetically modified hESC-DCs yielded a significant 
increase in survival in an animal breast cancer model. These promising 
results demonstrate potential applications of baculoviral modification of hESC-
DCs for activation of immune system against cancer. 
 
MSCs and NSCs have recently been proposed as cellular vehicles for the 
delivery of therapeutic reagents to tumor sites (Ahmed et al. 2010; Hu, Y. L. et 
al. 2010). However, their beneficial effects could be overshadowed by their 
immunosuppressive effect on important arms of immunity that are involved in 
cancer. In fact, MSCs have been shown to promote the growth of tumors via 
their immunosuppressive effects, which could dramatically diminish their 
potential clinical applications in cancer (Djouad et al. 2003). Due to important 
role of DCs in antitumor immunity, in the second part of this study, we 
concentrated on comparison of the effect of hESCs derived MSCs and NSCs 
on the differentiation of DCs in the human context. We observed that MSCs 
strongly suppressed the differentiation of DCs from monocytes, while NSCs 
were permissive for this initial differentiation. Additionally, MSCs triggered the 
secretion of the immunosuppressive cytokine IL-10 in the coculture, which is 




In contrast, NSCs exhibited an immunosuppressive effect upon the 
administration of LPS, which induces a maturation phenotype in DCs. Most 
importantly, we observed a suppression of the expression of the maturation 
marker CD83, while costimulatory molecules, such as CD80 and CD86, were 
less affected. Additionally, the secretion of pro-inflammatory cytokines as a 
result of maturation was significantly affected in the presence of both BM-
MSCs and NSCs. Furthermore, the presence of NSCs in the coculture with 
monocytes in the presence of LPS stimulation triggered the secretion of IL-10. 
These results demonstrate that while MSCs suppress the differentiation of 
DCs from monocytes, NSCs exhibit an immunosuppressive effect during the 
maturation of DCs. A functional analysis of DCs derived in the presence of 
MSCs and NSCs for the activation of allogeneic T cells demonstrated that 
while both MSCs and NSCs had immunosuppressive potential with regard to 
DCs, this suppression is was significantly stronger in BM-MSCs. Our results 
demonstrate that because NSCs have less of an immunosuppressive effect, 
they might be better candidates as cellular vehicles for tumor targeting. 
However, the levels of immunomodulation by these adult stem cells need to 
be confirmed for other immune lineages and in animal models before the cells 
can be used effectively in therapeutic applications. Our results further 
emphasise that a balanced consideration between the tumor-targeting 
properties and the immunoregulatory functions of hESC derivatives is 




In conclusion, hESC derivatives show promise in cancer therapy applications. 
In this study, we investigated the potential of hESCs derivatives with regard to 
DCs from two different angles. In the first chapter, the use of hESC-DCs as 
therapeutic reagents for the treatment of cancer was emphasized, and the 
promising results highlight the potential clinical application of these derivatives 
in the treatment of cancer. In the second chapter, we investigated the 
interactions of the hESC derivatives with regard to the activity of human DCs. 
The results suggested that NSCs have milder immunosuppressive effects 




Abdel-Latif, A., R. Bolli, I. M. Tleyjeh, V. M. Montori, E. C. Perin, C. A. 
Hornung, E. K. Zuba-Surma, M. Al-Mallah and B. Dawn (2007). "Adult 
bone marrow-derived cells for cardiac repair: a systematic review and 
meta-analysis." Arch Intern Med 167(10): 989-997. 
Abe, T., H. Hemmi, H. Miyamoto, K. Moriishi, S. Tamura, H. Takaku, S. Akira 
and Y. Matsuura (2005). "Involvement of the Toll-like receptor 9 
signaling pathway in the induction of innate immunity by baculovirus." J 
Virol 79(5): 2847-2858. 
Aboody, K. S., A. Brown, N. G. Rainov, K. A. Bower, S. Liu, W. Yang, J. E. 
Small, U. Herrlinger, V. Ourednik, P. M. Black, X. O. Breakefield and E. 
Y. Snyder (2000). "Neural stem cells display extensive tropism for 
pathology in adult brain: evidence from intracranial gliomas." Proc Natl 
Acad Sci U S A 97(23): 12846-12851. 
Aboody, K. S., R. A. Bush, E. Garcia, M. Z. Metz, J. Najbauer, K. A. Justus, D. 
A. Phelps, J. S. Remack, K. J. Yoon, S. Gillespie, S. U. Kim, C. A. 
Glackin, P. M. Potter and M. K. Danks (2006). "Development of a 
tumor-selective approach to treat metastatic cancer." PLoS ONE 1: 
e23. 
Aboody, K. S., J. Najbauer and M. K. Danks (2008). "Stem and progenitor 
cell-mediated tumor selective gene therapy." Gene Ther 15(10): 739-
752. 
Aggarwal, S. and M. F. Pittenger (2005). "Human mesenchymal stem cells 
modulate allogeneic immune cell responses." Blood 105(4): 1815-
1822. 
Ahmed, A. U., N. G. Alexiades and M. S. Lesniak (2010). "The use of neural 
stem cells in cancer gene therapy: predicting the path to the clinic." 
Curr Opin Mol Ther 12(5): 546-552. 
Akesson, E., N. Wolmer-Solberg, M. Cederarv, S. Falci and J. Odeberg 
(2009). "Human neural stem cells and astrocytes, but not neurons, 
suppress an allogeneic lymphocyte response." Stem Cell Res 2(1): 56-
67. 
Almand, B., J. R. Resser, B. Lindman, S. Nadaf, J. I. Clark, E. D. Kwon, D. P. 
Carbone and D. I. Gabrilovich (2000). "Clinical significance of defective 
dendritic cell differentiation in cancer." Clin Cancer Res 6(5): 1755-
1766. 
Altman, J. (1962). "Are new neurons formed in the brains of adult mammals?" 
Science 135: 1127-1128. 
Anderson, S. A., J. Glod, A. S. Arbab, M. Noel, P. Ashari, H. A. Fine and J. A. 
Frank (2005). "Noninvasive MR imaging of magnetically labeled stem 
cells to directly identify neovasculature in a glioma model." Blood 
105(1): 420-425. 
Attarbaschi, A., G. Mann, R. Panzer-Grumayer, S. Rottgers, M. Steiner, M. 
Konig, E. Csinady, M. N. Dworzak, M. Seidel, D. Janousek, A. Moricke, 
C. Reichelt, J. Harbott, M. Schrappe, H. Gadner and O. A. Haas 
(2008). "Minimal residual disease values discriminate between low and 
high relapse risk in children with B-cell precursor acute lymphoblastic 
leukemia and an intrachromosomal amplification of chromosome 21: 
132 
 
the Austrian and German acute lymphoblastic leukemia Berlin-
Frankfurt-Munster (ALL-BFM) trials." J Clin Oncol 26(18): 3046-3050. 
Augello, A., R. Tasso, S. M. Negrini, A. Amateis, F. Indiveri, R. Cancedda and 
G. Pennesi (2005). "Bone marrow mesenchymal progenitor cells inhibit 
lymphocyte proliferation by activation of the programmed death 1 
pathway." Eur J Immunol 35(5): 1482-1490. 
Avigan, D., B. Vasir, J. Gong, V. Borges, Z. Wu, L. Uhl, M. Atkins, J. Mier, D. 
McDermott, T. Smith, N. Giallambardo, C. Stone, K. Schadt, J. Dolgoff, 
J. C. Tetreault, M. Villarroel and D. Kufe (2004). "Fusion cell 
vaccination of patients with metastatic breast and renal cancer induces 
immunological and clinical responses." Clin Cancer Res 10(14): 4699-
4708. 
Bachleitner-Hofmann, T., J. Friedl, M. Hassler, H. Hayden, P. Dubsky, M. 
Sachet, E. Rieder, R. Pfragner, C. Brostjan, S. Riss, B. Niederle, M. 
Gnant and A. Stift (2009). "Pilot trial of autologous dendritic cells 
loaded with tumor lysate(s) from allogeneic tumor cell lines in patients 
with metastatic medullary thyroid carcinoma." Oncol Rep 21(6): 1585-
1592. 
Bak, X. Y., H. L. Dang, J. Yang, K. Ye, E. X. Lee, S. K. Lim and S. Wang 
(2011). "Human Embryonic Stem Cell-derived Mesenchymal Stem 
Cells as Cellular Delivery Vehicles for Prodrug Gene Therapy of 
Glioblastoma." Hum Gene Ther. 
Balduzzi, A., M. G. Valsecchi, C. Uderzo, P. De Lorenzo, T. Klingebiel, C. 
Peters, J. Stary, M. S. Felice, E. Magyarosy, V. Conter, A. Reiter, C. 
Messina, H. Gadner and M. Schrappe (2005). "Chemotherapy versus 
allogeneic transplantation for very-high-risk childhood acute 
lymphoblastic leukaemia in first complete remission: comparison by 
genetic randomisation in an international prospective study." Lancet 
366(9486): 635-642. 
Baleeiro, R. B., L. B. Anselmo, F. A. Soares, C. A. Pinto, O. Ramos, J. L. 
Gross, F. Haddad, R. N. Younes, M. Y. Tomiyoshi, P. C. Bergami-
Santos and J. A. Barbuto (2008). "High frequency of immature dendritic 
cells and altered in situ production of interleukin-4 and tumor necrosis 
factor-alpha in lung cancer." Cancer Immunol Immunother 57(9): 1335-
1345. 
Balkir, L., I. L. Tourkova, V. P. Makarenkova, G. V. Shurin, P. D. Robbins, X. 
M. Yin, G. Chatta and M. R. Shurin (2004). "Comparative analysis of 
dendritic cells transduced with different anti-apoptotic molecules: 
sensitivity to tumor-induced apoptosis." J Gene Med 6(5): 537-544. 
Banchereau, J., F. Briere, C. Caux, J. Davoust, S. Lebecque, Y. J. Liu, B. 
Pulendran and K. Palucka (2000). "Immunobiology of dendritic cells." 
Annu Rev Immunol 18: 767-811. 
Bandi, S. and R. Akkina (2008). "Human embryonic stem cell (hES) derived 
dendritic cells are functionally normal and are susceptible to HIV-1 
infection." AIDS Res Ther 5: 1. 
Becker, A. J., C. E. Mc and J. E. Till (1963). "Cytological demonstration of the 
clonal nature of spleen colonies derived from transplanted mouse 
marrow cells." Nature 197: 452-454. 




Benedetti, S., B. Pirola, B. Pollo, L. Magrassi, M. G. Bruzzone, D. Rigamonti, 
R. Galli, S. Selleri, F. Di Meco, C. De Fraja, A. Vescovi, E. Cattaneo 
and G. Finocchiaro (2000). "Gene therapy of experimental brain tumors 
using neural progenitor cells." Nat Med 6(4): 447-450. 
Berthold, F., J. Boos, S. Burdach, R. Erttmann, G. Henze, J. Hermann, T. 
Klingebiel, B. Kremens, F. H. Schilling, M. Schrappe, T. Simon and B. 
Hero (2005). "Myeloablative megatherapy with autologous stem-cell 
rescue versus oral maintenance chemotherapy as consolidation 
treatment in patients with high-risk neuroblastoma: a randomised 
controlled trial." Lancet Oncol 6(9): 649-658. 
Beyth, S., Z. Borovsky, D. Mevorach, M. Liebergall, Z. Gazit, H. Aslan, E. 
Galun and J. Rachmilewitz (2005). "Human mesenchymal stem cells 
alter antigen-presenting cell maturation and induce T-cell 
unresponsiveness." Blood 105(5): 2214-2219. 
Blattman, J. N. and P. D. Greenberg (2004). "Cancer immunotherapy: a 
treatment for the masses." Science 305(5681): 200-205. 
Bontkes, H. J., D. Kramer, J. J. Ruizendaal, E. W. Kueter, V. F. van Tendeloo, 
C. J. Meijer and E. Hooijberg (2007). "Dendritic cells transfected with 
interleukin-12 and tumor-associated antigen messenger RNA induce 
high avidity cytotoxic T cells." Gene Ther 14(4): 366-375. 
Borg, N. A., K. S. Wun, L. Kjer-Nielsen, M. C. Wilce, D. G. Pellicci, R. Koh, G. 
S. Besra, M. Bharadwaj, D. I. Godfrey, J. McCluskey and J. Rossjohn 
(2007). "CD1d-lipid-antigen recognition by the semi-invariant NKT T-
cell receptor." Nature 448(7149): 44-49. 
Boyce, F. M. and N. L. Bucher (1996). "Baculovirus-mediated gene transfer 
into mammalian cells." Proc Natl Acad Sci U S A 93(6): 2348-2352. 
Breckpot, K., C. Heirman, B. Neyns and K. Thielemans (2004). "Exploiting 
dendritic cells for cancer immunotherapy: genetic modification of 
dendritic cells." J Gene Med 6(11): 1175-1188. 
Brown, A. B., W. Yang, N. O. Schmidt, R. Carroll, K. K. Leishear, N. G. 
Rainov, P. M. Black, X. O. Breakefield and K. S. Aboody (2003). 
"Intravascular delivery of neural stem cell lines to target intracranial and 
extracranial tumors of neural and non-neural origin." Hum Gene Ther 
14(18): 1777-1785. 
Burgdorf, S. K., A. Fischer, P. S. Myschetzky, S. B. Munksgaard, M. B. Zocca, 
M. H. Claesson and J. Rosenberg (2008). "Clinical responses in 
patients with advanced colorectal cancer to a dendritic cell based 
vaccine." Oncol Rep 20(6): 1305-1311. 
Burgoyne, R. D., M. A. Cambray-Deakin, S. A. Lewis, S. Sarkar and N. J. 
Cowan (1988). "Differential distribution of beta-tubulin isotypes in 
cerebellum." EMBO J 7(8): 2311-2319. 
Carreno, B. M. and M. Collins (2002). "The B7 family of ligands and its 
receptors: new pathways for costimulation and inhibition of immune 
responses." Annu Rev Immunol 20: 29-53. 
Cattaneo, E. and R. McKay (1990). "Proliferation and differentiation of 
neuronal stem cells regulated by nerve growth factor." Nature 
347(6295): 762-765. 
Caux, C., B. Vanbervliet, C. Massacrier, M. Azuma, K. Okumura, L. L. Lanier 
and J. Banchereau (1994). "B70/B7-2 is identical to CD86 and is the 
134 
 
major functional ligand for CD28 expressed on human dendritic cells." 
J Exp Med 180(5): 1841-1847. 
Caux, C., B. Vanbervliet, C. Massacrier, C. Dezutter-Dambuyant, B. de Saint-
Vis, C. Jacquet, K. Yoneda, S. Imamura, D. Schmitt and J. Banchereau 
(1996). "CD34+ hematopoietic progenitors from human cord blood 
differentiate along two independent dendritic cell pathways in response 
to GM-CSF+TNF alpha." J Exp Med 184(2): 695-706. 
Chan, T., A. Sami, A. El-Gayed, X. Guo and J. Xiang (2006). "HER-2/neu-
gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-
specific immune responses compared to DNA vaccination." Gene Ther 
13(19): 1391-1402. 
Chang, C. N., Y. C. Huang, D. M. Yang, K. Kikuta, K. J. Wei, T. Kubota and 
W. K. Yang (2011). "A phase I/II clinical trial investigating the adverse 
and therapeutic effects of a postoperative autologous dendritic cell 
tumor vaccine in patients with malignant glioma." J Clin Neurosci 18(8): 
1048-1054. 
Chaput, N., R. Conforti, S. Viaud, A. Spatz and L. Zitvogel (2008). "The Janus 
face of dendritic cells in cancer." Oncogene 27(45): 5920-5931. 
Chaux, P., N. Favre, M. Martin and F. Martin (1997). "Tumor-infiltrating 
dendritic cells are defective in their antigen-presenting function and 
inducible B7 expression in rats." Int J Cancer 72(4): 619-624. 
Chen, C., A. Gault, L. Shen and N. Nabavi (1994). "Molecular cloning and 
expression of early T cell costimulatory molecule-1 and its 
characterization as B7-2 molecule." J Immunol 152(10): 4929-4936. 
Cheshenko, N., N. Krougliak, R. C. Eisensmith and V. A. Krougliak (2001). "A 
novel system for the production of fully deleted adenovirus vectors that 
does not require helper adenovirus." Gene Ther 8(11): 846-854. 
Chinnasamy, N., D. Chinnasamy, J. F. Toso, R. Lapointe, F. Candotti, R. A. 
Morgan and P. Hwu (2000). "Efficient gene transfer to human 
peripheral blood monocyte-derived dendritic cells using human 
immunodeficiency virus type 1-based lentiviral vectors." Hum Gene 
Ther 11(13): 1901-1909. 
Chomarat, P., J. Banchereau, J. Davoust and A. K. Palucka (2000). "IL-6 
switches the differentiation of monocytes from dendritic cells to 
macrophages." Nat Immunol 1(6): 510-514. 
Crop, M. J., C. C. Baan, S. S. Korevaar, J. N. Ijzermans, I. P. Alwayn, W. 
Weimar and M. J. Hoogduijn (2009). "Donor-derived mesenchymal 
stem cells suppress alloreactivity of kidney transplant patients." 
Transplantation 87(6): 896-906. 
Cummings, B. J., N. Uchida, S. J. Tamaki, D. L. Salazar, M. Hooshmand, R. 
Summers, F. H. Gage and A. J. Anderson (2005). "Human neural stem 
cells differentiate and promote locomotor recovery in spinal cord-
injured mice." Proc Natl Acad Sci U S A 102(39): 14069-14074. 
D'Ippolito, G., P. C. Schiller, C. Ricordi, B. A. Roos and G. A. Howard (1999). 
"Age-related osteogenic potential of mesenchymal stromal stem cells 
from human vertebral bone marrow." J Bone Miner Res 14(7): 1115-
1122. 
de Visser, K. E., A. Eichten and L. M. Coussens (2006). "Paradoxical roles of 




DeFrancesco, L. (2010). "Landmark approval for Dendreon's cancer vaccine." 
Nat Biotechnol 28(6): 531-532. 
DeKelver, R. C., V. M. Choi, E. A. Moehle, D. E. Paschon, D. Hockemeyer, S. 
H. Meijsing, Y. Sancak, X. Cui, E. J. Steine, J. C. Miller, P. Tam, V. V. 
Bartsevich, X. Meng, I. Rupniewski, S. M. Gopalan, H. C. Sun, K. J. 
Pitz, J. M. Rock, L. Zhang, G. D. Davis, E. J. Rebar, I. M. Cheeseman, 
K. R. Yamamoto, D. M. Sabatini, R. Jaenisch, P. D. Gregory and F. D. 
Urnov (2010). "Functional genomics, proteomics, and regulatory DNA 
analysis in isogenic settings using zinc finger nuclease-driven 
transgenesis into a safe harbor locus in the human genome." Genome 
Res 20(8): 1133-1142. 
Dhodapkar, M. V. (2009). "Harnessing human CD1d restricted T cells for 
tumor immunity: progress and challenges." Front Biosci 14: 796-807. 
Di Nicola, M., S. Siena, M. Bregni, P. Longoni, M. Magni, M. Milanesi, P. 
Matteucci, R. Mortarini, A. Anichini, G. Parmiani, I. Drexler, V. Erfle, G. 
Sutter and A. M. Gianni (1998). "Gene transfer into human dendritic 
antigen-presenting cells by vaccinia virus and adenovirus vectors." 
Cancer Gene Ther 5(6): 350-356. 
Dietz, A. B. and S. Vuk-Pavlovic (1998). "High efficiency adenovirus-mediated 
gene transfer to human dendritic cells." Blood 91(2): 392-398. 
Djouad, F., P. Plence, C. Bony, P. Tropel, F. Apparailly, J. Sany, D. Noel and 
C. Jorgensen (2003). "Immunosuppressive effect of mesenchymal 
stem cells favors tumor growth in allogeneic animals." Blood 102(10): 
3837-3844. 
Duan, X., H. Guan, Y. Cao and E. S. Kleinerman (2009). "Murine bone 
marrow-derived mesenchymal stem cells as vehicles for interleukin-12 
gene delivery into Ewing sarcoma tumors." Cancer 115(1): 13-22. 
Dzionek, A., A. Fuchs, P. Schmidt, S. Cremer, M. Zysk, S. Miltenyi, D. W. 
Buck and J. Schmitz (2000). "BDCA-2, BDCA-3, and BDCA-4: three 
markers for distinct subsets of dendritic cells in human peripheral 
blood." J Immunol 165(11): 6037-6046. 
Egeland, T., G. Tjonnfjord, R. Steen, G. Gaudernack and E. Thorsby (1993). 
"Positive selection of bone marrow-derived CD34 positive cells for 
possible stem cell transplantation." Transplant Proc 25(1 Pt 2): 1261-
1263. 
Ehtesham, M., P. Kabos, A. Kabosova, T. Neuman, K. L. Black and J. S. Yu 
(2002). "The use of interleukin 12-secreting neural stem cells for the 
treatment of intracranial glioma." Cancer Res 62(20): 5657-5663. 
Einstein, O. and T. Ben-Hur (2008). "The changing face of neural stem cell 
therapy in neurologic diseases." Arch Neurol 65(4): 452-456. 
Einstein, O., N. Fainstein, I. Vaknin, R. Mizrachi-Kol, E. Reihartz, N. 
Grigoriadis, I. Lavon, M. Baniyash, H. Lassmann and T. Ben-Hur 
(2007). "Neural precursors attenuate autoimmune encephalomyelitis by 
peripheral immunosuppression." Ann Neurol 61(3): 209-218. 
Engel, P., J. G. Gribben, G. J. Freeman, L. J. Zhou, Y. Nozawa, M. Abe, L. M. 
Nadler, H. Wakasa and T. F. Tedder (1994). "The B7-2 (B70) 
costimulatory molecule expressed by monocytes and activated B 




Engelmayer, J., M. Larsson, M. Subklewe, A. Chahroudi, W. I. Cox, R. M. 
Steinman and N. Bhardwaj (1999). "Vaccinia virus inhibits the 
maturation of human dendritic cells: a novel mechanism of immune 
evasion." J Immunol 163(12): 6762-6768. 
Erices, A., P. Conget and J. J. Minguell (2000). "Mesenchymal progenitor 
cells in human umbilical cord blood." Br J Haematol 109(1): 235-242. 
Eto, K., R. Murphy, S. W. Kerrigan, A. Bertoni, H. Stuhlmann, T. Nakano, A. 
D. Leavitt and S. J. Shattil (2002). "Megakaryocytes derived from 
embryonic stem cells implicate CalDAG-GEFI in integrin signaling." 
Proc Natl Acad Sci U S A 99(20): 12819-12824. 
Evans, M. J. and M. H. Kaufman (1981). "Establishment in culture of 
pluripotential cells from mouse embryos." Nature 292(5819): 154-156. 
Fernandez-Garcia, N., M. C. Marti, A. Jimenez, F. Sevilla and E. Olmos 
(2009). "Sub-cellular distribution of glutathione in an Arabidopsis 
mutant (vtc1) deficient in ascorbate." J Plant Physiol. 
Ford, C. E., J. L. Hamerton, D. W. Barnes and J. F. Loutit (1956). "Cytological 
identification of radiation-chimaeras." Nature 177(4506): 452-454. 
Frank, R. T., M. Edmiston, S. E. Kendall, J. Najbauer, C. W. Cheung, T. 
Kassa, M. Z. Metz, S. U. Kim, C. A. Glackin, A. M. Wu, P. J. Yazaki 
and K. S. Aboody (2009). "Neural stem cells as a novel platform for 
tumor-specific delivery of therapeutic antibodies." PLoS ONE 4(12): 
e8314. 
Friedenstein, A. J., R. K. Chailakhyan and U. V. Gerasimov (1987). "Bone 
marrow osteogenic stem cells: in vitro cultivation and transplantation in 
diffusion chambers." Cell Tissue Kinet 20(3): 263-272. 
Friedenstein, A. J., K. V. Petrakova, A. I. Kurolesova and G. P. Frolova 
(1968). "Heterotopic of bone marrow. Analysis of precursor cells for 
osteogenic and hematopoietic tissues." Transplantation 6(2): 230-247. 
Gabrilovich, D. I., J. Corak, I. F. Ciernik, D. Kavanaugh and D. P. Carbone 
(1997). "Decreased antigen presentation by dendritic cells in patients 
with breast cancer." Clin Cancer Res 3(3): 483-490. 
Gao, P., Q. Ding, Z. Wu, H. Jiang and Z. Fang (2010). "Therapeutic potential 
of human mesenchymal stem cells producing IL-12 in a mouse 
xenograft model of renal cell carcinoma." Cancer Lett 290(2): 157-166. 
Gay, D., P. Maddon, R. Sekaly, M. A. Talle, M. Godfrey, E. Long, G. 
Goldstein, L. Chess, R. Axel, J. Kappler and et al. (1987). "Functional 
interaction between human T-cell protein CD4 and the major 
histocompatibility complex HLA-DR antigen." Nature 328(6131): 626-
629. 
Geens, M., I. Mateizel, K. Sermon, M. De Rycke, C. Spits, G. Cauffman, P. 
Devroey, H. Tournaye, I. Liebaers and H. Van de Velde (2009). 
"Human embryonic stem cell lines derived from single blastomeres of 
two 4-cell stage embryos." Hum Reprod 24(11): 2709-2717. 
Geijtenbeek, T. B., R. Torensma, S. J. van Vliet, G. C. van Duijnhoven, G. J. 
Adema, Y. van Kooyk and C. G. Figdor (2000). "Identification of DC-
SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports 
primary immune responses." Cell 100(5): 575-585. 
Gerdoni, E., B. Gallo, S. Casazza, S. Musio, I. Bonanni, E. Pedemonte, R. 
Mantegazza, F. Frassoni, G. Mancardi, R. Pedotti and A. Uccelli 
(2007). "Mesenchymal stem cells effectively modulate pathogenic 
137 
 
immune response in experimental autoimmune encephalomyelitis." 
Ann Neurol 61(3): 219-227. 
Gilboa, E. (2007). "DC-based cancer vaccines." J Clin Invest 117(5): 1195-
1203. 
Giliarov, A. V. (2007). "[Nestin in the cells of the central nervous system]." 
Morfologiia 131(1): 85-90. 
Godfrey, D. I., J. McCluskey and J. Rossjohn (2005). "CD1d antigen 
presentation: treats for NKT cells." Nat Immunol 6(8): 754-756. 
Gonzalo-Daganzo, R., C. Regidor, T. Martin-Donaire, M. A. Rico, G. Bautista, 
I. Krsnik, R. Fores, E. Ojeda, I. Sanjuan, J. A. Garcia-Marco, B. 
Navarro, S. Gil, R. Sanchez, N. Panadero, Y. Gutierrez, M. Garcia-
Berciano, N. Perez, I. Millan, R. Cabrera and M. N. Fernandez (2009). 
"Results of a pilot study on the use of third-party donor mesenchymal 
stromal cells in cord blood transplantation in adults." Cytotherapy 11(3): 
278-288. 
Gotherstrom, C., O. Ringden, C. Tammik, E. Zetterberg, M. Westgren and K. 
Le Blanc (2004). "Immunologic properties of human fetal mesenchymal 
stem cells." Am J Obstet Gynecol 190(1): 239-245. 
Grassi, G., H. Kohn, B. Dapas, R. Farra, J. Platz, S. Engel, S. Cjsareck, R. 
Kandolf, C. Teutsch, R. Klima, G. Triolo and A. Kuhn (2006). 
"Comparison between recombinant baculo- and adenoviral-vectors as 
transfer system in cardiovascular cells." Arch Virol 151(2): 255-271. 
Grouard, G., M. C. Rissoan, L. Filgueira, I. Durand, J. Banchereau and Y. J. 
Liu (1997). "The enigmatic plasmacytoid T cells develop into dendritic 
cells with interleukin (IL)-3 and CD40-ligand." J Exp Med 185(6): 1101-
1111. 
Guillaume, D. J. and S. C. Zhang (2008). "Human embryonic stem cells: a 
potential source of transplantable neural progenitor cells." Neurosurg 
Focus 24(3-4): E3. 
Gur-Wahnon, D., Z. Borovsky, S. Beyth, M. Liebergall and J. Rachmilewitz 
(2007). "Contact-dependent induction of regulatory antigen-presenting 
cells by human mesenchymal stem cells is mediated via STAT3 
signaling." Exp Hematol 35(3): 426-433. 
Hao, H. N., J. Zhao, R. L. Thomas, G. C. Parker and W. D. Lyman (2003). 
"Fetal human hematopoietic stem cells can differentiate sequentially 
into neural stem cells and then astrocytes in vitro." J Hematother Stem 
Cell Res 12(1): 23-32. 
Heemskerk, M. H., E. Hooijberg, J. J. Ruizendaal, M. M. van der Weide, E. 
Kueter, A. Q. Bakker, T. N. Schumacher and H. Spits (1999). 
"Enrichment of an antigen-specific T cell response by retrovirally 
transduced human dendritic cells." Cell Immunol 195(1): 10-17. 
Hermann, A., R. Gastl, S. Liebau, M. O. Popa, J. Fiedler, B. O. Boehm, M. 
Maisel, H. Lerche, J. Schwarz, R. Brenner and A. Storch (2004). 
"Efficient generation of neural stem cell-like cells from adult human 
bone marrow stromal cells." J Cell Sci 117(Pt 19): 4411-4422. 
Hix, L. M., Y. H. Shi, R. R. Brutkiewicz, P. L. Stein, C. R. Wang and M. Zhang 
(2011). "CD1d-expressing breast cancer cells modulate NKT cell-
mediated antitumor immunity in a murine model of breast cancer 
metastasis." PLoS ONE 6(6): e20702. 
138 
 
Ho, Y. C., H. P. Lee, S. M. Hwang, W. H. Lo, H. C. Chen, C. K. Chung and Y. 
C. Hu (2006). "Baculovirus transduction of human mesenchymal stem 
cell-derived progenitor cells: variation of transgene expression with 
cellular differentiation states." Gene Ther 13(20): 1471-1479. 
Hofmann, C., V. Sandig, G. Jennings, M. Rudolph, P. Schlag and M. Strauss 
(1995). "Efficient gene transfer into human hepatocytes by baculovirus 
vectors." Proc Natl Acad Sci U S A 92(22): 10099-10103. 
Hu, Y. C. (2006). "Baculovirus vectors for gene therapy." Adv Virus Res 68: 
287-320. 
Hu, Y. C. (2008). "Baculoviral vectors for gene delivery: a review." Curr Gene 
Ther 8(1): 54-65. 
Hu, Y. L., Y. H. Fu, Y. Tabata and J. Q. Gao (2010). "Mesenchymal stem 
cells: a promising targeted-delivery vehicle in cancer gene therapy." J 
Control Release 147(2): 154-162. 
Hung, S. C., W. P. Deng, W. K. Yang, R. S. Liu, C. C. Lee, T. C. Su, R. J. Lin, 
D. M. Yang, C. W. Chang, W. H. Chen, H. J. Wei and J. G. Gelovani 
(2005). "Mesenchymal stem cell targeting of microscopic tumors and 
tumor stroma development monitored by noninvasive in vivo positron 
emission tomography imaging." Clin Cancer Res 11(21): 7749-7756. 
Huntington, N. D. and D. M. Tarlinton (2004). "CD45: direct and indirect 
government of immune regulation." Immunol Lett 94(3): 167-174. 
Hwang, N. S., S. Varghese, H. J. Lee, Z. Zhang, Z. Ye, J. Bae, L. Cheng and 
J. Elisseeff (2008). "In vivo commitment and functional tissue 
regeneration using human embryonic stem cell-derived mesenchymal 
cells." Proc Natl Acad Sci U S A 105(52): 20641-20646. 
Ignatius, R., M. Marovich, E. Mehlhop, L. Villamide, K. Mahnke, W. I. Cox, F. 
Isdell, S. S. Frankel, J. R. Mascola, R. M. Steinman and M. Pope 
(2000). "Canarypox virus-induced maturation of dendritic cells is 
mediated by apoptotic cell death and tumor necrosis factor alpha 
secretion." J Virol 74(23): 11329-11338. 
Ishida, T., T. Oyama, D. P. Carbone and D. I. Gabrilovich (1998). "Defective 
function of Langerhans cells in tumor-bearing animals is the result of 
defective maturation from hemopoietic progenitors." J Immunol 161(9): 
4842-4851. 
Itsykson, P., N. Ilouz, T. Turetsky, R. S. Goldstein, M. F. Pera, I. Fishbein, M. 
Segal and B. E. Reubinoff (2005). "Derivation of neural precursors from 
human embryonic stem cells in the presence of noggin." Mol Cell 
Neurosci 30(1): 24-36. 
Jemal, A., F. Bray, M. M. Center, J. Ferlay, E. Ward and D. Forman (2011). 
"Global cancer statistics." CA Cancer J Clin 61(2): 69-90. 
Jiang, X. X., Y. Zhang, B. Liu, S. X. Zhang, Y. Wu, X. D. Yu and N. Mao 
(2005). "Human mesenchymal stem cells inhibit differentiation and 
function of monocyte-derived dendritic cells." Blood 105(10): 4120-
4126. 
Joannides, A., P. Gaughwin, C. Schwiening, H. Majed, J. Sterling, A. 
Compston and S. Chandran (2004). "Efficient generation of neural 
precursors from adult human skin: astrocytes promote neurogenesis 
from skin-derived stem cells." Lancet 364(9429): 172-178. 
Joo, K. M., I. H. Park, J. Y. Shin, J. Jin, B. G. Kang, M. H. Kim, S. J. Lee, M. 
Y. Jo, S. U. Kim and D. H. Nam (2009). "Human neural stem cells can 
139 
 
target and deliver therapeutic genes to breast cancer brain 
metastases." Mol Ther 17(3): 570-575. 
Jori, F. P., M. A. Napolitano, M. A. Melone, M. Cipollaro, A. Cascino, L. 
Altucci, G. Peluso, A. Giordano and U. Galderisi (2005). "Molecular 
pathways involved in neural in vitro differentiation of marrow stromal 
stem cells." J Cell Biochem 94(4): 645-655. 
Joyce, S. (2001). "CD1d and natural T cells: how their properties jump-start 
the immune system." Cell Mol Life Sci 58(3): 442-469. 
Kallifatidis, G., B. M. Beckermann, A. Groth, M. Schubert, A. Apel, A. 
Khamidjanov, E. Ryschich, T. Wenger, W. Wagner, A. Diehlmann, R. 
Saffrich, U. Krause, V. Eckstein, J. Mattern, M. Chai, G. Schutz, A. D. 
Ho, M. M. Gebhard, M. W. Buchler, H. Friess, P. Buchler and I. Herr 
(2008). "Improved lentiviral transduction of human mesenchymal stem 
cells for therapeutic intervention in pancreatic cancer." Cancer Gene 
Ther 15(4): 231-240. 
Khakoo, A. Y., S. Pati, S. A. Anderson, W. Reid, M. F. Elshal, Rovira, II, A. T. 
Nguyen, D. Malide, C. A. Combs, G. Hall, J. Zhang, M. Raffeld, T. B. 
Rogers, W. Stetler-Stevenson, J. A. Frank, M. Reitz and T. Finkel 
(2006). "Human mesenchymal stem cells exert potent antitumorigenic 
effects in a model of Kaposi's sarcoma." J Exp Med 203(5): 1235-1247. 
Kidd, S., E. Spaeth, J. L. Dembinski, M. Dietrich, K. Watson, A. Klopp, V. L. 
Battula, M. Weil, M. Andreeff and F. C. Marini (2009). "Direct evidence 
of mesenchymal stem cell tropism for tumor and wounding 
microenvironments using in vivo bioluminescent imaging." Stem Cells 
27(10): 2614-2623. 
Kilpatrick, T. J. and P. F. Bartlett (1993). "Cloning and growth of multipotential 
neural precursors: requirements for proliferation and differentiation." 
Neuron 10(2): 255-265. 
Kim, C. H., J. S. Yoon, H. J. Sohn, C. K. Kim, S. Y. Paik, Y. K. Hong and T. G. 
Kim (2007). "Direct vaccination with pseudotype baculovirus 
expressing murine telomerase induces anti-tumor immunity 
comparable with RNA-electroporated dendritic cells in a murine glioma 
model." Cancer Lett 250(2): 276-283. 
Kim, J. H., H. J. Do, S. J. Choi, H. J. Cho, K. H. Park, H. M. Yang, S. H. Lee, 
D. K. Kim, K. Kwack, S. K. Oh, S. Y. Moon, K. Y. Cha and H. M. Chung 
(2005). "Efficient gene delivery in differentiated human embryonic stem 
cells." Exp Mol Med 37(1): 36-44. 
Kim, S. K., S. U. Kim, I. H. Park, J. H. Bang, K. S. Aboody, K. C. Wang, B. K. 
Cho, M. Kim, L. G. Menon, P. M. Black and R. S. Carroll (2006). 
"Human neural stem cells target experimental intracranial 
medulloblastoma and deliver a therapeutic gene leading to tumor 
regression." Clin Cancer Res 12(18): 5550-5556. 
Kitchens, R. L. (2000). "Role of CD14 in cellular recognition of bacterial 
lipopolysaccharides." Chem Immunol 74: 61-82. 
Kleinsmith, L. J. and G. B. Pierce, Jr. (1964). "Multipotentiality of Single 
Embryonal Carcinoma Cells." Cancer Res 24: 1544-1551. 
Klimanskaya, I., Y. Chung, S. Becker, S. J. Lu and R. Lanza (2006). "Human 




Kodama, H., M. Nose, S. Niida and S. Nishikawa (1994). "Involvement of the 
c-kit receptor in the adhesion of hematopoietic stem cells to stromal 
cells." Exp Hematol 22(10): 979-984. 
Komarova, S., Y. Kawakami, M. A. Stoff-Khalili, D. T. Curiel and L. Pereboeva 
(2006). "Mesenchymal progenitor cells as cellular vehicles for delivery 
of oncolytic adenoviruses." Mol Cancer Ther 5(3): 755-766. 
Kost, T. A., J. P. Condreay and D. L. Jarvis (2005). "Baculovirus as versatile 
vectors for protein expression in insect and mammalian cells." Nat 
Biotechnol 23(5): 567-575. 
Koulova, L., E. A. Clark, G. Shu and B. Dupont (1991). "The CD28 ligand 
B7/BB1 provides costimulatory signal for alloactivation of CD4+ T 
cells." J Exp Med 173(3): 759-762. 
Krampera, M., S. Glennie, J. Dyson, D. Scott, R. Laylor, E. Simpson and F. 
Dazzi (2003). "Bone marrow mesenchymal stem cells inhibit the 
response of naive and memory antigen-specific T cells to their cognate 
peptide." Blood 101(9): 3722-3729. 
Kuroda, T., N. Morikawa, K. Matsuoka, A. Fujino, T. Honna, A. Nakagawa, M. 
Kumagai, H. Masaki and M. Saeki (2008). "Prognostic significance of 
circulating tumor cells and bone marrow micrometastasis in advanced 
neuroblastoma." J Pediatr Surg 43(12): 2182-2185. 
Kusmartsev, S. and D. I. Gabrilovich (2002). "Immature myeloid cells and 
cancer-associated immune suppression." Cancer Immunol Immunother 
51(6): 293-298. 
Lamartina, S., E. Sporeno, E. Fattori and C. Toniatti (2000). "Characteristics 
of the adeno-associated virus preintegration site in human 
chromosome 19: open chromatin conformation and transcription-
competent environment." J Virol 74(16): 7671-7677. 
Lazarus, H. M., O. N. Koc, S. M. Devine, P. Curtin, R. T. Maziarz, H. K. 
Holland, E. J. Shpall, P. McCarthy, K. Atkinson, B. W. Cooper, S. L. 
Gerson, M. J. Laughlin, F. R. Loberiza, Jr., A. B. Moseley and A. 
Bacigalupo (2005). "Cotransplantation of HLA-identical sibling culture-
expanded mesenchymal stem cells and hematopoietic stem cells in 
hematologic malignancy patients." Biol Blood Marrow Transplant 11(5): 
389-398. 
Lechmann, M., S. Berchtold, J. Hauber and A. Steinkasserer (2002). "CD83 
on dendritic cells: more than just a marker for maturation." Trends 
Immunol 23(6): 273-275. 
Lee, D. H., Y. Ahn, S. U. Kim, K. C. Wang, B. K. Cho, J. H. Phi, I. H. Park, P. 
M. Black, R. S. Carroll, J. Lee and S. K. Kim (2009). "Targeting rat 
brainstem glioma using human neural stem cells and human 
mesenchymal stem cells." Clin Cancer Res 15(15): 4925-4934. 
Lee, H., G. A. Shamy, Y. Elkabetz, C. M. Schofield, N. L. Harrsion, G. 
Panagiotakos, N. D. Socci, V. Tabar and L. Studer (2007). "Directed 
differentiation and transplantation of human embryonic stem cell-
derived motoneurons." Stem Cells 25(8): 1931-1939. 
Lee, H. P., Y. C. Ho, S. M. Hwang, L. Y. Sung, H. C. Shen, H. J. Liu and Y. C. 
Hu (2007). "Variation of baculovirus-harbored transgene transcription 
among mesenchymal stem cell-derived progenitors leads to varied 
expression." Biotechnol Bioeng 97(3): 649-655. 
141 
 
Lee, O. K., T. K. Kuo, W. M. Chen, K. D. Lee, S. L. Hsieh and T. H. Chen 
(2004). "Isolation of multipotent mesenchymal stem cells from umbilical 
cord blood." Blood 103(5): 1669-1675. 
Lee, Y. B., C. P. Glover, A. S. Cosgrave, A. Bienemann and J. B. Uney 
(2005). "Optimizing regulatable gene expression using adenoviral 
vectors." Exp Physiol 90(1): 33-37. 
Lei, Y., C. L. Lee, K. I. Joo, J. Zarzar, Y. Liu, B. Dai, V. Fox and P. Wang 
(2011). "Gene editing of human embryonic stem cells via an 
engineered baculoviral vector carrying zinc-finger nucleases." Mol Ther 
19(5): 942-950. 
Lenz, G., M. Dreyling, E. Schiegnitz, R. Forstpointner, H. Wandt, M. Freund, 
G. Hess, L. Truemper, V. Diehl, M. Kropff, M. Kneba, N. Schmitz, B. 
Metzner, M. Pfirrmann, M. Unterhalt and W. Hiddemann (2004). 
"Myeloablative radiochemotherapy followed by autologous stem cell 
transplantation in first remission prolongs progression-free survival in 
follicular lymphoma: results of a prospective, randomized trial of the 
German Low-Grade Lymphoma Study Group." Blood 104(9): 2667-
2674. 
Li, Y. P., S. Paczesny, E. Lauret, S. Poirault, P. Bordigoni, F. Mekhloufi, O. 
Hequet, Y. Bertrand, J. P. Ou-Yang, J. F. Stoltz, P. Miossec and A. 
Eljaafari (2008). "Human mesenchymal stem cells license adult CD34+ 
hemopoietic progenitor cells to differentiate into regulatory dendritic 
cells through activation of the Notch pathway." J Immunol 180(3): 
1598-1608. 
Lian, Q., E. Lye, K. Suan Yeo, E. Khia Way Tan, M. Salto-Tellez, T. M. Liu, N. 
Palanisamy, R. M. El Oakley, E. H. Lee, B. Lim and S. K. Lim (2007). 
"Derivation of clinically compliant MSCs from CD105+, CD24- 
differentiated human ESCs." Stem Cells 25(2): 425-436. 
Liu, Y. J., H. Kanzler, V. Soumelis and M. Gilliet (2001). "Dendritic cell 
lineage, plasticity and cross-regulation." Nat Immunol 2(7): 585-589. 
Lorenz, E., D. Uphoff, T. R. Reid and E. Shelton (1951). "Modification of 
irradiation injury in mice and guinea pigs by bone marrow injections." J 
Natl Cancer Inst 12(1): 197-201. 
Lu, L., W. C. Lee, T. Takayama, S. Qian, A. Gambotto, P. D. Robbins and A. 
W. Thomson (1999). "Genetic engineering of dendritic cells to express 
immunosuppressive molecules (viral IL-10, TGF-beta, and CTLA4Ig)." 
J Leukoc Biol 66(2): 293-296. 
Lucas, P. A., G. T. Syftestad and A. I. Caplan (1988). "A water-soluble fraction 
from adult bone stimulates the differentiation of cartilage in explants of 
embryonic muscle." Differentiation 37(1): 47-52. 
Ludwig, T. E., M. E. Levenstein, J. M. Jones, W. T. Berggren, E. R. Mitchen, 
J. L. Frane, L. J. Crandall, C. A. Daigh, K. R. Conard, M. S. Piekarczyk, 
R. A. Llanas and J. A. Thomson (2006). "Derivation of human 
embryonic stem cells in defined conditions." Nat Biotechnol 24(2): 185-
187. 
Macmillan, M. L., B. R. Blazar, T. E. DeFor and J. E. Wagner (2009). 
"Transplantation of ex-vivo culture-expanded parental haploidentical 
mesenchymal stem cells to promote engraftment in pediatric recipients 
of unrelated donor umbilical cord blood: results of a phase I-II clinical 
trial." Bone Marrow Transplant 43(6): 447-454. 
142 
 
Mahonen, A. J., K. J. Airenne, S. Purola, E. Peltomaa, M. U. Kaikkonen, M. S. 
Riekkinen, T. Heikura, K. Kinnunen, M. M. Roschier, T. Wirth and S. 
Yla-Herttuala (2007). "Post-transcriptional regulatory element boosts 
baculovirus-mediated gene expression in vertebrate cells." J Biotechnol 
131(1): 1-8. 
Majumdar, M. K., M. Keane-Moore, D. Buyaner, W. B. Hardy, M. A. Moorman, 
K. R. McIntosh and J. D. Mosca (2003). "Characterization and 
functionality of cell surface molecules on human mesenchymal stem 
cells." J Biomed Sci 10(2): 228-241. 
Makinodan, T. (1956). "Circulating rat cells in lethally irradiated mice protected 
with rat bone marrow." Proc Soc Exp Biol Med 92(1): 174-179. 
Mareschi, K., E. Biasin, W. Piacibello, M. Aglietta, E. Madon and F. Fagioli 
(2001). "Isolation of human mesenchymal stem cells: bone marrow 
versus umbilical cord blood." Haematologica 86(10): 1099-1100. 
Marovich, M. A., J. R. Mascola, M. A. Eller, M. K. Louder, P. A. Caudrelier, R. 
El-Habib, S. Ratto-Kim, J. H. Cox, J. R. Currier, B. L. Levine, C. H. 
June, W. B. Bernstein, M. L. Robb, B. Schuler-Thurner, R. M. 
Steinman, D. L. Birx and S. Schlesinger-Frankel (2002). "Preparation of 
clinical-grade recombinant canarypox-human immunodeficiency virus 
vaccine-loaded human dendritic cells." J Infect Dis 186(9): 1242-1252. 
Martin, G. R. (1981). "Isolation of a pluripotent cell line from early mouse 
embryos cultured in medium conditioned by teratocarcinoma stem 
cells." Proc Natl Acad Sci U S A 78(12): 7634-7638. 
Martino, G. and S. Pluchino (2006). "The therapeutic potential of neural stem 
cells." Nat Rev Neurosci 7(5): 395-406. 
Meisel, R., A. Zibert, M. Laryea, U. Gobel, W. Daubener and D. Dilloo (2004). 
"Human bone marrow stromal cells inhibit allogeneic T-cell responses 
by indoleamine 2,3-dioxygenase-mediated tryptophan degradation." 
Blood 103(12): 4619-4621. 
Melian, A., E. M. Beckman, S. A. Porcelli and M. B. Brenner (1996). "Antigen 
presentation by CD1 and MHC-encoded class I-like molecules." Curr 
Opin Immunol 8(1): 82-88. 
Mellman, I. and R. M. Steinman (2001). "Dendritic cells: specialized and 
regulated antigen processing machines." Cell 106(3): 255-258. 
Moore, T., S. Huang, L. W. Terstappen, M. Bennett and V. Kumar (1994). 
"Expression of CD43 on murine and human pluripotent hematopoietic 
stem cells." J Immunol 153(11): 4978-4987. 
Morstyn, G., N. A. Nicola and D. Metcalf (1980). "Purification of hemopoietic 
progenitor cells from human marrow using a fucose-binding lectin and 
cell sorting." Blood 56(5): 798-805. 
Mueller, S. M. and J. Glowacki (2001). "Age-related decline in the osteogenic 
potential of human bone marrow cells cultured in three-dimensional 
collagen sponges." J Cell Biochem 82(4): 583-590. 
Nagy, A. (2000). "Cre recombinase: the universal reagent for genome 
tailoring." Genesis 26(2): 99-109. 
Nakamizo, A., F. Marini, T. Amano, A. Khan, M. Studeny, J. Gumin, J. Chen, 
S. Hentschel, G. Vecil, J. Dembinski, M. Andreeff and F. F. Lang 
(2005). "Human bone marrow-derived mesenchymal stem cells in the 
treatment of gliomas." Cancer Res 65(8): 3307-3318. 
143 
 
Nakano, T., H. Kodama and T. Honjo (1994). "Generation of 
lymphohematopoietic cells from embryonic stem cells in culture." 
Science 265(5175): 1098-1101. 
Nakano, T., H. Kodama and T. Honjo (1996). "In vitro development of 
primitive and definitive erythrocytes from different precursors." Science 
272(5262): 722-724. 
Nauta, A. J., A. B. Kruisselbrink, E. Lurvink, R. Willemze and W. E. Fibbe 
(2006). "Mesenchymal stem cells inhibit generation and function of 
both CD34+-derived and monocyte-derived dendritic cells." J Immunol 
177(4): 2080-2087. 
Nestle, F. O., G. Burg, J. Fah, T. Wrone-Smith and B. J. Nickoloff (1997). 
"Human sunlight-induced basal-cell-carcinoma-associated dendritic 
cells are deficient in T cell co-stimulatory molecules and are impaired 
as antigen-presenting cells." Am J Pathol 150(2): 641-651. 
Nielsen, J. S. and K. M. McNagny (2008). "Novel functions of the CD34 
family." J Cell Sci 121(Pt 22): 3683-3692. 
Nishida, S., N. Endo, H. Yamagiwa, T. Tanizawa and H. E. Takahashi (1999). 
"Number of osteoprogenitor cells in human bone marrow markedly 
decreases after skeletal maturation." J Bone Miner Metab 17(3): 171-
177. 
O'Sullivan, B. and R. Thomas (2003). "Recent advances on the role of CD40 
and dendritic cells in immunity and tolerance." Curr Opin Hematol 
10(4): 272-278. 
Ostenfeld, T., M. A. Caldwell, K. R. Prowse, M. H. Linskens, E. Jauniaux and 
C. N. Svendsen (2000). "Human neural precursor cells express low 
levels of telomerase in vitro and show diminishing cell proliferation with 
extensive axonal outgrowth following transplantation." Exp Neurol 
164(1): 215-226. 
Paczesny, S., J. Banchereau, K. M. Wittkowski, G. Saracino, J. Fay and A. K. 
Palucka (2004). "Expansion of melanoma-specific cytolytic CD8+ T cell 
precursors in patients with metastatic melanoma vaccinated with 
CD34+ progenitor-derived dendritic cells." J Exp Med 199(11): 1503-
1511. 
Palucka, K. and J. Banchereau (2012). "Cancer immunotherapy via dendritic 
cells." Nat Rev Cancer 12(4): 265-277. 
Palucka, K. A., N. Taquet, F. Sanchez-Chapuis and J. C. Gluckman (1998). 
"Dendritic cells as the terminal stage of monocyte differentiation." J 
Immunol 160(9): 4587-4595. 
Peh, G. S., R. J. Lang, M. F. Pera and S. M. Hawes (2009). "CD133 
expression by neural progenitors derived from human embryonic stem 
cells and its use for their prospective isolation." Stem Cells Dev 18(2): 
269-282. 
Pekny, M. and M. Pekna (2004). "Astrocyte intermediate filaments in CNS 
pathologies and regeneration." J Pathol 204(4): 428-437. 
Pevny, L. H. and S. K. Nicolis (2010). "Sox2 roles in neural stem cells." Int J 
Biochem Cell Biol 42(3): 421-424. 
Philpott, N. J., J. Gomos and E. Falck-Pedersen (2004). "Transgene 
expression after rep-mediated site-specific integration into 
chromosome 19." Hum Gene Ther 15(1): 47-61. 
144 
 
Pirtskhalaishvili, G., G. V. Shurin, A. Gambotto, C. Esche, M. Wahl, Z. R. 
Yurkovetsky, P. D. Robbins and M. R. Shurin (2000). "Transduction of 
dendritic cells with Bcl-xL increases their resistance to prostate cancer-
induced apoptosis and antitumor effect in mice." J Immunol 165(4): 
1956-1964. 
Pittenger, M. F., A. M. Mackay, S. C. Beck, R. K. Jaiswal, R. Douglas, J. D. 
Mosca, M. A. Moorman, D. W. Simonetti, S. Craig and D. R. Marshak 
(1999). "Multilineage potential of adult human mesenchymal stem 
cells." Science 284(5411): 143-147. 
Pluchino, S., L. Zanotti, E. Brambilla, P. Rovere-Querini, A. Capobianco, C. 
Alfaro-Cervello, G. Salani, C. Cossetti, G. Borsellino, L. Battistini, M. 
Ponzoni, C. Doglioni, J. M. Garcia-Verdugo, G. Comi, A. A. Manfredi 
and G. Martino (2009). "Immune regulatory neural stem/precursor cells 
protect from central nervous system autoimmunity by restraining 
dendritic cell function." PLoS ONE 4(6): e5959. 
Podsakoff, G., K. K. Wong, Jr. and S. Chatterjee (1994). "Efficient gene 
transfer into nondividing cells by adeno-associated virus-based 
vectors." J Virol 68(9): 5656-5666. 
Ponnazhagan, S., D. T. Curiel, D. R. Shaw, R. D. Alvarez and G. P. Siegal 
(2001). "Adeno-associated virus for cancer gene therapy." Cancer Res 
61(17): 6313-6321. 
Prechtel, A. T., N. M. Turza, A. A. Theodoridis and A. Steinkasserer (2007). 
"CD83 knockdown in monocyte-derived dendritic cells by small 
interfering RNA leads to a diminished T cell stimulation." J Immunol 
178(9): 5454-5464. 
Ralph, S. J., M. L. Thomas, C. C. Morton and I. S. Trowbridge (1987). 
"Structural variants of human T200 glycoprotein (leukocyte-common 
antigen)." EMBO J 6(5): 1251-1257. 
Ramachandra, C. J., M. Shahbazi, T. W. Kwang, Y. Choudhury, X. Y. Bak, J. 
Yang and S. Wang (2011). "Efficient recombinase-mediated cassette 
exchange at the AAVS1 locus in human embryonic stem cells using 
baculoviral vectors." Nucleic Acids Res 39(16): e107. 
Ramasamy, R., H. Fazekasova, E. W. Lam, I. Soeiro, G. Lombardi and F. 
Dazzi (2007). "Mesenchymal stem cells inhibit dendritic cell 
differentiation and function by preventing entry into the cell cycle." 
Transplantation 83(1): 71-76. 
Reubinoff, B. E., P. Itsykson, T. Turetsky, M. F. Pera, E. Reinhartz, A. Itzik 
and T. Ben-Hur (2001). Neural progenitors from human embryonic 
stem cells. Nat Biotechnol. 19: 1134-1140. 
Reynolds, B. A., W. Tetzlaff and S. Weiss (1992). "A multipotent EGF-
responsive striatal embryonic progenitor cell produces neurons and 
astrocytes." J Neurosci 12(11): 4565-4574. 
Reynolds, B. A. and S. Weiss (1992). "Generation of neurons and astrocytes 
from isolated cells of the adult mammalian central nervous system." 
Science 255(5052): 1707-1710. 
Ribas, A. (2005). "Genetically modified dendritic cells for cancer 
immunotherapy." Curr Gene Ther 5(6): 619-628. 
Richardson, R. M., W. C. Broaddus, K. L. Holloway and H. L. Fillmore (2005). 
"Grafts of adult subependymal zone neuronal progenitor cells rescue 
hemiparkinsonian behavioral decline." Brain Res 1032(1-2): 11-22. 
145 
 
Rouard, H., A. Leon, B. Klonjkowski, J. Marquet, L. Tenneze, A. Plonquet, S. 
G. Agrawal, J. P. Abastado, M. Eloit, J. P. Farcet and M. H. Delfau-
Larue (2000). "Adenoviral transduction of human 'clinical grade' 
immature dendritic cells enhances costimulatory molecule expression 
and T-cell stimulatory capacity." J Immunol Methods 241(1-2): 69-81. 
Sakurai, F., K. Kawabata, T. Yamaguchi, T. Hayakawa and H. Mizuguchi 
(2005). "Optimization of adenovirus serotype 35 vectors for efficient 
transduction in human hematopoietic progenitors: comparison of 
promoter activities." Gene Ther 12(19): 1424-1433. 
Salio, M., M. Cella, M. Suter and A. Lanzavecchia (1999). "Inhibition of 
dendritic cell maturation by herpes simplex virus." Eur J Immunol 
29(10): 3245-3253. 
Sallusto, F. and A. Lanzavecchia (1994). "Efficient presentation of soluble 
antigen by cultured human dendritic cells is maintained by 
granulocyte/macrophage colony-stimulating factor plus interleukin 4 
and downregulated by tumor necrosis factor alpha." J Exp Med 179(4): 
1109-1118. 
Sato, H., N. Kuwashima, T. Sakaida, M. Hatano, J. E. Dusak, W. K. Fellows-
Mayle, G. D. Papworth, S. C. Watkins, A. Gambotto, I. F. Pollack and 
H. Okada (2005). "Epidermal growth factor receptor-transfected bone 
marrow stromal cells exhibit enhanced migratory response and 
therapeutic potential against murine brain tumors." Cancer Gene Ther 
12(9): 757-768. 
Sauer, B. and N. Henderson (1988). "Site-specific DNA recombination in 
mammalian cells by the Cre recombinase of bacteriophage P1." Proc 
Natl Acad Sci U S A 85(14): 5166-5170. 
Schutz, A., N. Scheller, T. Breinig and A. Meyerhans (2006). "The Autographa 
californica nuclear polyhedrosis virus AcNPV induces functional 
maturation of human monocyte-derived dendritic cells." Vaccine 24(49-
50): 7190-7196. 
Schwartz, R. H. (1992). "Costimulation of T lymphocytes: the role of CD28, 
CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy." 
Cell 71(7): 1065-1068. 
Senju, S., H. Suemori, H. Zembutsu, Y. Uemura, S. Hirata, D. Fukuma, H. 
Matsuyoshi, M. Shimomura, M. Haruta, S. Fukushima, Y. Matsunaga, 
T. Katagiri, Y. Nakamura, M. Furuya, N. Nakatsuji and Y. Nishimura 
(2007). "Genetically manipulated human embryonic stem cell-derived 
dendritic cells with immune regulatory function." Stem Cells 25(11): 
2720-2729. 
Shi, S. and S. Gronthos (2003). "Perivascular niche of postnatal 
mesenchymal stem cells in human bone marrow and dental pulp." J 
Bone Miner Res 18(4): 696-704. 
Shi, Y., G. Hu, J. Su, W. Li, Q. Chen, P. Shou, C. Xu, X. Chen, Y. Huang, Z. 
Zhu, X. Huang, X. Han, N. Xie and G. Ren (2010). "Mesenchymal stem 
cells: a new strategy for immunosuppression and tissue repair." Cell 
Res 20(5): 510-518. 
Shibata, K. R., T. Aoyama, Y. Shima, K. Fukiage, S. Otsuka, M. Furu, Y. 
Kohno, K. Ito, S. Fujibayashi, M. Neo, T. Nakayama, T. Nakamura and 
J. Toguchida (2007). "Expression of the p16INK4A gene is associated 
closely with senescence of human mesenchymal stem cells and is 
146 
 
potentially silenced by DNA methylation during in vitro expansion." 
Stem Cells 25(9): 2371-2382. 
Shurin, M. R., M. Gregory, J. C. Morris and A. M. Malyguine (2010). 
"Genetically modified dendritic cells in cancer immunotherapy: a better 
tomorrow?" Expert Opin Biol Ther 10(11): 1539-1553. 
Simmons, D. L., S. Tan, D. G. Tenen, A. Nicholson-Weller and B. Seed 
(1989). "Monocyte antigen CD14 is a phospholipid anchored 
membrane protein." Blood 73(1): 284-289. 
Sims, T. L., Jr., J. B. Hamner, R. A. Bush, P. E. Fischer, S. U. Kim, K. S. 
Aboody, B. McCarville, M. K. Danks and A. M. Davidoff (2009). "Neural 
progenitor cell-mediated delivery of osteoprotegerin limits disease 
progression in a preclinical model of neuroblastoma bone metastasis." 
J Pediatr Surg 44(1): 204-210; discussion 210-201. 
Slukvin, II, M. A. Vodyanik, J. A. Thomson, M. E. Gumenyuk and K. D. Choi 
(2006). "Directed differentiation of human embryonic stem cells into 
functional dendritic cells through the myeloid pathway." J Immunol 
176(5): 2924-2932. 
Smits, E. L., S. Anguille, N. Cools, Z. N. Berneman and V. F. Van Tendeloo 
(2009). "Dendritic cell-based cancer gene therapy." Hum Gene Ther 
20(10): 1106-1118. 
Sonabend, A. M., I. V. Ulasov, M. A. Tyler, A. A. Rivera, J. M. Mathis and M. 
S. Lesniak (2008). "Mesenchymal stem cells effectively deliver an 
oncolytic adenovirus to intracranial glioma." Stem Cells 26(3): 831-841. 
Sotiropoulou, P. A., S. A. Perez, M. Salagianni, C. N. Baxevanis and M. 
Papamichail (2006). "Characterization of the optimal culture conditions 
for clinical scale production of human mesenchymal stem cells." Stem 
Cells 24(2): 462-471. 
Spenger, A., W. Ernst, J. P. Condreay, T. A. Kost and R. Grabherr (2004). 
"Influence of promoter choice and trichostatin A treatment on 
expression of baculovirus delivered genes in mammalian cells." Protein 
Expr Purif 38(1): 17-23. 
Steinman, R. M. and J. Banchereau (2007). "Taking dendritic cells into 
medicine." Nature 449(7161): 419-426. 
Steinman, R. M., D. Hawiger and M. C. Nussenzweig (2003). "Tolerogenic 
dendritic cells." Annu Rev Immunol 21: 685-711. 
Steinman, R. M., M. Pack and K. Inaba (1997). "Dendritic cells in the T-cell 
areas of lymphoid organs." Immunol Rev 156: 25-37. 
Steinman, R. M., S. Turley, I. Mellman and K. Inaba (2000). "The induction of 
tolerance by dendritic cells that have captured apoptotic cells." J Exp 
Med 191(3): 411-416. 
Stemple, D. L. and D. J. Anderson (1992). "Isolation of a stem cell for neurons 
and glia from the mammalian neural crest." Cell 71(6): 973-985. 
Stenderup, K., J. Justesen, C. Clausen and M. Kassem (2003). "Aging is 
associated with decreased maximal life span and accelerated 
senescence of bone marrow stromal cells." Bone 33(6): 919-926. 
Strauss, R., A. Huser, S. Ni, S. Tuve, N. Kiviat, P. S. Sow, C. Hofmann and A. 
Lieber (2007). "Baculovirus-based vaccination vectors allow for efficient 
induction of immune responses against plasmodium falciparum 
circumsporozoite protein." Mol Ther 15(1): 193-202. 
147 
 
Strelchenko, N., O. Verlinsky, V. Kukharenko and Y. Verlinsky (2004). 
"Morula-derived human embryonic stem cells." Reprod Biomed Online 
9(6): 623-629. 
Studeny, M., F. C. Marini, R. E. Champlin, C. Zompetta, I. J. Fidler and M. 
Andreeff (2002). "Bone marrow-derived mesenchymal stem cells as 
vehicles for interferon-beta delivery into tumors." Cancer Res 62(13): 
3603-3608. 
Su, Z., C. Frye, K. M. Bae, V. Kelley and J. Vieweg (2008). "Differentiation of 
human embryonic stem cells into immunostimulatory dendritic cells 
under feeder-free culture conditions." Clin Cancer Res 14(19): 6207-
6217. 
Sullivan, K. F., J. C. Havercroft, P. S. Machlin and D. W. Cleveland (1986). 
"Sequence and expression of the chicken beta 5- and beta 4-tubulin 
genes define a pair of divergent beta-tubulins with complementary 
patterns of expression." Mol Cell Biol 6(12): 4409-4418. 
Suzuki, T., M. O. Chang, M. Kitajima and H. Takaku (2010). "Baculovirus 
activates murine dendritic cells and induces non-specific NK cell and T 
cell immune responses." Cell Immunol 262(1): 35-43. 
Swistowski, A., J. Peng, Y. Han, A. M. Swistowska, M. S. Rao and X. Zeng 
(2009). "Xeno-free defined conditions for culture of human embryonic 
stem cells, neural stem cells and dopaminergic neurons derived from 
them." PLoS ONE 4(7): e6233. 
Szczypka, M. S., A. J. Westover, S. G. Clouthier, J. L. Ferrara and H. D. 
Humes (2005). "Rare incorporation of bone marrow-derived cells into 
kidney after folic acid-induced injury." Stem Cells 23(1): 44-54. 
Taniguchi, M., T. Tashiro, N. Dashtsoodol, N. Hongo and H. Watarai (2010). 
"The specialized iNKT cell system recognizes glycolipid antigens and 
bridges the innate and acquired immune systems with potential 
applications for cancer therapy." Int Immunol 22(1): 1-6. 
Tas, M. P., P. J. Simons, F. J. Balm and H. A. Drexhage (1993). "Depressed 
monocyte polarization and clustering of dendritic cells in patients with 
head and neck cancer: in vitro restoration of this immunosuppression 
by thymic hormones." Cancer Immunol Immunother 36(2): 108-114. 
Tavassoli, M. and W. H. Crosby (1968). "Transplantation of marrow to 
extramedullary sites." Science 161(836): 54-56. 
Temple, S. (1989). "Division and differentiation of isolated CNS blast cells in 
microculture." Nature 340(6233): 471-473. 
Temple, S. (2001). "The development of neural stem cells." Nature 414(6859): 
112-117. 
Thomson, J. A., J. Itskovitz-Eldor, S. S. Shapiro, M. A. Waknitz, J. J. 
Swiergiel, V. S. Marshall and J. M. Jones (1998). "Embryonic stem cell 
lines derived from human blastocysts." Science 282(5391): 1145-1147. 
Tokcaer-Keskin, Z., A. R. Akar, F. Ayaloglu-Butun, E. Terzioglu-Kara, S. 
Durdu, U. Ozyurda, M. Ugur and K. C. Akcali (2009). "Timing of 
induction of cardiomyocyte differentiation for in vitro cultured 
mesenchymal stem cells: a perspective for emergencies." Can J 
Physiol Pharmacol 87(2): 143-150. 
Tse, W. T., J. D. Pendleton, W. M. Beyer, M. C. Egalka and E. C. Guinan 
(2003). "Suppression of allogeneic T-cell proliferation by human 
148 
 
marrow stromal cells: implications in transplantation." Transplantation 
75(3): 389-397. 
Tsukayama, S., K. Omura, K. Yoshida, Y. Tanaka and G. Watanabe (2005). 
"Prognostic value of CD83-positive mature dendritic cells and their 
relation to vascular endothelial growth factor in advanced human 
gastric cancer." Oncol Rep 14(2): 369-375. 
Tyler, M. A., I. V. Ulasov, A. M. Sonabend, S. Nandi, Y. Han, S. Marler, J. 
Roth and M. S. Lesniak (2009). "Neural stem cells target intracranial 
glioma to deliver an oncolytic adenovirus in vivo." Gene Ther 16(2): 
262-278. 
Uccelli, A., A. Laroni and M. S. Freedman (2011). "Mesenchymal stem cells 
for the treatment of multiple sclerosis and other neurological diseases." 
Lancet Neurol 10(7): 649-656. 
Urban, B. C., N. Willcox and D. J. Roberts (2001). "A role for CD36 in the 
regulation of dendritic cell function." Proc Natl Acad Sci U S A 98(15): 
8750-8755. 
Van Der Vliet, H. J., N. Nishi, Y. Koezuka, M. A. Peyrat, B. M. Von Blomberg, 
A. J. Van Den Eertwegh, H. M. Pinedo, G. Giaccone and R. J. Scheper 
(1999). "Effects of alpha-galactosylceramide (KRN7000), interleukin-12 
and interleukin-7 on phenotype and cytokine profile of human 
Valpha24+ Vbeta11+ T cells." Immunology 98(4): 557-563. 
Vodyanik, M. A., J. A. Bork, J. A. Thomson and Slukvin, II (2005). "Human 
embryonic stem cell-derived CD34+ cells: efficient production in the 
coculture with OP9 stromal cells and analysis of lymphohematopoietic 
potential." Blood 105(2): 617-626. 
Vodyanik, M. A. and Slukvin, II (2007). "Directed differentiation of human 
embryonic stem cells to dendritic cells." Methods Mol Biol 407: 275-
293. 
Vodyanik, M. A., J. A. Thomson and Slukvin, II (2006). "Leukosialin (CD43) 
defines hematopoietic progenitors in human embryonic stem cell 
differentiation cultures." Blood 108(6): 2095-2105. 
Voll, R. E., M. Herrmann, E. A. Roth, C. Stach, J. R. Kalden and I. Girkontaite 
(1997). "Immunosuppressive effects of apoptotic cells." Nature 
390(6658): 350-351. 
Wagle, M. and S. Jesuthasan (2003). "Baculovirus-mediated gene expression 
in zebrafish." Mar Biotechnol (NY) 5(1): 58-63. 
Wakkach, A., N. Fournier, V. Brun, J. P. Breittmayer, F. Cottrez and H. Groux 
(2003). "Characterization of dendritic cells that induce tolerance and T 
regulatory 1 cell differentiation in vivo." Immunity 18(5): 605-617. 
Wang, C. Y., F. Li, Y. Yang, H. Y. Guo, C. X. Wu and S. Wang (2006). 
"Recombinant baculovirus containing the diphtheria toxin A gene for 
malignant glioma therapy." Cancer Res 66(11): 5798-5806. 
Wexler, S. A., C. Donaldson, P. Denning-Kendall, C. Rice, B. Bradley and J. 
M. Hows (2003). "Adult bone marrow is a rich source of human 
mesenchymal 'stem' cells but umbilical cord and mobilized adult blood 
are not." Br J Haematol 121(2): 368-374. 
Whiteside, T. L., J. Stanson, M. R. Shurin and S. Ferrone (2004). "Antigen-
processing machinery in human dendritic cells: up-regulation by 




Wiethe, C., K. Dittmar, T. Doan, W. Lindenmaier and R. Tindle (2003). 
"Provision of 4-1BB ligand enhances effector and memory CTL 
responses generated by immunization with dendritic cells expressing a 
human tumor-associated antigen." J Immunol 170(6): 2912-2922. 
Willis, R. A., W. J. Bowers, M. J. Turner, T. L. Fisher, C. S. Abdul-Alim, D. F. 
Howard, H. J. Federoff, E. M. Lord and J. G. Frelinger (2001). 
"Dendritic cells transduced with HSV-1 amplicons expressing prostate-
specific antigen generate antitumor immunity in mice." Hum Gene Ther 
12(15): 1867-1879. 
Woodman, R. C., B. Johnston, M. J. Hickey, D. Teoh, P. Reinhardt, B. Y. 
Poon and P. Kubes (1998). "The functional paradox of CD43 in 
leukocyte recruitment: a study using CD43-deficient mice." J Exp Med 
188(11): 2181-2186. 
Xiang, J., J. Tang, C. Song, Z. Yang, D. G. Hirst, Q. J. Zheng and G. Li 
(2009). "Mesenchymal stem cells as a gene therapy carrier for 
treatment of fibrosarcoma." Cytotherapy 11(5): 516-526. 
Xu, Y. and G. Song (2004). "The role of CD40-CD154 interaction in cell 
immunoregulation." J Biomed Sci 11(4): 426-438. 
Yamanaka, R., S. A. Zullo, J. Ramsey, N. Yajima, N. Tsuchiya, R. Tanaka, M. 
Blaese and K. G. Xanthopoulos (2002). "Marked enhancement of 
antitumor immune responses in mouse brain tumor models by 
genetically modified dendritic cells producing Semliki Forest virus-
mediated interleukin-12." J Neurosurg 97(3): 611-618. 
Yanagimoto, H., S. Takai, S. Satoi, H. Toyokawa, K. Takahashi, N. Terakawa, 
A. H. Kwon and Y. Kamiyama (2005). "Impaired function of circulating 
dendritic cells in patients with pancreatic cancer." Clin Immunol 114(1): 
52-60. 
Young, H. E., T. A. Steele, R. A. Bray, J. Hudson, J. A. Floyd, K. Hawkins, K. 
Thomas, T. Austin, C. Edwards, J. Cuzzourt, M. Duenzl, P. A. Lucas 
and A. C. Black, Jr. (2001). "Human reserve pluripotent mesenchymal 
stem cells are present in the connective tissues of skeletal muscle and 
dermis derived from fetal, adult, and geriatric donors." Anat Rec 264(1): 
51-62. 
Yu, J. M., E. S. Jun, Y. C. Bae and J. S. Jung (2008). "Mesenchymal stem 
cells derived from human adipose tissues favor tumor cell growth in 
vivo." Stem Cells Dev 17(3): 463-473. 
Yurkovetsky, Z. R., G. V. Shurin, D. A. Barry, A. C. Schuh, M. R. Shurin and 
P. D. Robbins (2006). "Comparative analysis of antitumor activity of 
CD40L, RANKL, and 4-1BBL in vivo following intratumoral 
administration of viral vectors or transduced dendritic cells." J Gene 
Med 8(2): 129-137. 
Zeng, J., J. Du, J. Lin, X. Y. Bak, C. Wu and S. Wang (2009). "High-efficiency 
transient transduction of human embryonic stem cell-derived neurons 
with baculoviral vectors." Mol Ther 17(9): 1585-1593. 
Zeng, J., J. Du, Y. Zhao, N. Palanisamy and S. Wang (2007). "Baculoviral 
vector-mediated transient and stable transgene expression in human 
embryonic stem cells." Stem Cells 25(4): 1055-1061. 
Zhang, X., P. Stojkovic, S. Przyborski, M. Cooke, L. Armstrong, M. Lako and 
M. Stojkovic (2006). "Derivation of human embryonic stem cells from 
developing and arrested embryos." Stem Cells 24(12): 2669-2676. 
150 
 
Zhao, Y. and S. Wang (2010). "Human NT2 neural precursor-derived tumor-
infiltrating cells as delivery vehicles for treatment of glioblastoma." Hum 
Gene Ther 21(6): 683-694. 
Zheng, C. and B. J. Baum (2005). "Evaluation of viral and mammalian 
promoters for use in gene delivery to salivary glands." Mol Ther 12(3): 
528-536. 
Zhou, L. J. and T. F. Tedder (1995). "Human blood dendritic cells selectively 
express CD83, a member of the immunoglobulin superfamily." J 
Immunol 154(8): 3821-3835. 
Zimmermann, S., M. Voss, S. Kaiser, U. Kapp, C. F. Waller and U. M. 
Martens (2003). "Lack of telomerase activity in human mesenchymal 
stem cells." Leukemia 17(6): 1146-1149. 
Zuk, P. A., M. Zhu, P. Ashjian, D. A. De Ugarte, J. I. Huang, H. Mizuno, Z. C. 
Alfonso, J. K. Fraser, P. Benhaim and M. H. Hedrick (2002). "Human 
adipose tissue is a source of multipotent stem cells." Mol Biol Cell 
13(12): 4279-4295. 
 
 
